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ABSTRACT OF DISSERTATION 
 
A BIOPHYSICAL INVESTIGATION OF STABILITY, LIGAND BINDING, 
AND IRON STATE OF CYP102A1 
 
Cytochrome P450s (CYPs) are cysteine ligated Fe-heme monooxygenases that are 
found in all domains of life. In mammals, they have a role in xenobiotic metabolism and 
steroid synthesis, making them a fundamental requirement for survival. In addition, their 
ability to perform a variety of chemical reactions on an array of substrates makes CYPs 
highly sought for biotechnical applications such as wastewater remediation, production of 
potential drug candidates, and creation of drug metabolites. By mutating specific amino 
acids, these enzymes can be engineered to change their substrate binding profiles and 
achieve stereo- and regio-specific chemistry. While these mutations are essential to change 
CYP activity, the major drawback to using them on an industrial scale is a decrease in 
stability of the enzyme. This work elaborated how CYP stability is effected by mutations, 
binding of native and non-native substrates, and changes in iron oxidation state.  
Cytochrome P450BM3 (BM3, or CYP102A1), a bacterial enzyme, was used as a 
model system. In contrast to membrane associated human CYPs, BM3 is soluble and has 
efficient turnover due to the fusion of the reductase partner the heme domain. BM3 is 
naturally selective, but mutations can be incorporated to make it promiscuous, similar to 
CYPs responsible for xenobiotic breakdown. This allowed for the comparison of a selective 
vs. a promiscuous CYP while conserving the greatest possible sequence identity. An 
approach was used combining experimental solution phase data, x-ray crystallography, and 
molecular dynamic simulations. The results showed that mutations resulted in an 
cumulative decrease in stability as promiscuity increased. This reduction in stability was 
due to a decrease in the number of salt bridges and disruption of hydrophobic contacts. 
Regions of P450BM3 were found that could be targeted through mutation to increase the 
stability of a highly promiscuous and active variant known as the pentuple mutant (PM). 
Further investigations demonstrated the impact of native and non-native substrate binding. 
The Gibbs free energy of binding (∆Gb°) was determined for a small library of molecules 
and was rationalized computationally, concluding that attractive dispersion forces negated 
the impact of electrostatic and repulsive forces. In addition, the impact of the iron-heme
 
 
   
 
charge state on CYP stability was examined as a function of promiscuity. In general, there 
was an association between promiscuity and similarities in the stability of the Fe(III) and 
Fe(II) states. This is consistent with a model where the promiscuous variants of the enzyme 
are in a more “reduction-ready” state, and can undergo catalysis with greater ease than the 
wild type enzyme. These findings have implications for the role of CYPs in human health 
and for biotechnical applications.  
KEYWORDS: Cytochrome P450s, Cytochrome P450BM3 (CYP102A1), enzyme 
stability, heme oxidation state 
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1 
 INTRODUCTION 
1.1 Cytochrome P450s (CYPs) 
Cytochrome P450s (CYPs) were first named by Omura and Sato in 1964 due to 
their observation that these enzymes had an absorbance band at 450 nm when reduced 
and CO-bound, leading to the name “pigment-450”.3 Since then, CYPs have been 
intensively studied in relation to their health implications in humans, biological roles 
in other species, and biotechnical applications.  
Cytochrome P450s are a superfamily of Fe-heme cysteine-ligated 
monooxygenases that exist in almost all life forms, including viruses, with 
approximately 20,000 genes currently known.4, 5 Astonishingly, they are all 
characterized by a similar fold and carry out somewhat similar reactions even though 
they have evolved to have distinct substrates and perform various functions that benefit 
a particular species. This includes steroid synthesis and xenobiotic metabolism in 
mammals,6  and playing a major role in the chemical defense of plants.4 The importance 
of CYPs’ roles in nature has made them highly studied, but much more work is needed 
to fully characterize and understand the biophysical properties that are important for 
them to function properly. This work is focused on parsing some of these biophysical 
properties to elucidate further how these amazing enzymes work. 
1.1.1 Catalytic cycle 
As CYPs are monooxygenases, the most common reaction is to use O2 to 
incorporate one oxygen atom into a substrate. Taking advantage of the Fe-heme active 
site, in which the Fe is able to cycle through multiple charge and spin states, allows 
CYPs to perform chemistry that is difficult for most organic chemists to accomplish. 
All CYPs are believed to utilize the catalytic cycle shown in Figure 1.1.  The enzyme 
2 
is considered in the resting state (1) when the Fe in the heme porphyrin is hexa-
coordinated. The four nitrogens of the porphyrin are ligated in the plane, and a thiol 
from a cysteine residue is coordinated in the distal position. This ligand plays an 
essential role in the generation of compound I (7). Lastly, a water molecule is bound in 
the proximal position, and is the labile ligand. At rest, the d electrons (e-) of Fe(III) 
occupy the lowest energy molecular orbitals, producing a low spin (LS) complex.  
 
When substrate (RH) enters the active site, it occupies space near the Fe heme, 
which causes the bound H2O molecule to dissociate (2). Upon this dissociation, the Fe-
heme becomes penta-coordinate, causing the Fe to move slightly below the plane of the 
heme. This movement leads to a weakening of the interactions of the Fe-heme, causing 
the d-block electrons to occupy higher molecular orbitals, producing a high spin (HS) 
state7, and making the complex a better e- acceptor. This triggers the transfer of one e- 
from the reductase partner, converting the HS ferric species to a HS ferrous species (3). 
At this point, molecular oxygen (O2) is able to bind, returning the Fe-heme to a low 
 
Figure 1.1 Catalytic cycle of Cytochrome P450s. 
3 
spin state (4).8 This species is a good e- acceptor, facilitating the second e- transfer from 
the reductase partner. The ferric-dioxo state of the heme9 (5) is an excellent Lewis base 
and readily accepts a proton to produce the ferric-hydroperoxy complex, also known as 
compound 0 (6). This complex is also a good Lewis base that allows a second 
protonation step to occur. Upon the release of a H2O molecule, the heme is now in its 
most active state, having formed a short lived iron-oxo intermediate called compound 
I (7)10.  In this state, the oxygen bound can now be transferred to the substrate (8)11-13 
and the enzyme returned to resting state.  
It has taken decades and the collaborative efforts of several research groups to 
fully characterize the complete catalytic cycle of CYPs. In fact, the existence of 
compound I was finally confirmed only recently in 2010 by Prof. Michael Green.10 
Though the general cycle is agreed upon, there are still several questions that remain. 
Recently, it was reported by Johnston et al. that a mixture of the Fe(III) and Fe(II) state 
were present at rest, not just Fe(III) state, for two bacterial and five mammalian CYPs 
expressed in Escherichia coli as well as rat hepatocytes.14 The ratio of Fe(III) to Fe(II) 
at rest can also be altered by the presence of substrate or electron donors,14 meaning the 
current catalytic cycle isn’t as static as previously believed. Our group is interested in 
probing overall protein stability in regards to the ease of transition from the Fe(III) to 
Fe(II) state and how substrates or inhibitors modulates this transition.  
1.1.1.1 Importance of the Fe-cysteine bond on catalysis 
Though the metal center is necessary for catalytic modification of substrates to 
occur, it is the protein environment that regulates the chemistry the metal is able to 
accomplish. In CYPs, the tuning ability comes from the thiolate ligand. The Fe-Cys 
bond plays an essential role in the function and stability of cytochrome P450s. Most 
4 
CYPs have a similar secondary structure, though they can differ in amino acid sequence 
by as much as 85%.15 There are some conserved sequences in most CYPs, such as an 
alcohol residue in the active site necessary for O2 activation16, 17 and a second acidic 
residue critical for proton transfer to O2, 18, 19  but the one mainstay is the cysteine 
residue that ligates the heme.  
The only heme proteins other than P450s that can cleave C-H bonds are 
chloroperoxidases (CPO).20 Both enzymes, like nitric oxide synthase (NOS), have Fe-
hemes that are Cys-ligated, in contrast to other heme proteins that store or transport O2. 
What makes heme-thiolate chemistry unique is that these enzymes are capable of 2 e- 
transfers, in contrast to His-ligated heme proteins.21 The Cys-ligation decreases the 
reduction potential of the Fe-heme which makes it one of the most powerful oxidants 
in nature21 and has been compared to a biological blowtorch.8  
This reduction in the Fe-heme potential is based on the fact that the Cys-ligand 
is a good electron donor. The electron donating ability of the thiolate drives the complex 
towards protonation, which leads to the incorporation of an oxygen into the substrate.21 
This is often referred to as the “push effect” which encourages the O2 molecule bound 
to the Fe to cleave, leading to the formation of compound I.22 In this way, the thiolate 
ligand impacts the stability of the enzyme when compound I is formed. This 
stabilization also occurs as a result of hydrogen bonding in the Cys-ligand loop between 
the cysteine ligand and other residues.23 
1.1.1.2 Implications of uncoupled catalysis  
The catalytic cycle of CYPs is tightly regulated to use one molecule of 
atmospheric dioxygen and two reducing equivalents to produce an oxygenated product 
and molecule of water (Figure 1.1, Equation 1.1). Misregulation of the catalytic cycle 
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leads to uncouple catalysis in which the dioxygen molecule is diverted from forming 
product from the substrate. The unintended consequence of unproductive catalysis is 
not only stalled metabolism of substrates but also the creation of radical oxygen species 
(ROS). 
 
There are three main pathways in which uncoupled catalysis can occur in CYPs. 
The first is the autoxidation pathway in which the free radical superoxide (O2-) is 
released from the Fe(III) complex, shown in step 4 in Figure 1.1 and Equation 1.2. 
Superoxide is quickly converted to hydrogen peroxide (H2O2), another potentially 
damaging compound. The second pathway is the peroxide shunt (Equation 1.3), in 
which H2O2 is released from the Fe(III) complex, shown as step 6 in Figure 1.1 
reverting to the HS Fe(III) state (Figure 1.1, step 2). This pathway can also be exploited 
to jumpstart catalysis without the presence of reducing agents (NADPH), as shown in 
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Equation 1.4. Addition of H2O2 allows for steps 3–5 to be skipped and still get 
productive metabolism of substrate. The peroxide shunt has been used to bypass the 
need for expensive reducing agents for CYP catalysis for large-scale biotechnical 
applications.24 The oxidase pathway is the third uncoupling pathway possible in the 
CYP catalytic cycle, shown in Equation 1.5. Compound I, which in itself is a radical, 
has very high reduction potential, which can lead to it being reduced twice more, 
leading to the formation of a second water molecule if misregulated.  
Several factors lead to uncoupled catalysis, including but not limited to identity 
of the substrate/inhibitor bound 25-28, mutation of residues 7, 17, 29, source of electrons 30-
32 (ex. Cytochrome b5 vs. FAD-FMN reductase), and enzyme promiscuity.33-35 
Regardless of cause, the immediate result of ROS production is damage to the enzyme 
itself, leading to decrease in function, degradation, and aggregation.36 In humans, the 
highest concentration of P450s are found in the liver, but CYPs are also present in the 
majority of organ systems. On a molecular level, the creation of ROS by CYPs leads to 
lipid peroxidation, protein degradation, and cell death. Over time, these molecular 
damages build up and are implicated in aging37-39, carcinogenesis40-42, and several other 
disease states.   
1.1.2 CYP chemistry 
 The canonical CYP reaction is insertion of oxygen into an unactivated C-H 
bond, as seen in the first step of modification of the chemotherapeutic 
cyclophosphamide by liver CYPs (Figure 1.2). Though hydroxylation is an important 
reaction catalyzed by CYPs, they are capable of carrying out a diverse range of 
reactions, including but not limited to sulfoxidation, oxidation, and oxidative 
dehalogenation (Figure 1.3). Of particular interest to xenobiotic metabolism is O- and 
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N-dealkylation (Figure 1.3) as many compounds go through this process to become 
more hydrophilic before elimination.  
 
As CYPs are capable of such complex chemistries, efforts have been made to 
harness their power for biotechnical applications, with an emphasis on controlling 
selectivity and specificity. Highlighting the importance of this field of research is the 
fact that Professor Frances Arnold won the 2018 Nobel Prize in Chemistry for her work 
on directed evolution of enzymes. Much of her research has been dedicated to 
engineering enzymes (particularly CYPs) to perform specific chemistries with high 
efficiencies and sufficient stability for use for commercial purposes.  
This use of engineered enzymes is particularly prominent in the development of 
pharmaceuticals. Whenever a new drug is tested, all metabolites that are made formed 
with percentages over a certain threshold must also be tested for toxicity. Many of these 
metabolites are difficult to synthesize, and those that can be made often use protocols 
that entail the use of harsh chemicals that are bad for the environment. As a result, a 
more efficient source is needed, and biocatalysts are a good solution. In addition, 
 
Figure 1.2. Insertion of oxygen into an inactivated C-H bond as shown by 
chemotherapeutic cyclophosphamide. 
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chemistry performed on a large scale can lead to significant impurities, which means 
extra steps are needed to purify the molecule of interest. 
 
In 2013, Dennig et al. showed that introduction of three mutations 
(R47S/Y51W/I401M) to cytochrome P450BM3 (CYP102A1), a bacterial CYP, made it 
able to hydroxylate monosubstituted benzene rings in the ortho-position, with a 
selectivity of 99:1 as compared to the meta- and para-positions. This finding is 
interesting as it means P450BM3 has potential to be used to make precursors for further 
synthesis of vitamins, flavorings, and several drug molecules.43 The L75/V78/F87 
P450BM3 variant was able to selectively hydroxylate and epoxidize β-cembrenediol, a 
terpenoid natural product, that is being investigated for its antitumor, anti-
 
Figure 1.3 Possible reactions performed by Cytochrome P450s. 
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inflammatory, and neuroprotective properties. Of 13 possible hydroxylation positions 
and three epoxidation positions, these three mutations only hydroxylated the substrate 
at 2 specific positions (C-9 and C-10), and introduced the epoxide at one position. 
However, this increase in specificity came at the detriment of coupling efficiency, with 
the highest reported as 56%.44 Reactivity can also be tuned by changing the residue 
ligated to the heme. Wang et al. showed that mutating the cysteine to a histidine 
diminished the oxidation abilities of P450BM3 but allowed it to be competent as a 
catalyst for cyclopropanation. Cyclopropanation of N,N-diethyl-2-phenylacrylamide 
and ethyl diazoacetate by His-ligated BM3 (with 4 added mutations) produced 
levomilnacipran, a serotonin-norepinephrine reuptake inhibitor used to treat 
depression. Surprisingly, levomilnacipran was produced with a yield greater than 92% 
in anaerobic conditions and 90% when aerobic. Diastereoselectivity of 98% was 
obtained, favoring the cis form with enantioselectivity of 92%.45 
1.2 Human Cytochrome P450s 
Human cytochrome P450s have evolved to be a very diverse family of enzymes. 
They are found in all organs, are involved in a variety of processes, and, if misregulated, 
can be involved in a plethora of disease states. Of the approximately 60 human CYPs, 
most have been characterized, though six still have unknown functions. Of the known 
CYPs, 12% are located in the mitochondrial membrane (Figure 1.4A) and are of the 
class I electron transfer type (electron transferred to CYP via ferredoxin reductase 
(FdR) and Fe-S containing ferredoxin (Fdx) proteins).46 All 12% are selective and 
modify steroids or are involved in vitamin D metabolism. The remaining majority of 
CYPs are localized in the endoplasmic reticulum (ER) and utilize the class II electron 
transfer system (electron transferred to CYP via FAD-FMN containing cytochrome 
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P450 reductase (CPR)) to carry out catalysis.46 Those in the ER range from being 
selective and only able to modify steroids, fatty acids, or vitamins (Figure 1.4C), to 
being extremely promiscuous. CYP3A4 is an example of a promiscuous CYP and 
metabolizes over 50% of xenobiotics in the liver (Figure 1.4D). This highlights the 
fascinating fact that one family of enzymes, all with similar structures, is able to 
perform a wide variety of functions.  
 
Figure 1.4 Human Cytochrome P450 characteristics. 
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1.2.1 Role in steroid and fatty acid turnover 
One of the main functions of human P450s is their role in steroid and fatty acid 
modification. All steroids have the same base structure of four fused rings, and differ 
in the functional groups on those rings, as shown in cholesterol (Figure 1.5A). In 
humans, steroids are necessary for sodium and potassium transport, stimulation of 
gluconeogenesis, and transport and synthesis of amino acids. This is in addition to the 
more commonly known roles, such as cortisol in the fight or flight response, and sex 
hormones in defining secondary sexual characteristics. Cytochrome P450s are involved 
in nearly every avenue of steroid synthesis or metabolism. For example, lanosterol 14α-
desmethylase (CYP51A1) removes 2 methyl groups from lanosterol, a necessary step 
in cholesterol formation that allows it to further differentiate into bile acids and 
hormones.  
 
Six CYPs are involved in the formation of hormones from cholesterol in a 
tightly regulated system. They are also extremely selective; for instance, CYP19A1 
(aromatase) selectively binds androstenedione and testosterone and converts them to 
 
 
Figure 1.5  Structure of an example (A) steroid and (B) fatty acid that both undergo 
modification by CYPs. 
A) B) 
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estrone and estradiol, respectively. Though this system is tightly regulated, loss of 
function and gain of function mutations occur. Inversions in the CYP19A1 gene cause 
it to be regulated by a different promotor, which leads to overexpression of the enzyme, 
leading to aromatase excess syndrome, resulting in shorten stature, osteoporosis, early 
onset of puberty, irregular menstrual cycles in females, and gynecomastia in males.47, 
48 Conversely, lack of CYP19A1 expression leads to aromatase deficiency syndrome, 
in which pseudo-hermaphroditism is reported in females and hypervirilization in 
males.49  
Fatty acids, like steroids, also play several important roles in the human body. 
An example structure, arachidonic acid, is shown in Figure 1.5B. There are two main 
classes: saturated and unsaturated fatty acids. Saturated fatty acids mostly come from 
animal sources, are linear, and tend to pack together, making them solid at room 
temperature. Unsaturated fatty acids usually come from plant and fish sources, contain 
double bounds that causes them to kink, and are liquid at room temperature. 
Unsaturated fatty acids are mostly obtained from our diet, and as they are integral to 
cell membranes, are necessary to maintain shape and porosity of our cells.50 In addition 
to allowing normal metabolic processes to occur,51 unsaturated fats are cardioprotective 
in that they decrease blood pressure and decrease aggregation of blood cells.52, 53 They 
are also involved in movement of smooth muscle and inflammation response an several 
other processes that occur in the human body.54 
It has long been speculated that xenobiotic-metabolizing human CYPs have at 
least one endogenous substrate, and for many of them, it has been found to be 
polyunsaturated fatty acids (PUFA), specifically arachidonic acid.55 CYPs are 
responsible for modifying arachidonic acid by hydroxylation, epoxidation, and allylic 
oxidation56-58 into over 100 distinct bioactive molecules.55, 59 These metabolites can be 
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separated into various classes, including hydroxyeicosatetraenoic acids (HETEs), 
epoxyeicosatrienoic acids (EETs), leukotrienes, and prostaglandins, all of which are 
considered eicosanoids or secondary messengers in signaling pathways derived from 
PUFAs. HETEs and EETs are involved in pathways that lead to vasodilation or 
constriction, promotion or reduction of inflammation, as well as salt uptake and cell 
injury.59 Prostaglandins are important for contractions and relaxations of smooth 
muscle and cardioprotective functions,54 whereas leukotrienes are necessary in the 
signaling pathway that regulates immune responses.60  
As expected for compounds so important to homeostasis of the human body, 
this system is highly regulated. CYP8A1, also known as prostacyclin synthase, a 
member of the class X electron transfer family (CYPs that don’t have a reductase 
partner),46 hydroxylates prostaglandin H2 to prostacyclin. As prostacyclin is a potent 
vasodilator, when too much is produced, prostaglandin H2 can also act as an 
irreversible inhibitor of CYP8A1 stopping catalysis.61 Tyrosine nitration is also known 
to occur in the active site of CYP8A1 to regulate prostacyclin production.62 Changes in 
expression of CYP8A1 that lead to a decrease in prostacyclin production can lead to 
pulmonary hypertension and cerebral infraction.63, 64  
1.2.2 Role in xenobiotic metabolism 
Most xenobiotic metabolism by CYPs in humans occurs in the liver, where 
enzymes convert their substrates into more hydrophilic products that can then be 
excreted from the body. In addition to breakdown of substrates, xenobiotic 
metabolizing CYPs can also activate prodrugs as well as create toxic by-products. 
CYP3A4 is the most prevalent and promiscuous P450 in the liver, making up 
approximately 30% of expressed CYPs in the liver and metabolizing over 50% of 
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current pharmaceuticals.65 To accomplish this, 3A4 has an extremely large and flexible 
active site that is able to accept molecules as large as the antibiotic erythromycin and 
the immunosuppressant cyclosporin, to smaller molecules such as the three ring 
containing omeprazole and two ring containing nifedipine.66 One way these large 
molecules are accommodated is that, unlike other xenobiotic-metabolizing CYPs, 
helices F and G, which are usually positioned directly over the active site and are 
considered its “lid” aren’t positioned this way for 3A4, and have less of a defined helical 
structure.67 The result of the flexibility and therefore promiscuity of CYP3A4 is a 
decrease in stability68 and an increase in drug interactions, whether from induction, 
inhibition, or activation.65  
As a direct consequence of their ability to eliminate foreign substances from the 
body, xenobiotic metabolizing P450s are implicated in the creation of mutagenic, 
carcinogenic, and toxic metabolites. It is thought that at least three-fourths of all 
possible carcinogens must first be activated by P450s.69, 70 Of particular interest is the 
role of the CYP1 family (CYP1A1, CYP1A2, and CYP1B1) in the activation of 
polycyclic aromatic hydrocarbons (PAHs). These planar aromatic compounds are very 
hydrophobic, making them a good substrate for the hydrophobic active site of 
cytochrome P450s. CYP1 enzymes hydroxylate PAHs, and, with the help of epoxide 
hydrolase, make compounds that can covalently bind and damage DNA.71 
Compounding the problem is the fact that PAHs induce expression of CYP1 enzymes 
by binding to the arylhydrocarbon receptor,72 so that the presence of PAHs leads to an 
increase in the concentration of their carcinogenic metabolites. Xenobiotic 
metabolizing CYPs convert exogenous compounds to carcinogens, but they can also do 
the same with endogenous compounds. One of the most prevalent examples of this is 
estrogen metabolism. CYP1B1 hydroxylates 17β-estradiol in the 4-position instead of 
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the 2-position, unlike other P450s,73 which leads to a compound able to covalently 
modify DNA; this has been identified as leading to progression of breast cancer.74 As 
CYP1B1 is mostly expressed in tumors as opposed to healthy tissue, one 
chemotherapeutic strategy is to selectivity inhibit 1B1 so it will no long be able to 
interact with procarcinogens, estradiol, and won’t be able to inactivate other 
chemotherapeutics used to fight the disease.75-77 
 
Xenobiotic metabolizing CYPs are also investigated for their role in activating 
pro-drugs. The use of pro-drugs in the fight against disease is an attractive strategy as 
the drug isn’t activated until an action is done upon it. This makes targeted delivery 
possible, therefore limiting unexpected reactions and decreasing side effects. As a 
chemotherapeutic strategy, currently, most prodrugs are made active by an oxidative 
mechanism, as shown in Figure 1.2, with the hydroxylation of cyclophosphamide. The 
drawback of oxidative activation is that it usually occurs in the liver, and therefore the 
activated drug must travel to the affected area, causing potentially negative interactions 
with healthy tissues along the way.78 As this is a large drawback, more recent strategies 
involve targeting CYPs overly expressed in tumors as well as those that use reductive 
 
Figure 1.6 Activation and deactivation of a 2-aryl-benzothiazole by CYPs.77 
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mechanisms to be activated. An example of the first strategy is 2-aryl-benzothiazoles.79-
82 Though these compounds have not yet entered clinical trials, they are activated by 
CYP1A1 and CYP2W1, where metabolites can either form DNA adducts or revert to 
the prodrug form by CYP2S1 (Figure 1.6).78 Neither of these enzymes is expressed in 
the liver, and CYP2W1 and CYP2S1 have been found to be more highly expressed in 
tumors as opposed to healthy tissue.83-85  AQ4N (Figure 1.7) is an example of a prodrug 
that uses a reductive mechanism for activation, which is especially important as tumors 
have a hypoxic core, making it difficult for reactions that involve insertion of oxygen 
to proceed. AQ4N is a topoisomerase II poison that is anaerobically activated by 
deoxygenation by CYP3A4, CYP2W1, and CYP2S1.86 
 
A third promising strategy to develop prodrugs combines manipulation of CYP 
activity, coordination compounds, and photodynamic therapy (PDT). As proof of 
concept we synthesized three ruthenium (II) complexes with coordinated P450 
inhibitors (Figure 1.8). When irradiated with light, the inhibitors were released from 
the complex and bound to the P450, while the remaining Ru complex was able to 
interact with DNA as a dual targeting strategy. Compound 3, after exposure to light 
inhibited P450 activity with an IC50 of 0.05 ± 0.00 µM, while simultaneously inducing 
DNA damage that significantly diminished protein production.87 
 
Figure 1.7 Reductive activation of the prodrug AQ4N by CYPs.84 
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1.3 Bacterial Cytochrome P450s 
Since the discovery of the first bacterial P450 isolated from a Rhizobium spp. in 
1967,88 over 1,000 bacterial P450s have been classified and named.89 Unlike their 
eukaryotic counterparts, bacterial P450s were found to be soluble, use more diverse 
electron transfer systems, and have a wider variety of functions. Additionally, unlike 
eukaryotes that need CYPs to survive, many bacteria, including Escherichia coli, don’t 
express any P450s. As P450s are mostly nonessential in bacteria, their main roles are 
in formation of secondary metabolites, detoxification, and enabling growth on 
alternative carbon sources.90   
Of the bacterial P450s, P450cam (CYP101) isolated from Pseudomonas putida 
is considered the archetypal P450 and is perhaps the most studied. P450cam, a class I 
P450, catalyzes the 5-exo hydroxylation of camphor that can be used as a carbon source 
for P. putida. P450cam was the first P450 for which the crystal structure was solved7 
and has been instrumental in piecing together the elusive steps of the P450 catalytic 
cycle.8, 16, 18, 91-93 
 
Figure 1.8 Ru(II) complexes capable of P450 inhibition and DNA damage.87 
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1.3.1 P450BM3 – Use as a model system 
 
Competing with P450cam for most studied bacterial P450 is CYP102A1, 
commonly referred to as P450BM3 (Figure 1.9). P450BM3 was first isolated from Bacillus 
megaterium by Miura and Fulco in 1974 as a “system” able to hydroxylate fatty acids.94 
Over a decade later, in 1986, Narhi and Fulco demonstrated the novel (at that time) 
finding that this system is a self-sufficient P450 with a high binding affinity for medium 
to long chain fatty acids.95 In a subsequent publication, Narhi and Fulco showed that 
P450BM3 is self-sufficient as a result of having a mammalian CPR-like FMN-FAD 
reductase fused to the heme domain.96 This fusion allows for extremely efficient 
turnover, and P450BM3 is considered to be the CYP with the highest activity discovered 
to date, with a kcat of 17,000 min-1 for hydroxylation of arachidonic acid.97  
Due to the solubility of P450BM3 and its similarity to class II mammalian 
microsomal CYPs, P450BM3 has been heavily investigated as a model system.15 
P450BM3 can be purified in its full-length form, or alternatively, just the heme or 
 
Figure 1.9 Crystal structure of the heme domain of wild type P450BM3 (PDB ID 
4ZFA). 
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reductase domains separately. As a result, studies on electron transfer can be performed 
that are extrapolated to class II P450s. Particular attention has been focused on the 
impact of how the linker connecting the reductase and heme domains of P450BM3 
modulates how the two partners interact, as compared to the CPR and it’s P450 partners. 
Both the reductase domain of P450BM3 and CPR bind close to the Cys-ligand loop of 
the P450 via the FMN-containing portion of the reductase so that electrons can be 
transferred easily to the heme.  
 
Differences are apparent in how this binding occurs, as P450BM3 interactions 
between the domains can be attributed mostly to weak electrostatic affects seen by 
complementary surface potentials on both domains. In contrast, CPR-P450 binding 
seems to be driven by ionic forces, as there is a cluster of negatively charged residues 
on the CPR surface where it interacts with its P450 partner.2 The impact of this 
difference in residues manifests in the reduction potentials of the FMN cofactor. The 
negatively charged residues at the CPR surface leads to destabilization of the FMN 
 
Figure 1.10 FMN quinone electron cycling that details how electrons are transferred 
in the CYP reductase partner. 
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semiquinone (FMNH), the one e- reduced species, and stabilization of the FMN 
hydroquinone (FMNH2), the two e- reduced species, so that electron transfer to the 
heme occurs from FMNH2 (Figure 1.10). In P450BM3, the hydrophobic and neutral 
residues at the reductase surface lead to a stabilization of FMNH over FMNH2 so that 
electron transfer occurs from FMNH to the substrate bound heme.2 Electron transfer 
from FMNH allows for quick transfer to the heme but also gives P450BM3 tighter control 
of catalysis to decrease the rate of uncoupled catalysis, which is especially important 
as the two domains are connected.  
P450BM3 is naturally a selective enzyme, but mutations can be made that make 
it more promiscuous, and thus similar in function to xenobiotic metabolizing human 
CYPs. Mutagenesis allows for study of the role of residues important for P450BM3 
catalysis, but also the study of conserved residues in order to elucidate their function. 
In addition, the biophysical properties of promiscuous P450BM3 variants can be 
compared to the selective WT enzyme to determine the impact of promiscuity on 
enzyme structure and function. For example, we showed that mutations that increased 
promiscuity of P450BM3  also decreased its stability as a result of a decrease in the 
number of highly stabilizing salt bridges and disruptions to the hydrophobic core.98  
Though there is a decrease in stability, non-native substrates are still able to bind 
favorably by overcoming negative repulsive and electrostatic effects with positive 
dispersion forces with active site residues.98  
1.4 Summary 
Cytochrome P450s are a large family of enzymes that are of continual interest 
to the scientific community due to their role in human health, prevalence in nature, vast 
chemical repertoire, and many more factors. Though much is already known, there are 
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still gaps in our understanding, and methods by which these enzymes can be 
manipulated to our advantage. This dissertation focuses on the biophysical properties 
of P450s to attempt to fill some of these knowledge gaps. Specifically, it focuses on the 
impact of substrate selectivity and iron oxidation state on enzyme stability and function 
as well as how P450s can be exploited to make new potential drug candidates.  
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 EFFECT OF MUTATION AND SUBSTRATE BINDING ON THE 
STABILITY OF CYTOCHROME P450 BM3 VARIANTS. 
Chapter adapted from: Geronimo, I., Denning, C. A., Rogers, W. E., Othman, 
T., Huxford, T., Heidary, D. K., Glazer, E. C., Payne, C. M. (2016). "Effect of mutation 
and substrate binding on the stability of cytochrome P450BM3 variants." Biochemistry 
55: 3594-3606. 
Author Contributions: IG, ECG, DKH, TH, and CMP designed the study, analyzed 
the data, and wrote the paper. IG conducted the molecular dynamics simulations. CAD 
and DKH expressed and purified the proteins, conducted the stability assays, and 
analyzed the data. WER, TO, and TH crystallized the proteins and solved the structures.  
2.1 Introduction 
Protein stability pertains to (a) thermodynamic stability, the resistance to 
unfolding defined by the free energy difference between the folded and unfolded states 
(ΔGstab), and melting temperature (Tm, the temperature at which 50% of the protein is 
unfolded), and (b) kinetic stability, the resistance to irreversible inactivation defined by 
the half-life of the enzyme (t½) at a specific temperature.99, 100 These two definitions of 
stability involve different processes but are usually related when the protein follows the 
classical two-step process , where the native structure (N) first undergoes 
reversible unfolding to an intermediate state (I), leading to an irreversibly 
denatured/unfolded state (U), and eventually, to permanent inactivation due to 
aggregation, misfolding, covalent changes, cofactor loss, or oxidation of sulfur-
containing residues.100-103  
Traditionally, thermodynamic stability has been thought of in regards to 
unfolding of an enzyme as a result of temperature, in which a Tm is determined. 
23 
Alternatively, thermodynamic stability can be probed by chemical denaturation in 
which a Cm – concentration midpoint (denaturation concentration at which the protein 
is 50% unfolded) is determined. Though chemical denaturation is highly amino acid 
dependent, it has been found that thermal and chemical denaturation impact protein 
unfolding in comparable fashion.104, 105 In addition, similar ∆Gfolding  values are reported 
from chemical denaturation and temperature studies when extrapolated to no chemical 
denaturant or low temperature.106, 107 A linear relationship has also been established 
between denaturation with urea and temperature the caveat being a deviation at high 
urea concentrations,108 Chemical denaturation of proteins can be studied in a variety of 
solvents, at various temperatures, and by a plethora of techniques including UV-Vis, 
circular dichroism (CD), fluorescence, and many more. Though kinetic stability may 
be a more important parameter in cost-effective industrial enzyme utilization, 
thermodynamic stability is inextricably linked to kinetic stability through the unfolding 
process. As increasing resistance to unfolding, via any mechanism, will likely also 
enhance kinetic stability, we focus our work on thermodynamic stability given the 
relative accessibility of thermodynamic stability as an engineering target.  
Human health and biotechnical applications are two fields in which 
understanding thermodynamic stability of proteins is crucial. Cytochrome P450s 
(CYPs) are a super family of heme dependent monooxygenases that have essential 
functions in organisms from all domains of life. Humans have approximately 60 CYP 
enzymes that are necessary for steroidogenesis and xenobiotic metabolism. CYPs 
involved in steroidogenesis tend to be selective whereas those involved in xenobiotic 
metabolism tend to be more promiscuous and turnover a wider variety of substrates. 
Many disease states, including certain cancers,109, 110 liver diseases,111-113 glaucoma,114-
116 and vitamin deficiencies117, 118 can be traced to mutation and misregulation of 
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particular CYPs. Mutations, in particular, impact protein folding, which can therefore 
lead to differences in stability. Understanding the thermodynamic stability of enzymes 
in various disease states could help develop possible remedies to improve those 
afflicted.   
Additionally, compounds and drugs made for commercial use are produced in 
large-scale preparations that often involve the use of harsh and toxic chemicals that 
have to disposed of. Using biocatalysts, such as CYPs, is an attractive solution as 
reactions can be done without the use of organic solvents and the chemistry done can 
be highly tuned. One of the main drawbacks to this strategy reaching fruition is the 
lowered stability of enzymes typically able to perform the reactions of interest. 
Understanding how to increase enzyme stability while not impacting their activity is of 
extreme importance.  
Cytochrome P450BM3 (CYP102A1) is a bacterial CYP from Bacillus megaterium 
that has been extensively studied in recent years because of its potential as a biocatalyst 
in the production of fine chemicals, environmental remediation, as well as a model for 
human CYPs. P450BM3 is an excellent candidate because it has the highest known 
monooxygenase activity among the P450 enzymes,97 which is attributed to efficient 
electron transfer due to fusion of the mammalian-like FAD-FMN reductase and heme 
domain in the single polypeptide chain.119 P450BM3 catalyzes the hydroxylation and/or 
epoxidation of fatty acids, fatty amides, and alcohols but can be engineered to bind non-
native substrates. Random mutagenesis and directed evolution have produced more 
promiscuous variants capable of catalyzing the oxidation of non-native substrates, 
particularly drugs normally metabolized by human P450s. For example, P450BM3 
containing the D251G and Q307H mutations is active toward nonsteroidal anti-
inflammatory drugs,120 that containing F87V and A82F toward proton pump 
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inhibitors,121 and that containing R47L, F87V, and L188Q  [triple mutant (TM)] toward 
drug-like molecules such as dextromethorphan and 3,4-
methylenedioxymethylamphetamine. 122 123 
There has been interest in using TM P450BM3 as a platform from which to develop 
additional variants that exhibit activity toward other nonnative substrates.124-127 A prior 
computational study of TM, as well as the R47L/F87V/L188Q/E267V quadruple 
mutant (QM) and R47L/F87V/L188Q/E267V/F81I pentuple mutant (PM), linked the 
enhanced catalytic activity of the mutants to the more closed conformation of the 
substrate channel and possibly to electrostatic effects resulting from the bending of 
heme propionate A toward the active site.128 Mutations that are beneficial for nonnative 
substrate catalysis, however, often cause loss of protein stability, limiting the 
application of P450BM3 mutants as industrial biocatalysts. It also precludes their use as 
a starting point in engineering more promiscuous and active variants, as they are less 
tolerant of destabilizing mutations that may be required for nonnative substrate 
binding.129-131  
Effective means of overcoming the destabilization of TM (and other variants 
derived from it) remain largely unknown because the mechanisms behind the 
phenomenon are not well understood. In the case of full-length wild-type (WT) 
P450BM3, the relatively low stability results from the low Tm of the reductase domain 
(47.5°C) compared to the heme domain (64.9°C and a shoulder at 58.7°C) as 
determined by differential scanning calorimetry.132 The appearance of a shoulder at the 
lower temperature for heme domain unfolding suggests WT may unfold by a biphasic 
transition. Thus, one approach to improving stability has been to replace the reductase 
domain with a more thermostable analogue, for example, that of CYP102A3.133 
However, chimeras such as this generally have lower coupling efficiencies and turnover 
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rates.134 Alternatively, Arnold, et al. developed an efficient peroxide-driven variant of 
the P450BM3 heme domain, 21B3, which requires neither the reductase domain nor 
NADPH or O2.24 The 21B3 variant has since been used as a starting point to create 
more thermostable variants through directed evolution,129, 135, 136 though this approach 
suffers from the required time-intensive variant screening process. 
As a rational approach to selection of mutation sites for the stabilization of 
P450BM3 variants, the molecular-level contributions to the stability of the heme domain 
were determined using biochemical, structural, and computational methods. As the 
heme domain can be used as a catalytic center using the peroxide shunt, the studies 
were focused on this one domain. The stabilities of WT, TM, QM, PM, and the single 
mutants E267V and F81I, in the presence and absence of small active site ligands, were 
experimentally measured by chemical denaturation using pulse proteolysis and circular 
dichroism (CD).137 Structural data for WT and PM, as well as PM in complex with the 
native substrate, palmitic acid, and the inhibitor, metyrapone, were obtained to directly 
examine the effects of mutation and binding. High-temperature molecular dynamics 
(MD) simulations were performed to model the unfolding process and describe the 
interactions underlying the biochemical results. Labile regions in PM, which can be 
targeted for mutation to improve stability, were identified based on the experimental 
and computational findings. 
2.2 Experimental procedures 
2.2.1 Biochemical procedures 
2.2.1.1 Cloning and site-directed mutagenesis of P450BM3 
The heme domain (Thr 1 to Thr 463) of P450BM3 containing a C-terminal 6xHis 
tag was cloned into the pCWori vector. All point mutations were incorporated into the 
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heme domain using the QuikChange (Stratagene) site-directed mutagenesis procedure. 
The DpnI-digested PCR reaction was transformed into ultracompetent cells 
(Stratagene) and screened for ampicillin resistance. Colonies were grown in Luria Broth 
with 100 μg/ml ampicillin, followed by plasmid isolation. All mutations were 
confirmed by sequence analysis (Eurofins Scientific). 
2.2.1.2 Expression and purification 
The P450BM3 heme domain proteins were expressed in E. coli BL21(DE3) cells. 
Cells were grown in 1 L of Terrific Broth at 37°C with shaking at 180 rpm until an 
OD600 of 0.7–0.8 was reached. Protein expression was then induced with addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM. 
Expression was continued for 20 h before the cells were harvested by centrifugation at 
4000 xg for 15 min at 4°C. The supernatant was decanted, and the cell pellet was stored 
at -80°C. For purification, the cell pellets were resuspended in Buffer A (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, and 0.1 mM EDTA, pH 8.0 with the 
addition of 0.1 mM phenylmethylsulfonyl fluoride. Lysis was then carried out by 
sonication on ice for 15 min using a microtip with output control of 3 and duty cycle of 
50% (Branson Sonifier 250). Cell debris was cleared by centrifugation at 20000 xg for 
1 h at 4°C. The supernatant was decanted and passed through a 0.45-μm 
polytetrafluoroethylene filter before loading onto a His-Trap column (GE Healthcare) 
equilibrated with five column volumes of Buffer A. The protein was eluted over a 
gradient where the imidazole concentration was linearly increased from 20 to 200 mM 
using buffer B (50 mM NaH2PO4, 300 mM NaCl, and 20 mM imidazole, pH 8.0). The 
fractions containing heme-bound protein were identified by measuring absorption at 
420 nm by UV-Vis spectroscopy (Figure A1), and concentrated to approximately 2 ml 
using Amicon Ultracel-30K Millipore centrifugal units at 4500 xg and 4°C. The protein 
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was then loaded onto a Hi-Prep 26/60 Sephacryl S200 HR column equilibrated in 20 
mM Tris and 150 mM NaCl, pH 8.0. Protein fractions containing an A420/280 absorption 
ratio >1.4 for WT, >1.3 for TM, and >1.2 for F81I, QM, and PM were collected and 
concentrated to between 10 and 20 mg/ml using an Ultracel-30K centrifugal filter unit. 
For E267V, the protein was isolated in the high-spin state, so fractions with an A394/280 
of >1.3 were collected and concentrated. Protein concentration and quality was 
determined by CO binding (Figure A2).138 For storage, glycerol was added to the 
protein for a final concentration of 20%, and aliquots were frozen in a dry ice ethanol 
bath and placed at -80°C. 
2.2.1.3 Pulse proteolysis 
The pulse proteolysis procedure was adapted from the work of Park and 
Marqusee.139 The protein was prepared by thawing on ice followed by buffer exchange 
into 10 mM Tris (pH 7.4) using a Micro Bio-Spin 6 chromatography column (Bio-Rad). 
The protein was then diluted to 1.7 mg/ml in pulse buffer (20 mM Tris, 10 mM CaCl2, 
and 20 mM NaCl, pH 7.4) with urea added to achieve concentrations ranging from 0 to 
6.8 M. The samples were then incubated for 2 h at room temperature. For experiments 
involving ligands, the midpoint concentration required to saturate binding (Kd) was first 
determined by measuring the change in heme absorption as a function of ligand 
concentration. The protein was then equilibrated in pulse buffer containing the ligand 
at 10x the Kd for 10 min prior to the addition of urea. 
After incubation with urea, thermolysin was added to the solution at a final 
concentration of 0.6 mg/ml, gently vortexed to mix, and allowed to react for 1 min at 
room temperature. The reaction was immediately quenched by addition of EDTA to 
give a final concentration of 37 mM and placed on ice. Laemlli sample buffer was 
added, and the samples were placed at 95°C for 1 min, followed by centrifugation for 
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30 s at 17000 xg. Samples (7 μg P450BM3) were resolved on a 4–12% Tris-glycine gel, 
followed by Coomassie Blue staining. Gels were then imaged and quantified using a 
ChemiDoc™ MP equipped with Image Quant software (Biorad), where the intensity of 
the P450BM3 bands were quantified and plotted against urea concentration. The 
concentration midpoint (Cm) was determined by normalizing the data to the fraction 
folded at 0 M denaturant. The data were fit on Graphpad Prism software with a 
sigmoidal dose response equation with variable slope. Cm values were averaged and 
error is reported as the standard deviation from three replicate experiments. 
2.2.1.4 Circular Dichroism 
The heme domain was equilibrated with urea (varying from 0 – 6.8 M) at a 
concentration of 1.7 mg/ml for near UV-visible spectra and 0.1 mg/ml for far UV 
spectra at room temperature as described above, and spectra were taken using a Jasco 
J-815 CD Spectrometer. Due to spectral interference, far UV spectra were taken from 
190–250 nm in 50 mM KH2PO4 buffer at pH 7.6, while near UV-visible spectra were 
taken between 300 and 450 nm with the sample in 20 mM Tris, 10 mM CaCl2, and 20 
mM NaCl at pH 7.6. The addition of ligands was carried out as described for pulse 
proteolysis. The change in ellipticity at 222 and 415 nm was determined and the data 
plotted as a function of urea concentration. 
2.2.2 Crystallography procedures. 
2.2.2.1 Complex formation for crystallization 
Separate samples of both purified WT and PM P450BM3 heme domain proteins 
were diluted in 20 mM Tris-HCl and 150 mM NaCl (pH 8.0) to a final concentration 
of 20 mg/ml with either 3 mM metyrapone (Sigma) or 5 mM sodium palmitate (Sigma). 
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Free protein and small molecule complexes were flash frozen in liquid nitrogen and 
stored in 50 μl aliquots at -80 °C. 
2.2.2.2 Crystallization 
P450BM3 heme domain protein crystals and complex co-crystals were grown at 
room temperature by the hanging-drop vapor-diffusion method. One microliter of 
protein or protein:small molecule complex (~20 mg/ml) was mixed with 1 μl of 
reservoir solution containing 0.10–0.25 M NiCl2 and 5–10% polyethylene glycol 
monomethyl ether (PEG 2000 MME) and then suspended in a sealed compartment over 
1 ml of reservoir solution. Ruby red hexagonal disc crystals grew to a final size of up 
to 0.3 × 0.3 × 0.2 mm in 3–4 days. 
2.2.2.3 Diffraction data collection and processing 
P450BM3 heme crystals and ligand-bound co-crystals were harvested with nylon 
loops and immersed in reservoir solution supplemented with 20 or 30% ethylene glycol 
before being flash-cooled directly in liquid nitrogen. Diffraction data were collected at 
100 K with 0.1° oscillations in continuous (shutterless) mode on a Pilatus-6MF pixel 
array detector at Advanced Photon Source (Argonne National Laboratory) NE-CAT 
Beamline 24ID-C. Because of one large unit cell dimension (c = 705–720 Å) in the 
crystals, diffraction data were collected using a mounted mini-kappa goniometer at a 
crystal-to-detector distance of 900 mm. Raw diffraction intensities were indexed, 
integrated, and scaled in X-ray Detector Software as part of the RAPD package.140 Data 
collection statistics are presented in Table 2.1. 
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Table 2.1 Data Collection, Structure Solution, and Model Refinement Statistics of 
Forms of the P450BM3 Heme Domain. 
 Wild-type  Pentuple mutant 
 No substrate  No substrate Metyrapone Palmitic acid 
Data Collection      
X-ray source APS 24ID-C  APS 24ID-C APS 24ID-C APS 24ID-C 
Wavelength (Å) 0.9792  0.9792 0.9792 0.9792 
Space group P6522  P6522 P6522 P6522 
Unit cell (Å)      
a 55.5  56.0 55.9 55.9 
b 55.5  56.0 55.9 55.9 
c 717.7  711.2 711.0 707.6 
Molecules/asymmetric 
unit 
1  1 1 1 
Resolution rangea 179.44-2.76 
(2.91-2.76) 
 177.81-2.77 
(2.92-2.77) 
177.76-2.77 
(2.92-2.77) 
176.89-2.84 
(2.99-2.84) 
Rsymm 0.077 (0.435)  0.070 (0.323) 0.065 (0.373) 0.091 (0.431) 
Observations 135,949  136,501 134,033 127,981 
Unique reflections 18,145  18,183 18,059 16,866 
Completeness (%) 97.0 (80.2)  97.2 (80.6) 96.2 (74.7) 98.5 (92.3) 
Redundancy 7.5 (3.5)  7.5 (3.4) 7.4 (3.7) 7.6 (5.0) 
Average intensity (I/σ) 16.2 (2.3)  17.7 (3.1) 18.0 (2.4) 14.2 (2.8) 
Structure Solution by Molecular Replacement 
Probe 3NPL  3NPL   
Resolution range (Å) 10.0-4.0  10.0-4.0   
Z-scoreb 11.1  12.8   
LLGb 3113.11  3083.44   
Refinement      
Resolution range (Å) 59.83-2.77 
(2.92-2.77) 
 59.27-2.77 
(2.92-2.77) 
48.42-2.77 
(2.91-2.77) 
117.93-2.84 
(3.02-2.84) 
Unique reflections 17,928 (1,853)  17,997 
(1,228) 
17,883 (1,732) 16,706 
(2,322) 
Protein atoms 3,699  3,688 3,688 3,688 
Ligand atoms 67  67 64 69 
Water atoms 57  61 83 56 
Rwork 0.2466 (0.3347)  0.2008 
(0.2923) 
0.2176 
(0.3219) 
0.2207 
(0.3075) 
Rfreec 0.3017 
(0.4245) 
 0.2572 
(0.4153) 
0.2627 
(0.4448) 
0.2741 
(0.3784) 
Geometry      
Rmsd bond lengths (Å) 0.002  0.004 0.003 0.003 
Rmsd. bond angles (°) 0.689  0.947 0.739 0.785 
Mean B (Å2)      
    Protein 51.96  49.11 59.21 49.98 
    Ligands 46.73  46.97 49.54 45.47 
    Waters 47.97  39.33 51.77 43.22 
Clashscore 5.61  4.55 5.09 4.94 
Ramachandran plotd      
   Favored 93.9  94.3 95.5 92.6 
   Disallowed 0.2  0.2 0.2 0 
MolProbity scoree 1.71  1.62 1.64 1.72 
PDB accession code 4ZFA  4ZF6 4ZF8 4ZFB 
 a Data in parentheses are for the highest resolution shell. b PHENIX.141 c Calculated 
against a cross-validation set of 5% of the data selected at random prior to refinement. 
d MolProbity.142 e Combines clashscore, rotamer, and Ramachandran evaluations into a 
single score, normalized to the same scale as x-ray resolution. 
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2.2.2.4 X-ray structure solution and refinement. 
The X-ray crystal structures of the P450BM3 heme domains were determined by 
molecular replacement using PHASER within the PHENIX crystallography suite.141, 
143 The coordinates that were used for molecular replacement were from the P450BM3 
heme domain in space group P41212 [Protein Data Bank (PDB) entry 3NPL, no 
associated publication]. The structure was modified to remove all nonbonded atoms 
other than those in the heme prosthetic group, which were set to an occupancy of zero, 
and the sites of the five mutated amino acids were replaced with alanine. The raw data 
scaled as P622, and systematic absences along the 001 face suggested a six-fold screw 
axis along c. When rotation and translation functions were performed on the probe 
against data from 10 to 4 Å, a clear solution arose for space group P6522. The solution 
contained one complex in the asymmetric unit. Model building was conducted in 
COOT using 2FO-FC electron density maps and maximum likelihood refinement with 
REFMAC5.144, 145 Stereochemical analysis and final adjustments to the model were 
directed by MolProbity.142 WT and PM models were then used to determine complex 
co-crystal structures by removing nonbonded atoms, reassigning B-factors to 15.00 Å2, 
and performing rigid body refinement against all data to a limit of 3.4 Å. The resulting 
models were then refined against all data and the electron density of the bound small 
molecules was identified unambiguously from FO-FC difference maps. Statistics for the 
refined crystallographic models are presented in Table 2.1. 
2.2.3 MD simulations 
A total of 11 systems were simulated: (1) substrate-free WT, R47L, F81I, F87V, 
L188Q, E267V, and PM; (2) WT and PM in complex with palmitic acid (modeled as 
palmitate); and (3) WT and PM in complex with metyrapone. The enzyme was modeled 
using the AMBER ff14SB force field146 and the solvent using TIP3P.147 Force field 
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parameters for the heme-Cys moiety and partial charges for the high-spin, 
pentacoordinate form (characteristic of the substrate-bound enzyme) were taken from 
a previous study.72 Partial charges for the low-spin, hexacoordinate (water being the 
sixth ligand) form (characteristic of the substrate-free enzyme) were calculated using 
the method described therein. The suitability of the heme-Cys parameters was verified 
by monitoring the rmsd and planarity of the heme (Figure A3). Parameters for unbound 
metyrapone and palmitate were derived using the antechamber module148 at the HF/6-
31G* level to be consistent with the GAFF force field.149 The bond between the 
pyridine N and heme Fe in the metyrapone complexes was restrained using a harmonic 
force constant of 10 kcal/mol/Å and an equilibrium bond length of 2.6 Å. 
Using AMBER 14,150 production MD simulations in the NVT ensemble at 300 
K were run for 100 ns using the same simulation parameters that were used during 
equilibration. For the high-temperature simulations, 550 K was chosen for the 
observation of significant structural changes in the protein on a feasible simulation time 
scale (50 ns). A similar temperature (500 K) was used to study substrate-bound 
mesophilic (CYP101 and CYP176A) and thermophilic (CYP119, CYP231A2, and 
CYP175A1) P450s.151 Previous MD studies, employing a temperature as high as 600 
K, have demonstrated that the unfolding mechanism of an enzyme remains essentially 
the same regardless of the simulation temperature.152-154 Three independent trials, each 
with a new set of velocities, were performed for the 550 K simulations. Trajectories 
were analyzed using the cpptraj module of AmberTools 14.150, 155 Native contacts and 
salt bridge networks were determined from the 300 K simulations. A native contact is 
defined as contact between Cα atoms that is (a) at least three residues away in sequence, 
(b) is within a distance cutoff of 6.5 Å, and (c) has an occupancy greater than 67%. A 
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salt bridge is defined as interaction between the O atom of Asp/Glu and protonated N 
atom of Arg/Lys/His within a distance cutoff of 4.0 Å. 
2.2.3.1 Preparation of systems for MD simulations 
The systems were prepared using the tleap module of AmberTools 14.15078 
Initial coordinates of the substrate-free wild-type (WT) P450BM3 and 
R47L/F87V/L188Q/E267V/F81I pentuple mutant (PM) were taken from the crystal 
structures 1BU7 (molecule B)2 and 4ZF6, respectively. Substrate-free, single-point 
mutants were prepared from 1BU7 (molecule B). For the substrate-bound enzymes, 
4ZFA, 4ZFB, 4ZFD, and 4ZF8, were used as starting structures for the WT:palmitic 
acid, PM:palmitic acid, WT:metyrapone, and PM:metyrapone complexes, respectively. 
Protonation states of titratable residues were assigned based on pK values calculated 
using H++156-158 and visual inspection at pH 7.4. Asp and Glu residues were 
deprotonated, except for the buried residue E409, while Arg and Lys residues were 
protonated. H361 was assigned as HID (Nδ protonated); H116, H171, H388, and H408 
as HIE (Nε protonated); and H92, H100, H138, H285, H410, and H426 as HIP (both N 
protonated). H236 and H266 were assigned as HIP and HID in the substrate-free 
enzyme, and HIE and HIP in the substrate-bound enzyme. The total charge of WT 
P450BM3 is -7. The appropriate number of sodium ions, depending on the mutation and 
substrate present, was added to neutralize each system. Crystallographic water 
molecules were retained, and the whole system was solvated in a truncated octahedral 
box of TIP3P water,147 with a buffer distance of 12 Å between each wall and the closest 
atom in each direction. After solvation, each system consisted of approximately 53,000 
atoms.  
All simulations were performed using AMBER 14.15078 The force constants 
used are discussed in the main text. Periodic boundary conditions were applied using 
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the Particle Mesh Ewald method159 with a non-bonded cutoff of 10 Å. Energy 
minimization was done in two stages: (1) with the solute initially restrained with a 
harmonic force constant of 5.0 kcal/mol/Å2 to allow water and ions to relax, followed 
by (2) minimization of the entire system. At each stage, minimization was done using 
the steepest descent algorithm for the first 1000 steps and conjugate gradient algorithm 
for the last 1000 steps. In the case of the mutants, residues within 5 Å of the mutated 
residue were allowed to relax for 2000 steps prior to unrestrained minimization of the 
entire system.  
The system was then heated from 0 to 300 K for 50 ps with Cα atoms restrained 
with a harmonic force constant of 5.0 kcal/mol/Å2. Bonds involving hydrogen were 
constrained using the SHAKE algorithm,160 and a 2-fs time step was used for time 
integration. The temperature was controlled using Langevin dynamics161 with a 
collision frequency of 1.0 ps-1. NMR weight restraints were also used to linearly 
increase the temperature to avoid instabilities in the simulation. The system was 
equilibrated at constant pressure over a 200-ps period, during which the force constant 
was incrementally reduced (5.0, 2.0, 1.0, and 0.5 kcal/mol/Å2). Equilibration of the 
unrestrained system was then continued for 2 ns. Isotropic position scaling was used to 
maintain the pressure at 1 atm, with a relaxation time of 2 ps. As the system proved to 
be initially unstable in the case of substrate-free enzymes, heating was done in two 
stages (0–100 K for 20 ps at constant volume followed by 100–300 K for 80 ps at 
constant pressure), the duration of restrained equilibration was doubled, and a smaller 
time step of 1 fs was used. 
The final structure was used as the starting point for production simulations in 
the NVT ensemble at 300 and 550 K using a 2-fs time step. Heating from 300 to 550 K 
and equilibration of the system prior to production followed the same procedure 
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described above, except for unrestrained equilibration, which was conducted for only 
200 ps.  
2.3 Results 
2.3.1 Mutation-induced substrate promiscuity is correlated with reduced P450BM3 
stability 
  
It has previously been shown that the introduction of five mutations (R47L, 
F81I, F87V, L188Q, and E267V) into the heme domain of P450BM3 allows the enzyme 
to shift from selectively oxidizing fatty acids to modifying larger, more complicated 
 
Figure 2.1. Mutations in P450BM3 that result in substrate promiscuity destabilize the 
protein. (A) Wild-type (WT) P450BM3  (1.7 mg/ml) was equilibrated in urea for 2 
hr, followed by a 1 min incubation with thermolysin (10 mg/ml) and then resolved 
by SDS-PAGE. The upper band corresponds to P450BM3 and the lower band to 
thermolysin. The amount of intact P450BM3 was quantified for each urea 
concentration to determine the midpoint for stability. Pulse protelysis experiments 
were done at room temperature in pulse buffer (20 mM Tris, 10mM CaCl2, 20 mM 
NaCl pH 7.6). (B) SDS-PAGE of the pentuple mutant, PM, after pulse proteolysis 
at varying urea concentrations. The procedure followed was the same as that for 
WT. (C) Normalized data from panels A and B, where the fraction of intact P450BM3 
is plotted vs. urea concentration. The filled squares correspond to data for PM and 
filled circles for WT.   
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drug-like molecules.124, 127, 162, 163 To gain insight into the effect of these mutations on 
the global stability of the protein, the heme domain of WT and the promiscuous mutant, 
PM, were subjected to chemical denaturation studies (Figure 2.1). The urea 
concentration midpoint for stability (Cm) was measured for WT and PM (Table 2.2), 
with a Cm of 5.4 ± 0.5 M for substrate-free WT. The PM P450BM3 protein was much 
less stable, with a midpoint of 2.7 ± 0.2 M. Subsequent studies of WT unfolding by 
pulse proteolysis, similar to results published by Munro,132 indicated a biphasic 
unfolding with a higher Cm of 5.3 ± 0.4 M and a lower Cm of 3.2 ± 0.2 M. 
Table 2.2 Urea concentration at the denaturation midpoint (Cm, M) determined by pulse 
proteolysis for substrate-free and bound P450BM3 variants.a 
 
 
 
 
 
 
 
a Error is report as standard deviation from three independent experiments. b WT 
exhibits biphasic unfolding. The higher Cm is reported, but other experiments       
demonstrate more clear biphasic character resulting in two Cm values. 
 
Because pulse proteolysis primarily uncovers changes in tertiary structure, the 
effect of the mutations on the stability of protein secondary structure, particularly α-
helical content, was measured in the presence of urea by CD (Figure 2.2A). As 
anticipated, the WT and PM denaturation Cm values were higher than those observed 
by pulse proteolysis, with values of 5.9 M for WT and 4.1 M for PM. This is consistent 
Variant Substrate 
None Metyrapone Palmitic acid 
WT 5.4 ± 0.5b 3.9 ± 0.2 4.9 ± 0.4  
F81I 4.7 ± 0.1 4.8 ± 0.1 4.8 ± 0.1 
E267V 4.4 ± 0.1 3.6 ± 0.2 4.5 ± 0.1 
TM 3.2 ± 0.1 3.4 ± 0.2 3.3 ± 0.1 
QM 3.2 ± 0.2 4.0 ± 0.2 3.3 ± 0.1 
PM 2.7 ± 0.2 3.8 ± 0.2 2.7 ± 0.2 
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with the expectation that loss of secondary structure will require higher concentrations 
of denaturant than for disruption of the tertiary structure. The stability of the heme 
cofactor environment was also measured by following the change in the Soret region at 
415 nm (Figure 2.2B). The implication of different Cm values by various techniques 
suggests a number of intermediate states of unfolding are present that can only be found 
by probing the enzyme by numerous methods. The stability of the heme in PM was 
reduced compared to that of WT, with a Cm of 3.1 M versus a Cm  of  5.4 M for WT. In 
both cases, the stability of the heme environment was lower than that of the overall 
protein secondary structure. As the protein concentration was held constant for CD 
experiments, the difference in the baselines is the result of differentness of compaction 
(Figure 2.2A) and heme environment (Figure 2.2B) between the WT and PM. Pulse 
proteolysis of the single-point variants, E267V and F81I, and multiple mutants, TM 
and QM, indicated that all mutations had a destabilizing effect on the substrate-free 
enzyme (Table 2.2). 
 
Figure 2.2. Mutations induce destabilization of secondary and active site structure. 
(A) Changes in secondary structure measured by circular dichroism as a function of 
urea. P450BM3  (0.1 mg/ml) was incubated in varying concentrations of urea (in 50 
mM KH2PO4  buffer pH 7.6) for 2 hr before CD spectra were obtained. (B) Stability 
of the heme monitored in the Soret region. To monitor active site stability, P450BM3 
(1.7 mg/ml) was incubated in varying concentrations of urea for 2 hr before spectra 
were taken. Due to spectral interference, pulse buffer (20 mM Tris, 10 mM CaCl2, 
20 mM NaCl, pH 7.6) was used. In all plots, WT is shown as filled circles and PM 
as filled squares. 
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2.3.2 Inhibitor and substrate binding modulates stability 
The effects of inhibitor binding on the stability of WT and PM BM3 were 
measured using metyrapone, which inhibits P450 enzymes through direct coordination 
of the pyridine nitrogen with the heme Fe; this prevents the enzyme from oxidizing its 
substrate. Surprisingly, by pulse proteolysis, the stability of the WT enzyme decreased 
when it was bound to metyrapone, from 5.4 ± 0.5 to 3.9 ± 0.2 M (Figure 2.3A). The 
destabilizing effect of metyrapone on WT secondary structure was also observed by 
CD by which the Cm reduced from 5.9 to 5.1 M. The heme environment too reflected a 
disruption, with a reduction in the Cm from 5.4 to 4.7 M (Figure 2.3C, D). In marked 
contrast, the tertiary structure stability of metyrapone-bound PM increased from a Cm 
of 2.7 ± 0.2 to 3.8 ± 0.2 M (Figure 2.3B). No significant modulations in the stability of 
the secondary structure were observed by CD, with Cm values of 4.1 M vs 4.2 M (Figure 
2.3C). However, the stability of the heme environment increased, with a shift from 3.1 
to 4.1 M (Figure 2.3D). The tertiary structure of metyrapone-bound E267V was less 
stable, while the F81I, TM, and QM complexes were more stable than their respective 
substrate-free forms, with the greatest effect seen for the least stable variants (Table 
2.2). 
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The WT P450BM3 enzyme is selective for the hydroxylation of fatty acid 
substrates, such as palmitic acid. Binding requires the hydrophobic tail of the fatty acid 
hydrocarbon chain to be in the proximity of the heme for hydroxylation to occur. 
Substrate binding was expected to increase the stability of WT based on previous 
studies.164 Instead, only a minor change was observed, with a decrease to 4.9 ± 0.4 M 
determined by pulse proteolysis, and a slight decrease detected by CD, to 5.7 M. For 
PM, palmitic acid had no significant impact on the stability of the secondary structure, 
with the Cm decreasing from 4.1 to 4.0 M (Table 2.3). This was also seen with pulse 
proteolysis, where the Cm was 2.7 ± 0.2 M in the presence or absence of palmitic acid. 
The stabilities of E267V, F81I, TM, and QM were also unaffected by palmitic acid 
binding.      
 
Figure 2.3. The inhibitor, metyrapone, shifts the stability of WT and PM in opposite 
directions. (A) WT stability as measured by pulse proteolysis, where filled circles 
correspond to the enzyme without the inhibitor and open circles to the enzyme with 
the inhibitor. (B) PM stability measured by pulse proteolysis, where filled squares 
correspond to the enzyme without the inhibitor and open squares to the enzyme with 
the inhibitor. (C) Stability of the secondary structure and (D) heme environment in 
the presence of metyrapone measured by circular dichroism. For all data in panels 
(C) and (D), WT is shown as open circles and PM as open squares. 
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Table 2.3. Urea concentration at the denaturation midpoint (Cm, M) determined by CD 
of substrate-free and bound BM3 variants. 
Variant Ligand Active Site Secondary Structure 
 
WT 
None 5.4 5.9 
Metyrapone 4.7 5.1 
Palmitic acid - 5.7 
 
PM 
None 3.1 4.1 
Metyrapone 4.1 4.2 
Palmitic acid - 4.0 
 
2.3.3 X-ray crystal structure of the P450BM3 heme domain is in a closed confirmation 
 To directly observe the effects of mutation and ligand binding on the P450BM3 
structure, X-ray crystallography was conducted on WT and PM P450BM3 proteins. 
Though the conditions of crystallization differ from the experimental conditions, 
crystallization is helpful to understand the lowest energy conformations of the P450BM3 
variants. The C-terminal His-tagged proteins used in this study failed to crystallize 
under conditions reported in previous structural studies.2, 165 However, crystals of a 
unique hexagonal crystal form grew under conditions of nickel and low molecular 
weight polyethylene glycol (PEG). Refinement of the WT X-ray crystal structure was 
performed against diffraction data at a limit of 2.76 Å resolution and resulted in a model 
with excellent stereochemistry (4ZFA). The structure revealed that, in this hexagonal 
crystal form, P450BM3 exhibits the closed conformation that is typically observed in 
substrate-bound complex models (Figure 2.4A). Movement between the open and 
closed conformations involves en bloc rotation of a segment composed roughly of 
amino acids 168 to 267 that encompass helices F - I, as well as the loops that join them 
(Figure 2.4B). Helices F and G, along with helix B', form the lid domain of the substrate 
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access channel, which is lined by the F/G loop on one side and the 310 helix (residues 
16–20) and β-sheet 1 on the other (Figures 2.4C and 2.4D). 
 
Crystal packing is mediated by a nickel ion that is coordinated by amino acid 
residues D338 and E348 and the N-terminal threonine at the interface between 
crystallographic neighbors along the six-fold screw axis. However, besides slight 
changes to the side chain geometries, this interaction does little to perturb the local 
 
Figure 2.4. Crystal structures of substrate-free (open conformation) and substrate-
bound (closed conformation) WT P450BM3. The protein is shown in cartoon 
representation and the heme and residues of interest are shown in stick. (A) The 
closed conformation, represented by 4ZFA is shown in gray while the fully open 
conformation is represented by 1BU72, molecule B (green). (B) Helices F, G, and 
I undergo significant displacement upon substrate binding. A PEG molecule 
found in the substrate channel of 4ZFA is shown in ball-and-stick. E267 forms a 
salt bridge with K440 in both conformations and hydrogen bond with T438 in the 
closed conformation. F81 forms contacts with L181, F205, I209, and I263, which 
rearrange upon substrate binding. (C) and (D) The region nomenclature and 
mutated residues in PM P450BM3 are illustrated to aid in discussion. R47 is located 
in β-sheet 1, F81 in helix B', F87 between helices B' and C, L188 in helix F, and 
E267 in helix I. Crystal structure solved by W.E. Rogers, T. Othman, and T. 
Huxford. 
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structure relative to either the open- or closed-conformation P450BM3 crystallographic 
models  (1BU7,2 molecule B and 1FAG,165 respectively). Similarly, coordination of a 
nickel ion by the side chains of H138 and H426 appears to do little more than change 
these surface-exposed residues to alternate rotamers. H285 rotates to contact a surface-
exposed nickel ion. Even less change is observed due to nickel ion binding at H236. 
Therefore, the involvement of nickel in mediating crystal packing does not appear to 
be responsible for the closed conformation observed in the substrate-free WT model. 
Analysis of the heme does not reveal any differences from previously reported 
P450BM3 crystal structures. What is evident within proximity of the enzyme’s active 
site, however, is a strong peak of electron density that occupies the space previously 
observed to house palmitoleic acid in the complex X-ray co-crystal structure (1FAG). 
The ligand density refines best as a PEG fragment that is five ethylene glycol units in 
length (Figures 2.5 A, B). As in the previously reported P450BM3:palmitoleic acid 
complex model, the bound ligand displaces R47, F87, and L188, as well as I263 and 
L437. Therefore, it is apparent that binding of the linear PEG molecule at a distance of 
> 8 Å from the heme iron within the base of the substrate access channel casts the WT 
P450BM3 crystal structure in its closed conformation. The structure also contains an 
ethylene glycol molecule bound at the active site where a water molecule is typically 
found (Figure 2.5 C, D). 
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Figure 2.5 Omit maps for bound ligands in WT and PM P450BM3 x-ray crystal 
structures. (A) 2Fo-Fc difference electron density map for the crystallographic 
model of WT (4ZFA) contoured at 2.0σ showing the heme and PEG. (B) Fo-Fc omit 
map contoured at 7.0σ and calculated for a modified final WT model lacking only 
the PEG shown covering the same portion of the final refined model. (C) A portion 
of the final refined 2Fo-Fc difference electron density map (blue) for the WT model 
contoured at 2.0σ with the corresponding portion of the final refined model 
containing the heme and bound ethylene glycol (yellow carbon atoms). (D) Fo-Fc 
omit map (green/red) contoured at 9.0σ and calculated for a modified final WT 
model lacking only the ethylene glycol molecule shown covering the same portion 
of the final refined model. (E) 2Fo-Fc difference electron density map for the 
crystallographic model of PM bound to palmitic acid (4ZFB) contoured at 2.0σ 
showing the heme and palmitic acid. (F) Fo-Fc omit map contoured at 7.0σ and 
calculated for a modified final PM:palmitic acid complex model lacking only the 
palmitic acid shown covering the same portion of the final refined model. (G) 2Fo-
Fc difference electron density map for the crystallographic model of PM bound to 
metyrapone (4ZF8) contoured at 2.0σ showing the heme bound to metyrapone.  (H) 
Fo-Fc omit map contoured at 9.0σ and calculated for a modified final 
PM:metyrapone complex model lacking only the metyrapone shown covering the 
same portion of the final refined model. Crystal structure solved by W.E. Rogers, 
T. Othman, and T. Huxford. 
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2.3.4 The X-ray crystal structure of PM P450BM3 is similar to that of WT 
Crystals of the PM P450BM3 formed in the same space group as the WT protein, 
and X-ray diffraction data of nearly identical quality were obtained for both crystals. 
Independent solution and refinement of the PM P450BM3 X-ray crystal structure 
revealed that it also adopts the closed conformation (4ZF6), with a PEG molecule 
positioned within the normally solvent-filled base of the substrate access channel. 
 
Though the replacement of five amino acid side chains in PM does not 
significantly influence the fold or conformation of the P450BM3 protein, there are a few 
notable differences (Figure 2.6). Replacement of R47 with leucine (R47L) creates a 
cavity into which the side chain of Q73 moves, positioning it for interaction with Q188, 
which occupies the same position in WT near the end of the bound PEG. The E267V 
 
Figure 2.6 Crystal structures of WT (4ZFA, gray) and PM (4ZF6, green) BM3. 
The protein is shown in cartoon representation and the heme and mutated residues 
are shown in stick. The PEG molecule in the channel is not shown for clarity. E267 
forms interactions with T438 and K440, which are lost upon mutation to valine. 
Q73 moves into the cavity left by the R47L mutation and could potentially interact 
with Q188. Crystal structure solved by W.E. Rogers, T. Othman, and T. Huxford. 
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mutation eliminated the interaction with the T438 and K440 side chains observed in the 
WT closed conformation model. 
Mutation of F87 to valine (F87V) creates space above the heme porphyrin ring 
system adjacent to the O2 binding site. The effect of this mutation on the environment 
at the O2 binding site is evidenced by the severe change in orientation of the proximally 
bound ethylene glycol molecule relative to its position in the WT structure. Moreover, 
replacement with valine obviates the need for movement of the longer F87 side chain 
upon substrate binding. That movement, together with similar rearrangement of the 
I263 side chain, creates a hydrophobic cavity into which the hydrocarbon tail of long-
chain fatty acids can anchor themselves. Therefore, the F87V mutation expands the 
active site, which would allow closer approach of substrates to the heme. 
Comparison of the crystal structures of the PM:PEG complex (4ZF6) and the 
substrate-free R47L/Y51F/F87V/E267V/I401I mutant (4RNS166) (Figure A4 A) 
suggests that the predominant form of PM in the absence of a ligand in the channel 
would be the closed conformation. Among the common substitutions of the two 
mutants, only L47 differed significantly in side chain position. Additionally, the 
neighboring Q73 side chain points outward unlike in PM (Figure A4 B).  
 
2.3.5 X-ray co-crystal structures of WT and PM P450BM3 with substrate or inhibitor 
Complexes of PM P450BM3 with the ligands palmitic acid (substrate) and 
metyrapone (inhibitor) were crystallized in the same crystal form as the WT and PM 
proteins described previously, and X-ray co-crystal structures were refined to 2.84 Å 
(4ZFB) and 2.77 Å (4ZF8), respectively. The PM:palmitic acid complex model is 
similar to the WT P450BM3 structure in complex with palmitoleic acid. In both, the 
carboxylate group of the substrate forms a hydrogen bond with the hydroxyl group of 
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Y51. However, the PM enzyme also involves the side chain of Q188 in anchoring the 
substrate. At the opposite end, the F87V mutation leaves a hydrophobic pocket that is 
amenable to accommodating the hydrocarbon tail without requiring movement of the 
phenylalanine side chain. In general, PM P450BM3 appears to be better suited to stably 
enfold its substrate, palmitic acid, in its binding site (Figure 2.5 E, F). 
The PM:metyrapone complex crystal structure reveals a clear density for the 
inhibitor ligand at the active site and no evidence of elongated electron density in the 
vicinity of the fatty acid/PEG binding site (Figure 2.5 G, H). The pyridine nitrogen of 
metyrapone coordinates with the heme iron, as observed in complexes of P450cam and 
CYP3A4.167, 168 The Fe–N distance in the P450BM3 PM:metyrapone complex is 2.62 Å. 
The average error in coordinate positions throughout the model as estimated by the 
maximum likelihood target function is 0.4 Å. The F87V mutation allows for 
metyrapone binding since the F87 side chain in either the substrate-bound or unbound 
conformation of WT would collide with metyrapone as it appears in the refined 
PM:metyrapone crystallographic model. This provides direct evidence of how mutating 
residues near the heme active site can significantly alter both the activity and specificity 
of the P450BM3 enzyme toward substrates and inhibitors. 
In addition to these differences at the site of the heme, the lack of a fatty acid or 
PEG molecule within the enzyme causes the leucine side chain that substitutes for R47 
in the PM enzyme to move into a solvent-exposed position. It is unclear what stabilizes 
this conformation. However, it appears that the absence of a fatty acid or its analogue 
allows for conformational flexibility within this region. None of the remaining mutated 
residues, F81I, L188Q, or E267V, appear to change relative to their positions in the PM 
and PM:palmitic acid complex crystallographic models. 
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2.3.6 Molecular dynamic simulations. 
Simulations at 300 K were performed primarily to predict the native contacts in 
each system. Several interesting structural changes were also observed during the 
simulations. In substrate free WT, E267V, and L188Q (modeled from IBU7, molecule 
B), helix A and β-sheets 1-1 (residues 38-44) and 1-2 (residues 47-53) moved closer to 
the core of the protein, resulting in a partially closed substrate channel (Figure A5 A 
and Table A1) similar to IBU7 (molecule A). Helices D – H and β-sheet 4 were also 
shifted in position in E267V because of the elimination of the salt bridge with K440. 
Structural changes in R47L, F81I, and F87V were relatively less significant and mainly 
occurred in helices F and G (Table A1). On the other hand, the lid domain of substrate-
free PM opened from the initial closed conformation (4ZF6) during the 300 K 
simulation (Figure A5 B). For the substrate-bound enzymes, larger backbone rmsds, 
with respect to the crystal structure, were observed for PM:palmitic acid (1.5 Å) and 
PM:metyrapone (1.1 Å) complexes. In addition to the movement of helix F to the N-
terminal end of helix I, the substrates also changed in position in the PM active site. 
Palmitic acid moved closer to the heme, with its carboxylate group within hydrogen 
bonding distance of S72 (Figure A5 C). Metyrapone rotated slightly, bringing the 
uncoordinated pyridine ring in close contact with V87, T260, and I263 (Figure A5 D).  
The unfolding of substrate-free and substrate-bound WT and PM was simulated 
using high-temperature (550 K) MD to rationalize the biochemical results. Simulations 
of the individual mutations R47L, F81I, F87V, L188Q, and E267V were also conducted 
to isolate the effect of each mutation on stability. As a technique, the thermally induced 
unfolding of these proteins provides mechanistic insights into regions of relative 
instability, which are identified by monitoring the native contacts of each residue. 
Native contact plots, averaged over three simulations, for helices F and G [residues 
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171-226 (Figure A6)] and the Cys ligand loop [residues 393-400 (Figure A7)] of 
substrate-free WT and PM are provided in the appendix as examples.  Approximately 
50% of the contacts were lost at the end of the 50-ns run for all simulations of substrate-
free and substrate-bound enzymes. 
 
 
The different regions of P450BM3 are illustrated in panels C and D of Figures 
2.4 to aid in the discussion of the results. Loss of contacts in substrate-free WT began 
at 3 ns in β-sheet 3, particularly those at the C-terminal end of the enzyme (Figure A5). 
A few contacts at helix B' were broken at 4 ns, followed by those of helix G residues 
near the F/G loop at 6 ns (Figure A6 A). In all simulations, the F/G loop and helix B' 
continue to unfold, along with β-sheet 1 and the N-terminal end, exposing the substrate 
channel (Figure 2.7 A and Figure A8 A, B). 
 
Figure 2.7 Snapshots at 25 ns from the 550 K simulations of substrate-free (A) WT 
and (B) PM viewed through the channel entrance. The protein is shown in cartoon 
representation, with helices colored purple, β-sheets green, and loops blue. The 
heme, bound water molecule, Cys ligand, and F393 at the other end of the loop are 
shown as sticks. The hydrogen bond distance between the Cys amide H and F393 
carbonyl O (dO-H) is represented by a dashed line. The Cys ligand loop is still intact 
in WT (dO-H = 1.75 Å), but has begun to unfold in PM (dO-H = 3.98 Å). MD 
simulations performed by I. Geronimo.  
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The total number of native contacts in substrate-free PM is lower (659) 
compared to WT (680), which could explain the loss of PM stability. The increase in 
backbone rmsd within the first 10 ns was slightly faster than in WT (Figure A9 A, B). 
In addition to helix G, contacts were also lost in helices C and F (Figures A6 B), the 
Cys ligand loop [a β-bulge segment below the heme (Figure A7 B)], and β-sheet 1 
within the first 5 ns (Figure A6). This was followed by helix K' and β-sheet 2, which 
are connected to the latter, and helix D. The unfolding process in all simulations is 
similar to that of WT, but with helices D and E unfolding concurrently (Figure 2.7 B 
and Figure A8 C, D). Among the single mutants, early loss of contacts in the β-sheets 
was also observed with L188Q, helix D with L188Q and E267V, and the Cys ligand 
loop with F81I, L188Q, and E267V. Surprisingly, F87V and R47L did not exhibit 
significant unfolding in the first 10 ns, although the increase in backbone rmsd was 
similar to those of the other mutants (Figure A9 C–G).  
The unfolding of metyrapone-bound WT also began at β-sheet 3 albeit earlier 
in the simulation (1 ns). Unlike the substrate-free enzyme, the Cys ligand loop started 
to unfold after 4 ns, followed by helices C, F and G, and β-sheet 4 (5–6 ns). The latter 
is inserted into the channel and forms close contacts with the substrate. Shortly 
thereafter, the other side of the channel (β-sheets 1–2 and helix A) unfolded as well (7 
ns). In comparison, fewer regions unfolded in the PM:metyrapone complex within the 
first 10 ns. Helix B' lost contacts first (2 ns) followed closely by helices F and G (3–4 
ns), and then, β-sheet 1 (6 ns). As with the substrate-free and metyrapone-bound WT, 
helix G (3 ns) and β-sheet 3 (5 ns) in the WT:palmitic acid complex were involved in 
the early stages of unfolding. For the PM:palmitic acid complex, loss of contacts began 
at β-sheet 1 (3 ns), followed by β-sheet 3 (4 ns), helices G and H (5 ns), the Cys ligand 
loop (5 ns), β-sheet 4 (7 ns), and helix J' (8 ns). Generally, the substrate-bound variants 
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displayed the same unfolding process as the substrate-free ones (Figures A10 and A11). 
Each side of the substrate access channel continued to unfold, with the destruction of 
helices F and G extending to β-sheet 5 and, in some cases, even to part of helix I. The 
unfolding of the other portion of the lid domain (helix B') also extended to helix C, 
which consequently allowed the solvent to enter the active site. In contrast, a few 
strands of β-sheet 1 on the other side of the channel remained intact at the end of the 
simulation. For all substrate-bound enzymes, the hierarchy of unfolding in each trial 
simulation is essentially similar. However, the rate at which each side unfolds usually 
differs after ~10 ns (Figure A12); hence, the extent of damage to the channel at the end 
of the 50 ns simulation was not the same.  
2.4 Discussion 
The effects of mutations in the substrate access channel (R47L, F81I, F87V, 
L188Q, and E267V) and binding of the ligands palmitic acid and metyrapone on protein 
conformation and stability were analyzed using experimental and computational 
methods. Pulse proteolysis, which probes the global stability of a protein, indicated that 
PM is less stable than WT P450BM3. Subsequent studies of WT by pulse proteolysis and 
UV-VIS indicate that it may not follow traditional unfolding described by most 
thermodynamic models ( ), as biphasic unfolding was apparent. We 
hypothesize that there are either two populations present unfolding at different rates, or 
an intermediate state that exists long enough to be detected. Further studies will be 
discussed in chapter four elucidating the most likely mode of WT unfolding.  
The crystal structures of WT and PM provide a possible explanation of how the 
mutations destabilize the enzyme. At the entrance of the channel, mutation of 188 in 
helix F from the nonpolar leucine to the polar asparagine can impact its interaction with 
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Q73 in helix B'. Previous studies have shown that variants with substitution at or near 
this residue (L188P, F162I/K187E, F162I/K187E/M237I, and 
F162I/K187E/L188P/M237I) are less stable.169, 170 Within the channel, the mutation of 
E267 to valine, in helix I eliminated the salt bridge with K440 in β-sheet 4, which would 
account for the 1 M decrease in the Cm of E267V. However, its effect on global stability 
appears to be less significant when combined with R47L, F87V, and L188Q mutations, 
as the similar Cm of TM and QM indicates. Residue F81, located in the lid domain (helix 
B'), is within contact distance of L181 in helix F, F205 and I209 in helix G, and I263 
in helix I. Its mutation to the smaller isoleucine would therefore affect hydrophobic 
packing in this region, although pulse proteolysis of F81I suggests that this has a 
relatively minor effect on stability compared to the other mutations. 
The chemical denaturation stabilities could be correlated to high-temperature 
simulations demonstrating the effect of mutations on the unfolding process. A linear 
correlation between Cm and Tm determined from heat inactivation curves of CO binding 
difference spectra was observed for P450BM3.129 A MD study of chymotrypsin inhibitor 
2 also indicated that the overall unfolding mechanisms of chemical denaturation with 
urea and thermal denaturation are similar, in that key residues in the hydrophobic core 
are exposed first.171 Monitoring the decrease in the number of native contacts per 
residue over time revealed that the most labile regions of substrate-free WT P450BM3 
are helices B’ and G in the lid domain and β-sheet 3 in the C-terminal end of the protein. 
Hydrophobic contacts in the lid domain, aside from those observed in the crystal 
structure, include F205 (helix G)–A180 (helix F) and V211/M212 (helix G)–F173 
(helix F) contacts.  
As a biophysical technique to investigate global protein structure, pulse 
proteolysis is advantageous in that it doesn’t require expensive instrumentation, and 
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can be done relatively quickly. Pulse proteolysis uses a protease, thermolysin, to 
determine the proteolytic susceptibility of a partially denatured protein. Using this 
technique, concentration midpoint (Cm) values can be determined and compared for 
various proteins with and without ligands bound. By first incubating the protein of 
choice in urea, it is assumed that after a set period of time there will be an equilibrium 
between the folded and unfolded populations of the enzyme. Thermolysin can then 
digest the unfolded regions of the protein that have been partially denatured. 
Thermolysin is an ideal protease for this application as it can work under a wide range 
of temperatures, pH, and denaturant concentrations.172 Though relatively small, given 
its mass of approximately 35 kDa,173 thermolysin is not small enough to access the 
interior of a larger protein that is properly folded. As thermolysin preferentially cleaves 
at the N-terminus of hydrophobic residues (though there is evidence of broader 
specificity in several proteins),172 this implies that the hydrophobic core must be 
exposed to solvent for cleavage to occur.    
Importantly, for this method to be successful, protein cleavage must be faster 
than protein unfolding while it is incubated with thermolysin, allowing for 
discrimination between the folded and unfolded populations. Determining the length of 
the pulse is essential. Park and Marqusee showed that when the urea concentration is 
below 7 M and thermolysin is in excess,137, 174 a pulse of 1 min is effective for cleavage 
of the unfolded protein.137, 139 As thermolysin is a zinc metalloenzyme that also requires 
calcium,175 addition of EDTA will quickly inhibit activity, so the pulse can be timed 
exactly.176 For our experiments, the thermolysin concentration was approximately 10 
times that of the P450BM3 concentration, and the denaturant concentration was kept 
below 7 M. In addition, when P450BM3 was pulsed with thermolysin without first being 
incubated in urea, generally there was no indication of fragmentation on the gel. 
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Fragmentation would be expected if the enzyme had been cleaved, which indicates 
thermolysin wasn’t able to cut P450BM3 when it is fully folded. Hydrogen/deuterium 
exchange (H/D exchange) coupled to mass spectrometry is another commonly used 
technique to monitor global structure stability of proteins. Unlike pulse proteolysis, 
which takes a snapshot of the protein at one set time, H/D exchange can monitor 
dynamics over a wide time scale taking place from 10 s-1 to days.177 Though this may 
be preferable for some applications, H/D exchange mass spectrometry is often 
prohibitively costly, requires specialized equipment and training, and data analysis is 
time consuming.  
Protein conformational dynamics occur on different time scales, depending on 
the type of motion. Side chain rotations occur on a picosecond to nanosecond time 
scale.178 This is opposed to proline isomerization which is known to be slow, on the 
order of tens to thousands of seconds.179 Thus, observations of different kinetic phases 
by a slow technique such as pulse proteolysis suggests results are due to large 
conformational changes that occur over a 2 hr time frame, and cannot be due to 
rearrangement of residues. 
Additional regions were shown to unfold earlier in PM, notably β-sheet 1 and the 
Cys ligand loop. Early unfolding of the Cys ligand loop is consistent with CD data 
indicating that the heme environment of substrate-free PM is less stable than that of 
WT. L188Q similarly lost contacts early in both regions, suggesting that this mutation 
has a significant contribution to destabilization. Simulations of the single-point mutants 
at 300 K showed that the L188Q mutation caused the most significant structural change, 
based on backbone rmsd at the N-terminal end up to β-sheet 1 of the substrate-free 
enzyme (Table A1), which is presumably destabilizing and might have affected the Cys 
ligand loop. On the basis of analysis of time-correlated atomic motions, these two 
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regions were assigned to the same protein domain, which implies that they move 
cooperatively and cohesively during structural transitions of the protein.180  
As for E267, simulations support the importance of its salt bridge with K440, as 
it was maintained even at high temperature in WT. The concurrent unfolding of helices 
D and E with sections of the substrate channel in PM may also be attributed to the 
E267V mutation, which disrupted hydrophobic contacts such as L150 (helix E)–H266 
(helix I) and I122 (helix D)–L148 (helix E) contacts. R47L did not exhibit significant 
unfolding during the early stages of high-temperature simulations, despite the 
elimination of a salt bridge with another β-sheet 1 residue, E352 (Table A2). This may 
be explained by the fact that leucine is a better β-sheet-former.181 F87V was also 
relatively stable during the simulations, which is inconsistent with differential scanning 
calorimetry data showing that its melting temperature is lower by ~ 4°C than that of 
WT.164 The discrepancy may be attributed to the difficulty in accurately predicting 
slight differences in stability in the case of conservative (in terms of hydrophobicity) 
substitutions such as F81I and F87V using MD simulations, which is exacerbated by 
the lack of available crystallographic evidence; initial coordinates for single-point 
mutant and WT simulations were all derived from 1BU7 (molecule B), which may not 
be adequately representative of the F87V structure. 
Substrate binding generally stabilizes an enzyme.137, 182 However, pulse 
proteolysis and CD data demonstrated that this was not the case with the 
WT:metyrapone complex. This finding suggests a mismatch in complementarity 
between the ligand and enzyme. High-temperature simulations showed that additional 
regions, particularly the Cys ligand loop, unfolded early, which is consistent with the 
observed decrease in Cm for the heme environment. In contrast, the stability of the heme 
region of PM was enhanced by metyrapone, although it is not certain whether this can 
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be attributed to covalent bonding with the heme iron because simulations of P450cam in 
complex with 4-phenylimidazole (Fe–N bond length of 2.21 Å in the crystal 
structure167) showed instability of the Cys ligand loop.151 However, a new salt bridge, 
E380–K312, formed during the simulation (Table A2), and its proximity to the heme 
might contribute to the stabilization of PM. On the other hand, the stability of WT and 
PM was not significantly affected by the presence of palmitic acid, as indicated by pulse 
proteolysis. This finding implies that enzyme conformation of the palmitic acid bound 
and substrate free enzyme are similar with little change to overall structure with ligand 
bound. Computationally it was discovered that though the labile regions in the palmitic 
acid-bound complex of WT and PM are different from the corresponding substrate-free 
enzyme, the unfolding process was observed to be similar. The Cys ligand loop 
unfolded early in both forms of PM but was relatively stable in both forms of WT.  
Increasing the stability of PM is advantageous if it is to be used as a starting point 
to develop more promiscuous variants for biotechnical applications. The lid domain, β-
sheet 1, and Cys ligand loop would be the logical targets for mutation based on the 
hypothesis that delaying the unfolding of the most labile regions would increase the 
global stability of the protein. On the basis of analysis of physical factors that 
differentiate (hyper)thermophilic proteins from mesophilic ones,183-185 several 
approaches for protein stabilization have been attempted such as introducing salt 
bridges,186 increasing structural rigidity,187 and improving hydrophobic core packing.188  
The latter method is promising for P450BM3 on the basis of a previous study on 
the 21B3 variant of this enzyme.135 Five of the eight mutations introduced through 
directed evolution, resulted in an increase of 15°C in T50, happened to conserve 
hydrophobicity. Residues L52I (β-sheet 1) and A184V (helix F) are buried, while L324I 
(helix K), V340M (β-sheet 2), and I366V (helix K”) are located on the surface. The 
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authors hypothesized that these stabilizing mutations counteracted structural 
perturbations caused by previously introduced activity-enhancing mutations given the 
proximity of some residues in the two sets of mutations.135 Interestingly, most of the 
stabilizing mutations are located at or near the labile regions identified in this study. 
Packing interactions in PM P450BM3 can be enhanced by introducing substitutions at 
the hydrophobic patches in the (a) lid domain, consisting of I81, A180, L181, F173, 
F205, I209, V211, M212, and I263, and (b) heme region, including W367, F379, and 
F390. This cluster of aromatic residues presumably stabilizes the Cys ligand loop, as is 
the case in the thermophilic CYP119.151  
Salt bridges contribute to the stability of thermophilic P450s at elevated 
temperatures through hydration effects.189 For instance, CYP175A1 (Tm = 88°C), 
whose closest homologue is P450BM3 (26% sequence identity), has eight salt bridge 
networks (i.e., one that involves more than two charged residues).190 MD simulations 
of P450BM3 variants showed that there are only three networks in substrate-free WT 
(R323/E320/R378/D370, K3/E344/R56/E38, and K94/E247/K98) and four in PM 
(R375/D370/R378, K3/E344/R56/E38, K94/E247/K98/D250, and E292/R296/E293). 
At the N-terminal end of P450BM3, T339 (β-sheet 2) can be mutated to Asp to form an 
extended network with R66 (β-sheet 1) and E60 (helix B). New salt bridges in the other 
labile regions can also be introduced, for example, the D388 (mutated from His)-
K391salt bridge in the loop region near the heme, and the K445 (mutated from Val)-
E140 salt bridge in β-sheet 3.  
Pulse proteolysis, CD spectroscopy, x-ray crystallography, and MD simulations 
elucidated how mutations that destabilize P450BM3 impart affinity for nonnative 
substrates such as metyrapone. The method-dependent variation in stability 
measurements indicates that use of global, secondary structure, and active site 
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characterizing methods is necessary to effectively evaluate the effects of mutation on 
P450BM3 stability. Utilizing multiple techniques, when using a chemical denaturant, to 
probe various aspects of protein stability is important as denaturants effect various 
structures differently. In general, more urea was necessary for secondary structure 
unfolding than for global and active site unfolding. This may be due to the fact that 
hydrophobic contacts that keep the global structure together are easier to disrupt than 
the hydrogen bonding of the secondary structure.  
Our models suggest that destabilization generally arose from disruption of 
important salt bridges and hydrophobic contacts and unfolding of the Cys ligand loop 
connected to the heme. The identification of the conserved Cys ligand loop as a key 
contributor to instability suggests that some findings may be generalizable to other 
CYP102A subfamily fatty acid hydroxylases.191 A commonly held view among the 
protein design community is that increasing the promiscuity of an enzyme comes with 
a requisite expense of protein stability. However, Arnold, et al. demonstrated that this 
is not necessarily the case, as more thermostable variants have been produced through 
further directed evolution of an existing mutant without compromising enzyme 
activity.129, 135, 136  
2.5 Conclusions 
Biochemical techniques that used chemical denaturation as well as structural and 
computational methods were used to probe the thermodynamic stability of P450BM3, a 
model system for human CYPs and a candidate for biotechnical applications. From the 
biochemical results it was evident that mutations that increase promiscuity, destabilize 
enzyme stability, but in some cases this stability can be recovered when substrates are 
bound. Though, the crystal structures of WT and PM were globally similar, mutations 
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at position 188 and 267 were most detrimental to enzyme stability. MD simulations 
further parsed the differences that lead to a decrease in stability. Primarily, these 
differences are a loss of contacts in PM, and early unfolding of β-sheet 1 and the Cys-
ligand loop.  
Studies of the role of the Cys ligand loop for protein stability were undertaken; 
particularly the role of residue I401 was investigated. I401 is directly next to the 
cysteine ligated to the heme and was mutated to a proline, which is the naturally 
occurring residue in some CYPs.192, 193 Disruption of the Cys ligand loop by P401 in 
P450BM3 leads to the enzyme being in a naturally high spin state, but also has further 
reaching consequences in that it changes the residue contacts in the I-helix of the 
enzyme, causing it to be more open. This openness leads to a more promiscuous but 
less stable enzyme, similar to PM. More discussion of this mutation will be included in 
chapter four. Additionally, this study and subsequent work demonstrated the possibility 
of biphasic unfolding of WT P450BM3 which will also be discussed in chapter four.  
The characterization of the unfolding process of the P450BM3 variants presented 
herein provides fundamental knowledge that could be used to rationally design stability 
upon an enhanced specificity platform as well as understand the role in stability in 
promiscuous CYPs. Regions involved in the early stages of unfolding are potential 
targets for mutation to develop thermostable variants of the promiscuous PM P450BM3. 
 
 
 
 
 
 
60 
 MOLECULAR DETERMINANTS OF SMALL MOLECULE 
AFFINITY AND ENZYME ACTIVITY OF A CYTOCHROME P450BM3 
VARIANT. 
Chapter adapted from: Geronimo, I., Denning, C. A., Heidary, D. K., 
Glazer, E. C., Payne, C. M. (2018). "Molecular Determinants of Substrate Affinity 
and Enzyme Activity of a Cytochrome P450BM3 Variant." Biophysical Journal 115(7): 
1251-1263. 
Author Contributions: IG, CAD, ECG, and CMP designed the study, analyzed the 
data, and wrote the manuscript. IG performed the molecular dynamics simulations. 
CAD and DKH conducted the experiments and analyzed the data. 
3.1 Introduction 
 
Characterization of the metabolite profile of a drug candidate is a crucial part of 
the drug discovery and development process. Drug metabolites, largely produced by 
hepatic cytochrome P450 enzymes (P450s), are needed as reference compounds and 
 
Figure 3.1 Peroxide and oxidase uncoupling pathways. The substrate is 
represented by R–H. 
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reactive intermediates for assessing toxicity, drug-drug interactions, and biological 
activity.194, 195 For the preparative-scale synthesis of human drug metabolites, 
CYP102A1 (P450BM3), a fatty acid hydroxylase from Bacillus megaterium, is 
considered an ideal biocatalyst because it has the highest known monooxygenase 
activity among P450s, is relatively stable compared to human P450s, and can be 
expressed at high levels in Escherichia coli.97, 134, 196.Wild-type (WT) P450BM3 has been 
shown to catalyze the oxidation of nifedipine, propranolol, and chlorzoxazone, which 
are substrates of the human P450s CYP3A4, CYP2D6, and CYP2E1, respectively.197 
To take full advantage of P450BM3 in an industrial setting, much research has been 
devoted to further expanding its substrate promiscuity and chemical reactivity through 
protein engineering.122, 125, 127, 166, 196, 198, 199 However, the molecular factors responsible 
for the stability of substrate binding and potential consequences of introducing 
nonnative substrates on the activity and coupling efficiency (i.e., ratio of substrate 
reacted to NAD(P)H cofactor consumed34) of P450BM3 have yet to be determined. 
Peroxide or oxidase uncoupling (Figure 3.1) is of particular concern because it prevents 
product formation, thereby wasting reducing equivalents from the expensive NAD(P)H 
cofactor.33, 200 Furthermore, the production of these oxygen species can do further 
damage to the enzyme itself, causing it to unfold. 
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Interestingly, the P450BM3 variants developed to metabolize additional drug 
classes (e.g., nonsteroidal anti-inflammatory drugs (NSAIDs) like diclofenac, 
ibuprofen, and naproxen), including D251G/Q307H120, 201, RP/FV/EV/FW166, 
RT2/AP/FW166, M11127, 198, 199, and W7D8122 (Table 3.1), do not all share common 
substitutions. However, the mutations, generally located far from the heme active site, 
appear to have a similar functional effect of increasing the flexibility of the lid domain 
(helices B', F, and G, Figure 3.2), as revealed by the unresolved (or very high B factors 
of) lid domain residues in the crystal structures of the substrate-free variants.122, 164, 166, 
199, 201, 202 Molecular dynamics simulations of R47L/F87V/L188Q/E267V/F81I 
pentuple mutant (PM) showed that the lid domain is, indeed, highly labile, and 
consequently, one of the regions that first unfolds at high temperature1. In the case of 
D251G/Q307H (PDB ID: 5DYP201), M11 (PDB ID: 5E9Z199), and RP/FV/EV (PDB 
ID: 4RSN166), the cause of increased flexibility is evident; D251 and E267 are part of 
the region that moves during the opening and closing of the substrate channel and form 
 
Figure 3.2 P450BM3 structure. Regions involved in substrate binding, including 
the lid domain (helices B', F, and G), are labeled in the figure. The heme is shown 
as sticks. 
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salt bridges with K224 and K440, respectively, in WT.191, 203 The higher flexibility of 
the lid domain would account for the ability of P450BM3 variants to accept a broader 
range of substrates.122, 164 Additionally, many of these mutations are made in, or close 
to, substrate recognition sites (SRS) which are regions of high variability in bacterial 
and eukaryotic CYPs thought to be responsible for substrate binding.204 Mutations in 
these regions can easily impact enzyme promiscuity. At least three of the six possible 
SRS are associated with the main ingress/egress pathway way (pw2a) of P450BM3 as 
demonstrated by replica-exchange molecular dynamics (REMD) simulations and 
thermal motion pathway (TMP) analysis of published P450BM3 crystal structures.205, 206 
The crystal structures further showed that substrate-free variants adopt the closed 
conformation characteristic of substrate-bound WT instead of the open conformation. 
This shift to the catalytically ‘ready’ conformation caused by mutation results in a more 
positive heme reduction potential. Consequently, the rate of the first electron transfer 
(believed to be the rate-limiting step207) increases, improving the oxidative activity of 
P450BM3 toward nonnative substrates. 120, 166, 201, 202, 208 
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Table 3.1. List of mutations in functional BM3 variants. 
 
The only crystal structures of drug-bound P450BM3 variants that have been 
reported thus far are A82F and A82F/F87V with omeprazole (PDB IDs: 4KEW and 
4KEY164), A82F/F87V with esomeprazole (PDB ID: 4O4P121), antifungals tioconazole, 
voriconazole, fluconazole and clotrimazole (PDB IDs: 6H1L, 6H1O, 6H1S, and 
6H1T209), as well as PM with metyrapone (PDB ID: 4ZF81). In all structures, the 
Variant Mutations 
RP/FV/EV 166 R47L/Y51F/F87V/E267V/I401P 
RP/FV/EV/FW 166 RP/FV/EV/F81W 
RT2/AP/FW 166 R47L/Y51F/A191T/N239H/I259V/A276T/L353I/A330P/ 
F81W 
M01 125 R47L/F87V/L188Q/E267V/G415S 
M02 125 R47L/L86I/F87V/L188Q/N319T/A964V 
M05 125 M01/F81I/G1049E 
M11 127, 198, 199 M01/E64G/F81I/E143G/Y198C/H285Y 
MT35 127 M11/L437S 
W7D8 122 L52I/I58V/L75R/L86L/F87A/H100R/S106R/F107L/Q109L/
A135S/E140G/F162I/A184V/N239H/S274T/L324I/V340M/ 
I366V/K434E/E442K/V446I 
9-10A 196 V78A/H138Y/T175I/V178I/A184V/H236Q/E252G/R255S/A
290V/A295T/L353V/Y138H/I178V/F205C/S226R/A290V/ 
R47C/K94I/ P142S 
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conformation is notably similar to that of the WT-fatty acid complex (PDB ID: 
1FAG165), raising two important questions: (1) What interactions stabilize a structurally 
different and highly polar drug molecule in the largely hydrophobic active site? (2) 
How would the lack of structural and electrostatic complementarity between substrate 
and enzyme affect activity and coupling efficiency? This study aims to address these 
key mechanistic questions by investigating the binding of a set of drugs of varying size, 
charge, polar surface area, and human P450 affinity. PM P450BM3 was chosen as the 
model system because it serves as a good platform to develop biocatalysts for the 
synthesis of drug metabolites, as well as for diversification of lead compounds; this was 
demonstrated by a study in which a library of mutants containing the PM mutations 
was able to metabolize 77% of the 43 commercial drugs tested by more than 20% .127  
The binding free energies of CYP2C9 (diclofenac, naproxen, S-warfarin), 
CYP2D6 (astemizole, dextromethorphan, 3,4-methylenedioxymethamphetamine or 
MDMA), and CYP2A6 (nicotine, cotinine) substrates, CYP2C9 inhibitors (lovastatin, 
R-warfarin), and metyrapone (Table 3.3, Table B1) were determined using 
spectroscopic binding titrations and supported by calculations using free energy 
perturbation with Hamiltonian replica-exchange molecular dynamics (FEP/λ-REMD). 
To gain insight on the nature of the interaction that enables the binding of nonnative 
small molecules in the P450BM3 mutant, the calculated free energy was further 
decomposed into repulsive, dispersive, and electrostatic contributions. Residues that 
play a role in substrate binding were identified by analyzing hydrogen bond, ionic, and 
van der Waals interactions from the molecular dynamics (MD) trajectories. The 
possibility of reduced heme oxidizing ability and uncoupling, caused by the binding of 
nonnative substrates, was assessed by examining electrostatic interactions and water 
density in the active site. 
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Table 3.2 Drug molecules used in this study with function and CYP chemistry. 
Compound Name Chemical Structurea Drug Class CYP Chemistry  
Astemizole 
 
Antifungal  O-demethylaion, 
N-demethylation, 
Hydroxylation210 
Cotinine 
 
Nicotine metabolite N-demethylation, 
Hydroxylation, 
Oxidation211 
 
Dextromethorphan 
 
Cough suppressant O-demethylation, 
N-demethylation212 
Diclofenac  
 
NSAID Hydroxylation213 
Lovastatin 
 
Statin  Hydroxylation, 
Desaturation214 
MDMA  Stimulant, 
Hallucinogen 
N-demethylation, 
O-demethylenation215 
Metyrapone 
 
Inhibitor of 11β-
hydroxylase 
Inhibitor 
Naproxen 
 
NSAID O-demethylation216 
Nicotine 
 
Stimulant N-demethylation, 
Hydroxylation, 
Desaturation, 
Oxidation211 
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Table 3.2 (continued) 
a.  Color of each structure represents polarity at physiological pH, where green is 
neutral, blue is positively charged, and red is negatively charged.  
3.2 Experimental procedures 
3.2.1 Biochemical procedures 
3.2.1.1 Chemicals for spectroscopic binding titrations 
Dextromethorphan hydrobromide monohydrate, metyrapone, and sodium 
palmitate (palmitic acid) were purchased from Sigma Aldrich. (-)-Cotinine, lovastatin, 
and naproxen sodium were purchased from Alfa Aesar. Nicotine and warfarin sodium 
were purchased from TCI America.  
3.2.1.2 Cloning and site-directed mutagenesis of P450BM3 
The heme domain of P450BM3 (Thr 1-Thr 463) with a C-terminal 6xHis tag was 
cloned into the pCWori plasmid. Mutations for generating PM P450BM3 were 
incorporated using QuikChange site-directed mutagenesis (Stratagene). The 
polymerase chain reaction product was DpnI treated, transformed into XL-Gold 
ultracompetent cells, and selected on carbenicillin Luria Broth-Agar plates. Colonies 
were grown in 5 mL of LB with 100 µg/mL ampicillin, followed by plasmid isolation 
R-Warfarin 
 
Anticoagulant  Hydroxylation217 
S-Warfarin 
 
Anticoagulant Hydroxylation217 
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using the E.Z.N.A.® Plasmid Mini Kit (Omega Bio-tek®). All mutations were 
confirmed by sequence analysis.  
3.2.1.3 Expression and purification of PM P450BM3 
The pCWori vector containing the PM P450BM3 heme domain was transformed 
in E. coli BL21(DE3) cells. Colonies were grown overnight in 5 mL LB with 100 
µg/mL ampicillin in a shaking incubator set to 190 rpm and 37 °C before being 
transferred to 1 L Terrific Broth supplemented with 8 mL of 80% glycerol and 100 
µg/mL ampicillin. The cells were grown until an OD600 of 0.7–0.8 was reached. 
Expression of PM P450BM3 was induced upon addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM. Cells were harvested 
after approximately 16 h by centrifugation at 4 °C and 3000 xg for 15 min. The cell 
pellets were stored at -80 °C until purification.  
Cell pellets were resuspended in 30 mL lysis buffer (50 mM NaH2PO4, 300 mM 
NaCl, 10 mM imidazole, 0.1 mM EDTA, pH 8.0) with 0.1 mM phenylmethylsulfonyl 
fluoride. Cells were lysed on ice for 15 min by a microtip sonifier with output control 
of 3 and duty cycle of 50% (Branson Sonifier 250). The lysate was centrifuged at 4 °C 
and 17000 xg for 1 h, the supernatant decanted, and filtered through a 0.45 µM 
polytetrafluoroethylene syringe filter.  
The clarified lysate was loaded onto a His-Trap column (GE Healthcare) 
equilibrated with Buffer A (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole), and 
the protein was eluted with a linear gradient using Buffer B (50 mM NaH2PO4, 300 
mM NaCl, 200 mM imidazole), where the concentration increased from 10 to 200 mM 
imidazole. Fractions containing PM P450BM3 were collected and concentrated to 
approximately 2 mL at 4500 xg and 4 °C with Ultracel-30K Millipore centrifugal units. 
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The concentrated protein was loaded onto a Hi-Prep 26/60 Sephacryl S200 HR size 
exclusion column equilibrated with 20 mM Tris and 150 mM NaCl buffer at pH 8.0. 
Fractions containing PM P450BM3 were analyzed by absorbance spectroscopy, and all 
fractions with a spectrophotometric index (A420/A280) above 1.2 were combined and 
concentrated. The protein concentration was determined by CO binding (ε = 91,000 M-
1cm-1)138. Glycerol was added to approximately 50%, with the final protein 
concentration between 15 and 20 mg/mL. The protein was aliquoted, snap-frozen in a 
dry ice ethanol bath, and stored at -80 °C until use.  
3.2.1.4 Binding constant determination by spectroscopic 
titration 
Dextromethorphan hydrobromide monohydrate, naproxen sodium, nicotine, 
and warfarin sodium stock solutions were prepared in 18.2 MΩ water. (-)-Cotinine, 
lovastatin, metyrapone, and palmitic acid were prepared in dimethyl sulfoxide. 
UV/Visible absorption spectra were recorded using an Agilent 8453 
spectrophotometer. Titrations were carried out in 2 mL of 100 mM KH2PO4 (pH 7.4) 
in a 1-cm optical path length cuvette, with protein concentrations between 0.15 and 
0.25 mg/mL. All titrations were carried out with the organic solvent concentration kept 
below 1%. 
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Difference spectra were generated by subtracting the absorption spectrum at 
each concentration point in the titration from the original compound-free P450BM3 
absorption spectrum. The wavelength where the maximum change occurred was 
identified and used to determine the binding dissociation constant (Kd), which was 
calculated in GraphPad Prism version 6 by fitting the data for the ligand-induced 
absorbance changes in the difference spectra (Amax - Amin) vs. ligand concentration to a 
one-site total binding equation. The ΔGb value was determined using the equation ΔGb 
= RT ln Kd, where R = 1.99 x 10-3 kcal K-1 mol-1 and T = 298.15 K. A full spin shift 
was obtained using omeprazole as the substrate. For all other ligands, the percentage of 
protein in the high-spin state was calculated based on the assumption that water-bound 
PM P450BM3 is 100% low spin, and PM P450BM3 fully bound to omeprazole is 100% 
high spin (Figure 3.3).  
 
 
Figure 3.3 Comparison of a full type I spectral shift to the water bound resting 
state. Omeprazole bound (red dashed line) is 100% high spin, compared to the 
water bound state (black line). Saturation of PM P450BM3 (0.15 mg/ml) with 
omeprazole in 2 mL of 100 mM KPi pH 7.4 at room temperature in a 1 cm quartz 
cuvette. 
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3.2.1.5 5-Ethoxyresorufin-O-deethylase activity assay 
Inhibition of PM P450BM3 was detected via a turnover assay for nicotine, 
cotinine, and metyrapone. Each compound was added to 2.5 µM PM P450BM3 in 1x 
phosphate buffered saline (PBS, pH 7.5). The concentration of compound used was 10 
x Kd. The compound and enzyme were incubated for 5 min at RT before 5-
ethoxyresorufin was added to a final concentration of 5 mM. The solution was allowed 
to incubate for another 5 min before 0.1 M H2O2 was added. The Greiner clear bottom 
96 well plate was immediately placed in a Tecan Spectrafluor plus microplate reader 
for 5 min. Fluorescence was monitored as a function of time with excitation 525 nm 
and emission 595 nm.  
3.2.2 Computational procedures 
3.2.2.1 Molecular dynamics (MD) simulations  
Initial coordinates for the PM-metyrapone complex were obtained from the 
crystal structure PDB ID: 4ZF8.1 The other enzyme-substrate complexes were prepared 
by ligand docking using AutoDock 4.2.218 The structure of the solvent-free target 
protein (including the heme) was taken from the last point of the 100-ns, fully atomistic 
simulation of the PM-metyrapone complex performed in a previous study.1 The charges 
used for the protein atoms were the same as the ones used in the MD simulation, while 
ligand charges were calculated using the Restrained Electrostatic Potential (RESP) 
method (vide infra).219 The size of the grid box, centered on the Fe atom, was 60 Å × 
60 Å × 60 Å, with a spacing of 0.250 Å. During the docking simulations, the protein 
was kept rigid while all rotatable dihedrals in the ligands were allowed to move freely. 
The Lamarckian genetic algorithm was used to search for low-energy ligand poses that 
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will yield the metabolites known to be produced by human P450s and/or P450BM3 
mutants containing the PM mutations. 
Preparation of the enzyme-substrate complexes for MD simulations, including 
assignment of the protonation state of titratable residues, has been described in detail 
in reference.1 The solvated ligand system was prepared by neutralizing the ligand with 
Na+ or Cl– and solvating it in a truncated octahedron box of TIP3P water147 with a buffer 
distance of 25 Å between each wall and the closest atom in each direction. The AMBER 
ff14SB force field146 was used to describe the protein. Force field parameters and partial 
charges for the high-spin, pentacoordinate ferric form of the heme active site 
(characteristic of substrate-bound P450BM3191) were taken from literature.72 These 
parameters have been tested for stability and consistency with the expected heme 
geometry in implicit and explicitly solvated MD simulations of the heme active site 
alone and CYP3A4. Moreover, the use of the partial charges in docking calculations 
reproduced the experimentally observed metabolism of raloxifene by CYP3A4.72 
Ligands parameters were calculated using antechamber148 at the HF/6-31G* level to be 
consistent with the GAFF force field.149 Periodic boundary conditions were applied 
using the Particle Mesh Ewald method159 with a non-bonded cutoff of 10 Å. Energy 
minimization was performed in four stages: (1) protein and ligand were restrained with 
a harmonic force constant of 5.0 kcal/mol/Å2 to allow water and ions to relax, (2) 
residues within 5 Å of the docked ligand were released from the restraint, (3) the whole 
protein was again restrained while the ligand was allowed to relax, and (4) the restraint 
was removed. At each stage, 1000 steps of steepest descent minimization was 
performed, followed by 1000 steps of conjugate gradient minimization. 
The system was then heated from 0 to 300 K for 50 ps using NMR weight 
restraints to linearly increase the temperature (≈6 K/ps) in order to avoid instabilities in 
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the simulation. Cα atoms were restrained with a harmonic force constant of 5.0 
kcal/mol/Å2 during heating. Bonds involving hydrogen were constrained using the 
SHAKE algorithm160, and a 2-fs time step was used for time integration. The 
temperature was controlled using Langevin dynamics161 with a collision frequency of 
1.0 ps-1. The system was equilibrated at constant pressure over a 200-ps period, during 
which the force constant was incrementally reduced (5.0, 2.0, 1.0, and 0.5 kcal/mol/Å2). 
Isotropic position scaling was used to maintain the pressure at 1 atm, with a relaxation 
time of 2 ps. Equilibration of the unrestrained system was then continued for 2 ns. 
Production MD simulations in the NVT ensemble were performed at 300 K for 100 ns 
using the same parameters as equilibration. During production, a harmonic restraint of 
10 kcal/mol/Å was applied to the distance between the heme Fe and protonated nitrogen 
of dextromethorphan and MDMA to prevent large displacement of the substrate due to 
strong ionic interaction with heme propionate A.  
Minimization, heating, and equilibration were run using Amber 14220 and 
production using nanoscale molecular dynamics (NAMD).221 Residue-ligand 
interaction energies were calculated using NAMD (Table B1,B2, and B3) . Hydrogen 
bond occupancy (i.e., fraction of time that the bond is present in each trajectory) and 
water density around the ligand and heme were calculated using the cpptraj module of 
Amber 2015.155, 222 The distance and angle cutoffs for the hydrogen bond are 3.0 Å and 
135° (Table B4 and B5). The grid dimensions of the ligand + heme region used in the 
water density calculation were determined using the bounds command (grid spacing = 
0.5 Å). The water density was visualized with PyMOL133 using a contour level of 3.0 
and mesh width of 0.5. 
3.2.2.2 Free energy perturbation with Hamiltonian replica-
exchange molecular dynamics (FEP/λ-REMD) 
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In the FEP/λ-REMD method223, the binding process is divided according to the 
thermodynamic cycle, wherein the bound ligand is decoupled from the enzyme (Eq. 1) 
and the solvated ligand is decoupled from bulk solution (Eq. 2). The free energy for the 
overall process (Eq. 3) is ΔGb° = ΔG2 – ΔG1.  
  
(1) 
     (2)
 
 (3)
 
The ligand is decoupled from the binding pocket or bulk solution in three stages 
using the thermodynamic coupling parameters λrep, λdisp, and λelec ∈ [0,1] (Eqs. 4–6), 
giving the repulsive (ΔGrep), dispersive (ΔGdisp), and electrostatic (ΔGelec) 
contributions, respectively.
 
 (4)
  
  (5) 
  (6) 
For the decoupling of the bound ligand from the enzyme, an additional 
parameter, λrstr, is used to control the translational and orientational restraints (Eq. 7) 
and gives ΔGrstr.  
  (7) 
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The initial structure for the enzyme-substrate complex was taken from the 25-
ns snapshot of the production MD simulation, while that for the solvated ligand was 
taken from the last point of the equilibration. The same simulation parameters outlined 
above were used except for the time step, which was reduced to 1 fs. Nonbonded forces 
were evaluated every step and full electrostatic forces every other step. A harmonic 
restraint was applied with a force constant of 10.0 kcal/mol/Å2 to maintain the center-
of-mass distance between the ligand and enzyme. 128 replicas (72 repulsive, 24 
dispersive, and 32 electrostatic) were used with an exchange frequency of 1/100 steps. 
Sequential 0.1-ns simulations were performed until the calculation has converged (at 
least 2 ns), as evaluated from the fluctuation in the absolute free energy of the system 
over time (Figure B2). Repulsive, dispersive, and electrostatic contributions were 
determined using the Multistate Bennett Acceptance Ratio method.224 The average and 
standard deviation of the binding free energy were calculated using the last 1 ns of data. 
3.3 Results and discussion 
3.3.1 Experimental and calculated binding free energies 
Substrate binding displaces the water molecule coordinated to the sixth position 
of the heme iron, resulting in a type I shift in the absorption spectrum, with the peak at 
approximately 390 nm in the difference spectra.225 The native substrate, palmitic acid, 
as well as diclofenac, naproxen, warfarin (the racemic mixture), lovastatin, and 
dextromethorphan exhibited a type I spectral shift upon binding (Figures 3.4 and 3.5). 
In the case of warfarin, the type I binding observed is presumably that of S-warfarin, as 
the R enantiomer is known to be inhibitory and would bind in a nonproductive manner 
that does not lead to metabolism.226  
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Displacement of the water ligand changes the iron spin state from low to high 
spin and, consequently, alters the redox potential of the heme.227 The population of the 
high spin state for PM P450BM3 upon drug binding was lower than that observed with 
palmitic acid (Table 3.3), suggesting that the drug molecules possibly bind in the active 
site without displacing the water ligand in a fraction of the protein.228 A type II spectral 
shift occurred with metyrapone, nicotine, and cotinine, as evidenced by the absorption 
shift to about 430–455 nm (Figures 3.4 and 3.5).225 The type II shift indicates that these 
compounds directly coordinated the heme iron through the pyridine nitrogen. 
Generally, the type II shift is associated with enzyme inhibition; nevertheless, with 
nicotine or cotinine bound, the enzyme was active, as metabolism was observed using 
 
Figure 3.5  Spectral titration of PM BM3 with the native substrate palmitic acid (A–
C) and inhibitor metyrapone (D–F). The red curve corresponds to the ligand-
saturated enzyme, and the blue curve indicates the ligand-free enzyme. Palmitic acid 
exhibited a type I spectral shift, characterized by λmax at 394 nm and trough 
around 420 nm (B), while metyrapone exhibited a type II spectral shift, 
characterized by λmax at 427 nm and trough around 390 nm (E). The dissociation 
constant (Kd) was calculated by plotting the absorbance at λmax as a function of 
ligand concentration (C, F). Plots were fit with a one-site total equation in GraphPad 
Prism. All titations were done in a 1 cm quartz cuvetter with 2 mL of 100 mM KPi, 
pH 7.4 buffer with protein at a concentration between 0.15 – 0.25 mg/ml. 
Concentrated compound was titrated in 1 – 5 µL increments, with DMSO 
concentration kept below 1%. 
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the fluorescence-based 7-ethoxyresorufin-O-deethylase (EROD) activity assay (Figure 
3.6).123     
 
The binding affinity of various drug molecules for PM P450BM3 was determined 
upon titrating small molecules and quantifying the change in absorption to obtain their 
Kd values. Based on predicted titration curves, diclofenac, naproxen, and warfarin are 
acidic; dextromethorphan and nicotine are basic; and cotinine, lovastatin, and 
metyrapone are neutral at physiological pH (Table B1). All substrates have negative 
ΔGb°, indicating that binding to PM P450BM3 is stable, regardless of the type of drug 
 
Figure 3.6 Difference spectra of all compounds bound to PM P450BM3 studied 
experimentally.The blue line is PM P450BM3 in which no compound is present, and 
the red line is fully saturated. (A) Dextromethorphan, (B) diclofenac, (C) 
lovastatin, (D) naproxen, and (E) racemic warfarin exhibit a type I spectral shift. 
(F) Cotinine and (G) nicotine exhibit a type II spectral shift. All titrations were 
done in a 1 cm quartz cuvette in 2 mL of 100 mM KPi pH 7.4 buffer at RT. Protein 
was kept at a concentration between 0.15 – 0.25 mg/mL. Concentrated compound 
was titrated in 1 – 5 µL increments, with DMSO concentration kept below 1%.  
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(acidic, basic, or neutral) (Table 3.3). Moreover, the binding affinities of naproxen, 
warfarin, dextromethorphan, and lovastatin are comparable to that of palmitic acid. 
Cotinine was the weakest binder, as indicated by the largest Kd value (415 ± 11 µM), 
about 20x higher than that of nicotine (23.5 ± 6.3 µM). The two molecules have the 
same ring systems but, unlike nicotine, cotinine has an additional carbonyl group and 
is neutral. The binding free energies calculated using FEP/λ-REMD agree with 
experimental data for diclofenac, lovastatin, and dextromethorphan (Table 3.3). S-
warfarin has a six-fold higher affinity than its enantiomer, and the calculated ΔGb° is 
closer to the experimental value for the racemic mixture. On the other hand, the 
calculated ΔGb° of naproxen is much more negative than the experimental value, 
possibly due to overestimation of the electrostatic contribution. As nicotine and cotinine 
are subject to metabolism by P450BM3, the productive binding modes leading to 
metabolism were modeled instead of the inhibitory type II binding mode indicated by 
the absorbance spectra. Cotinine was predicted to bind with higher affinity than its 
parent compound with this orientation, unlike the case observed via spectroscopic 
titration determined for the type II binding mode. The ΔGb° of the basic substrates, 
MDMA and astemizole, were also calculated to compare the free energies of different 
binding poses. The binding poses leading to N- and O-dealkylation have comparable 
ΔGb°. A much more positive ΔGb° was obtained when astemizole is positioned for C–
H hydroxylation at C6. 
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The repulsive, electrostatic, and dispersive energy contributions are illustrated 
in Figure B3. The repulsive contribution is unfavorable (positive net energy) for the 
large ligands, astemizole, S-warfarin, and lovastatin, which could be attributed to 
expulsion of water and displacement of residues in the active site upon insertion of the 
ligand.229 On the other hand, smaller ligands, such as metyrapone, nicotine, and 
cotinine, have slightly favorable repulsive contribution since their small size allows 
binding without causing steric clashes. As expected, the electrostatic contribution 
generally become unfavorable as the ligand moves from bulk solution to the 
hydrophobic active site because of the loss of ligand-solvent hydrogen bonding 
interactions.229 Only the two acidic substrates, naproxen and S-warfarin, have negative 
 
Figure 3.7 A 7-ethoxyresorufin-O-deethylase (EROD) activity assay was 
performed to determine if compounds that induced a type II spectral shift 
efficiently inhibited metabolism of the fluorescent substrate. PM P450BM3  (2.5 
µM in 1x PBS pH 7.5 buffer); fluorescence was monitored by excitation at 535 
nm and emission at 595 nm. Saturating concentrations of compounds were 
incubated with protein for 5 min before 5 mM of 7-ethoxyresorufin was added, 
followed by 5 min incubation before H2O2 was added. The gray box indicates the 
dead time of the instrument, and the dashed lines are projected emissions during 
that time (approximately 50 seconds). The black crosses indicate metabolism of 
7-ethoxyresorufin when PM P450BM3 was not inhibited. In contrast, the red 
triangles indicate the response when 7-ethoxyresorufin is not metabolized. 
Metyrapone-bound PM P450BM3 (purple squares) was fully inhibited, whereas 
when cotinine was bound (green diamonds), activity was barely impacted. 
Interestingly, nicotine (blue circles) had an inhibitory effect on 7-ethoxyresorufin 
metabolism, but activity was still observed. 
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net electrostatic energies. Thus, the binding of nonnative substrates in PM is mainly 
facilitated by dispersion interactions. This contribution correlates with molecular size 
and compensates for the unfavorable repulsive contribution, particularly in the binding 
of astemizole and lovastatin.  
Table 3.3 High spin fractions, dissociation constants (Kd), and binding free energies 
(∆Gb) of palmitic acid and various drug molecules in PM BM3. Theoretical values 
calculated by I. Geronimo.  
a Positioned for N-dealkylation. b Positioned for O-dealkylation. c Positioned for C–H 
hydroxylation. d Type II binding mode. e Calculated using productive binding mode. 
 
3.3.2 Protein-ligand interactions in the PM BM3 active site 
 Residues that facilitate the binding of nonnative substrates were 
identified from analysis of the MD trajectories. The calculated average structures of the 
Substrate %High 
spin 
Kd (μM) ΔGb (kcal/mol) 
Experimental Theoretical 
palmitic acid 94 ± 10 1.3 ± 0.9 -8.1 ± 0.4 - 
diclofenac 83 ± 4 64.9 ± 3.9 -5.7 ± 0.1 -4.95 ± 0.62 
naproxen 80 ± 2 4.6 ± 2.9 -7.4 ± 0.4 -15.20 ± 0.77 
S-warfarin 75 ± 3 0.7 ± 0.4 -8.4 ± 0.3 -11.44 ± 0.68 
R-warfarin -1.84 ± 0.68 
lovastatin 77 ± 3 3.3 ± 1.5 -7.5 ± 0.3 -6.15 ± 0.78 
dextromethorphan 74 ± 5 3.7 ± 1.2 -7.4 ± 0.2 -6.89 ± 0.64 
MDMA - - - -6.76 ± 0.57a 
-6.21 ± 0.42b 
astemizole - - - -10.68 ± 0.91a 
-8.57 ± 0.88b 
-3.17 ± 0.53c 
nicotined - 23.5 ± 6.3 -6.3 ± 0.2 -4.60 ± 0.66e 
cotinined - 415 ± 11 -4.6 ± 0.1 -7.07 ± 0.60 e 
metyraponed - 3.6 ± 0.6 -7.4 ± 0.1 -9.09 ± 0.41 
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different enzyme-substrate complexes are shown in Figures 3.7, 3.8, and 3.9. The 
discussion of the different drug molecules is divided below by the human P450s 
primarily responsible for their metabolism. 
3.3.2.1 CYP2C9 substrates and inhibitors 
CYP2C9 metabolizes ~15% of clinical drugs and exhibits selectivity toward 
lipophilic anions, including the NSAIDs diclofenac and naproxen and anticoagulant S-
warfarin.230 Diclofenac yields 4'-hydroxydiclofenac upon oxidation by CYP2C9231; this 
metabolite was also obtained using P450BM3 variants containing some or all of the 
mutations found in PM (e.g., RP/FV/EV166, M11198, and MT35127, Table 3.1). When 
bound to the PM P450BM3 binding site, diclofenac has hydrophobic interactions with 
L75, V87, L437, and T438 (Figure 3.7, Table B2). Docking calculations predicted that 
the carboxylate group is hydrogen bonded to T438; however, the substrate changed 
position after ~12 ns of the simulation to form a hydrogen bond with S72 (Table B5). 
Both orientations place the C4' atom above the heme iron, though the orientation with 
the S72 hydrogen bond is presumably more stable. Naproxen undergoes O-
demethylation by CYP2C9 to form desmethylnaproxen.232 The RP/FV/EV variant also 
metabolized naproxen but at a lower conversion rate (58%) compared to diclofenac 
(91%).166 The naproxen hydrophobic contacts in PM are L75, V87, and A330 (Figure 
3.7, Table B2.). As in the diclofenac complex, the carboxylate group faces the substrate 
channel entrance and forms not only hydrogen bonds with the hydroxyl group and 
backbone nitrogen of S72 and backbone nitrogen of S332, but also a salt bridge with 
K69 (Table B5). This facilitates a binding orientation that positions the methoxy group 
over the heme for O-demethylation.  
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S-warfarin is an acidic molecule under physiological conditions (pKa = 4.94) 
due to the resonance stabilization of the anion and ketone-enol tautomerization that 
results in delocalization of charge between O2 and O4 of the benzopyran ring. It is 
hydroxylated at C7 by CYP2C9.233 In PM, it is positioned for reaction at C7 due to 
hydrophobic interaction primarily with L75, V87, and L437 (Figure 3.7, Table B2), 
while the oxo substituent in the benzopyran ring also forms a hydrogen bond with K69 
(Table B5). There was no interaction with S72. The less potent R-warfarin is known to 
competitively inhibit the metabolism of its enantiomer.226 It is positioned for C4’ attack 
in PM, which will yield the observed CYP2C9 product.217 Unlike its enantiomer, R-
warfarin does not form hydrogen bonds with substrate channel residues; its interactions 
 
Figure 3.8 MD-averaged structures (green) superimposed on the PM-palmitic acid 
crystal structure (PDB ID: 4ZFB1, gray). Naproxen is positioned for O-
dealkylation, while diclofenac, S-warfarin, R-warfarin, and lovastatin are 
positioned for C–H hydroxylation at C4', C7, C4', and C6, respectively. MD 
simulations done by I. Geronimo.  
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are primarily hydrophobic, specifically with L75, V78, L437, and T438 (Figure 3.7, 
Table B2).  
Statins (or 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors) such as 
lovastatin are substrates of CYP3A4 but are competitive inhibitors themselves of 
CYP2C9.234 Oxidation of lovastatin can occur at C6 or C3'235, but only the hydroxylated 
product, 6β-hydroxy lovastatin, and oxidized product, 6-exomethylene lovastatin, were 
obtained using PM/E143G and PM/E143G/E64G variants.163 Unlike the other drugs 
discussed in this section, lovastatin is neutral at physiological pH. Its hydrophobic 
contacts in PM include L75, A330, L437, and T438 (Figure 3.7, Table B2). Hydrogen 
bonding of the hydroxyl substituent in the lactone ring with S72 was short lived (~22 
ns), as it eventually formed interactions with solvent molecules. These interactions 
were also observed in the shorter (5 ns) MD simulations of lovastatin complexes of 
PM/E143G and PM/E143G/E64G.163 This suggest that this hydrogen bonding 
interaction may not play a significant role in defining ligand binding orientation or 
affinity. 
The MD simulations suggest that, for acidic drug molecules, residues S72 in 
helix B' and K69 in β-sheet 1 in P450BM3 generally play a role in substrate recognition 
and product regiospecificity, analogous to R108 in CYP2C9.236 The crystal structure of 
CYP2C9 in complex with a similar substrate, flurbiprofen (PDB ID: 1R9O236), has the 
carboxylate group buried within the active site cavity and held by a salt bridge with 
R108, which is located in the B–C loop (equivalent to helix B' in P450BM3). 
Unfortunately, the crystal structure of S-warfarin in complex with CYP2C9 (PDB ID: 
1OG5233) provides no information on the active site residues critical to the binding of 
this drug class, because the substrate is bound in a nonproductive position (C7 is more 
than 10 Å from the oxygen binding site). The interactions with either S72 or K69 
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identified by this current simulation would account for the favorable net electrostatic 
energy that contributes to the negative ΔGb° for naproxen and S-warfarin binding in 
PM (Figure B3).   
3.3.2.2 CYP2D6 substrates 
 
CYP2D6 is responsible for the metabolism of ~25% of clinical drugs despite 
constituting <2% of hepatic CYPs.237 Typical substrates, such as antihistamines and 
amphetamines, contain a protonated basic nitrogen at physiological pH, and planar 
aromatic ring.237, 238 The major pathway for metabolism for these classes of molecules 
is O-dealkylation.239-241 Two negatively charged residues in the active site, E216 and 
D301, are responsible for substrate specificity and product regioselectivity.242, 243 
 
Figure 3.9 MD-averaged structures (green) superimposed on the PM-palmitic acid 
crystal structure (PDB ID: 4ZFB 1, gray). The substrates are positioned for N-
dealkylation in A, B, and D, O-dealkylation in C and E, and C–H hydroxylation (C6) 
in F. MD simulations done by I. Geronimo.  
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In the absence of such residues in the P450BM3 active site, the protonated 
nitrogen of dextromethorphan, MDMA, and astemizole forms an ionic interaction with 
heme propionate A. This positions the substrates for N-dealkylation, a reaction mainly 
catalyzed by a different human P450, CYP3A4244; N-demethylation is the second main 
metabolic pathway for these three molecules. Experiments confirm that 3-
methoxymorphinan and 3,4-methylenedioxyamphetamine are the major metabolites for 
dextromethorphan and MDMA, respectively, from oxidation by P450BM3 variants 
containing some or all of the PM substitutions such as M01, M02, and M05 (Table 
3.1).125 The N-dealkylation product of astemizole, norastemizole, is a minor product of 
CYP3A4 metabolism241, 245 and has only been obtained so far using chimeras of 
P450BM3 with other enzymes from the CYP102A subfamily.196 Hydrophobic contacts 
in the active site are V87, T260, I263, and L437 for dextromethorphan; L75, A330, and 
L437 for MDMA; and V87, L181, I263, A264, L437, and T438 for astemizole (Figure 
3.8, Table B3). A pronounced structural rearrangement was observed in the case of 
astemizole; helix F (M177, L181, A184) moved away from the protein core to 
accommodate the fluorophenyl ring. This would also account for the large repulsive 
contribution to the binding free energy (Figure B3). A suitable orientation for N-
demethylation was not observed in the simulation. 
The substrate-binding pose leading to O-dealkylation was found for MDMA 
and astemizole (Figure 3.8). The protonated nitrogen of MDMA forms a hydrogen bond 
with the backbone oxygen of L437 (Table B5), bringing it closer to E435 for ionic 
interaction. On the other hand, the benzimidazole ring of astemizole extends toward the 
loop connecting β-sheet 1-5 and helix B', causing a slight distortion in this region 
(residues 69–74) and breaking the heme propionate A-K69 salt bridge at different 
points during the simulation. MDMA forms favorable hydrophobic contacts with L75, 
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V87, L437, and T438, and astemizole mainly with L75, V87, and L437 (Table B3). In 
modeling the formation of another metabolite obtained with CYP2D6, 6-
hydroxyastemizole241, astemizole is forced into a folded conformation within the PM 
active site. The methoxyphenyl ring displaced the entire β-sheet 1, causing the heme 
propionate A-K69 salt bridge to break as well (Figure 3.8). Hydrophobic contacts of 
astemizole in this binding pose include V78, V87, I263, A328, L437, and T438 (Table 
B3). CYP2D6 metabolites of astemizole (desmethylastemizole and 6-
hydroxyastemizole; note that these reactions occur at aromatic rings at opposite ends 
of the large drug molecule) have been obtained with the 9-10A/A78F and 9-
10A/A78F/A82G/A328F variants of P450BM3 (Table 3.1).5 The A78F and A82G 
substitutions, presumably conferred greater flexibility to helix B’, allowing the enzyme 
to easily accept this large drug molecule in different binding orientations without 
causing the disruption of structure observed in simulations of PM. 
3.3.2.3 CYP2A6 substrates. 
 
CYP2A6 has relatively narrow substrate specificity but has gained interest due 
to its involvement in the metabolism of toxic and procarcinogenic compounds.246 The 
 
Figure 3.10 MD-averaged structures (green) of superimposed on the PM-palmitic 
acid crystal structure (PDB ID: 4ZFB 1, gray). Cotinine and nicotine are positioned 
for oxidation at C5' and C3'/C4', respectively. Metyrapone acts as an inhibitor by 
forming a covalent bond with the heme iron. MD simulation done by I. Geronimo. 
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crystal structure of the nicotine complex of CYP2A6 (PDB ID: 4EJJ247) indicates that 
F209 and I300 play a role in substrate orientation within the active site. However, 
nicotine does not form hydrogen bond interactions with any active site residues; its 
pyridine nitrogen is too far from N297, a conserved residue in CYP2A enzymes. In the 
PM P450BM3 active site, the protonated nitrogen of nicotine forms an ionic interaction 
with heme propionate A (Figure 3.9), similar to the CYP2D6 substrates. Significant 
hydrophobic contacts of nicotine include V87, A328, and L437 (Table B4). The major 
metabolite of nicotine, cotinine, is positioned for 3'- or 4'-hydroxylation in the active 
site (Figure 3.9). Cotinine is known to be further metabolized to trans-3'-
hydroxycotinine, the major urinary metabolite of nicotine, by CYP2A6 and 
CYP2A13.248, 249 In the simulation, cotinine is held by hydrophobic interactions with 
L75, A264, and L437 (Table B4), which orient it for reaction. Unlike nicotine and 
cotinine, the P450 inhibitor metyrapone, which also contains a pyridine ring, interacts 
primarily through formation of a coordinative bond to the heme iron. This binding mode 
is consistent with its role as a P450 inhibitor specifically of 11β-hydroxylase250 though 
off-target affects are known.251, 252 Metyrapone is not subject to oxidative metabolism 
by P450s; rather, it undergoes reductive metabolism to form the alcohol, metyrapole, 
before glucuronide conjugation.253  
3.3.3 Factors contributing to uncoupling. 
Low turnover number and coupling efficiency are often observed with oxidation 
of nonnative substrates by P450BM3 variants. This may be attributed to catalytic 
uncoupling.33, 34 The two major pathways for this alternative reaction pathway are (1) 
protonation of the proximal oxygen in the ferric hydroperoxide complex to release H2O2 
(peroxide uncoupling) and (2) two-electron reduction and deprotonation of oxygen in 
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the oxo-ferryl porphyrin radical intermediate (Compound I) to yield a second water 
molecule (oxidase uncoupling; Figure 3.1).200 
An experimental study of the mechanisms of the different uncoupling modes in 
P450cam indicates that excess water in the active site plays an important role in both 
pathways by acting as a proton source. Moreover, for peroxide uncoupling, charge 
separation at Fe during dissociation of HOO– is favored by the increased polarity of the 
environment. Water is also thought to destabilize the ferric hydroperoxide complex by 
disrupting its putative hydrogen bond with a threonine residue in the active site (T268 
in P450BM3).254 Figure 3.10 shows high water density in the substrate channel when 
dextromethorphan, MDMA, astemizole, diclofenac, or warfarin is bound, in contrast to 
when palmitic acid is bound (Figure B4). This may be attributed to the positioning of 
hydrophilic groups of these molecules deep within the cavity. Moreover, high water 
density near T268, where the hydroperoxo ligand would be bound, was observed when 
dextromethorphan, MDMA, and astemizole are oriented for N-dealkylation. This 
would be consistent with the relatively low fraction of high-spin protein found with the 
PM-dextromethorphan complex (Table 3.3), which indicates that there is room for 
excess water around the heme iron even in the presence of this large substrate. 
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In oxidase uncoupling, electron transfer to Compound I competes with substrate 
oxidation. This likely occurs if the substrate is too mobile and/or the reacting atom is 
too distant from the oxidizing species, a consequence associated with lack of 
complementarity within the active site.93 The MD-averaged structures show that the 
 
Figure 3.11 Water density at the PM P450BM3 substrate channel, with the reference 
structure averaged from the MD simulation. MDMA is positioned for N- and O-
dealkylation in B and C. Astemizole is positioned for N- and O-dealkylation in D 
and E, and C–H hydroxylation in F. T268, located at the distal side of the heme 
(helix I) and believed to play a role in proton delivery and oxygen activation, is also 
shown. Water density is relatively lower in the presence of palmitic acid, naproxen, 
lovastatin, nicotine, and cotinine (Figure B4). MD simulation done by I. Geronimo. 
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shape of the PM P450BM3 active site, meant to accommodate long-chain fatty acids, is 
essentially unaltered in the presence of drug molecules (Figures 3.7–3.9). Thus, small 
substrates or those that do not form stable ionic/hydrogen bond interactions with active 
site residues would be highly mobile during the simulations, as was the case with 
astemizole, diclofenac, lovastatin, cotinine, and R-warfarin (Figure B5).  
Reducing substrate mobility and water access to the active site can be achieved 
by substituting smaller active site residues with leucine, isoleucine, methionine, or 
phenylalanine.254 β-sheet 1-4 (residues 329–336) offers a promising mutation site for 
P450BM3 because substitution with large residues would not hinder substrate access to 
the oxidizing heme intermediate. For example, variants containing tryptophan at 
position 330 within β-sheet 1-4 had high conversion rates for chlorzoxazone and 
lidocaine.166 On the other hand, the A330P mutation (PDB ID: 3M4V208) was found to 
reduce the size of the cavity by displacing the side chain of the adjacent P329 into the 
active site. A330P-containing variants exhibited improved coupling efficiencies for the 
oxidation of small alkanes and aromatic compounds208 and high conversion rates for 
naproxen, chlorzoxazone, and amitriptyline.166 The key is combining structural 
flexibility to allow for promiscuity with sufficient water exclusion to increase catalytic 
efficiency. 
3.3.4 Heme interactions affecting oxidizing ability. 
Heme propionate groups not only play the structural role of anchoring the heme, 
but may also be involved in regulating electrostatic interactions that are key to the 
catalytic reaction.255, 256 Propionate A forms a salt bridge with K69, while propionate D 
forms a salt bridge with R398 and a hydrogen bond with W96 in P450BM3. The binding 
of acidic and basic ligands, but not neutral ligands, disrupted these interactions. With 
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dextromethorphan, MDMA, and nicotine oriented for N-dealkylation, propionate A 
bent toward the active site (dihedral angle of ≈60°) during the simulations (Figures 3.8, 
3.9 and B6), while maintaining interaction with K69 (Table B6). Propionate bending 
also occurred in the M01, M02, and M05 variants (substrate-free and in complex with 
dextromethorphan and MDMA) based on Resonance Raman and MD simulations.128 
Hydrogen bonding between propionate A and the protonated nitrogen was observed for 
nicotine and MDMA, which would facilitate electron transfer from the substrate to the 
porphyrin π-cation radical and then to Fe(IV) of Compound I.256 Thus, basic functional 
groups that can interact directly with heme propionates do not seem to jeopardize 
catalytic reactivity.  
In contrast, as discussed earlier, the acidic drugs S-warfarin and naproxen 
interact with K69 (Figure 3.7), thus competing with propionate A (Table B5) for 
interaction with this residue. In the PM-naproxen complex, the interaction with K69 
was broken during the simulation and propionate A, instead, forms a hydrogen bond 
with the backbone nitrogen of N395 (Table B6). This may reduce the oxidizing ability 
of Compound I, which depends on the spin density localized on the porphyrin ring.256 
Density functional theory calculations indicated that the salt bridge formed by heme 
propionates with Arg or Lys stabilizes the cationic porphyrin radical by weakening 
charge donation from the carboxylate group.255, 257 Interaction with K69 could explain 
the low activity of most P450BM3 variants toward acidic substrates.122, 166 Introducing 
another hydrogen-bond-forming residue in the active site to interact with acidic 
substrates would therefore improve activity, as appears to be the case with the MT35 
variant (Table 3.1), which contains the L437S substitution.127  
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3.4 Conclusions 
P450BM3 variants are capable of metabolizing a wide variety of nonnative 
substrates, and have been the subject of extensive protein engineering efforts. The 
resulting enzymes typically contain mutations far from the active site that increase the 
flexibility of the lid domain and SRS without significantly altering the active site 
architecture. In order to better understand the features that regulate binding, key 
molecular interactions that impact substrate positioning, and factors that impact 
catalytic efficiencies, we performed an investigation combining experimental and 
computational analyses of diverse small molecules that bind to P450BM3.  
Structurally different and highly polar human P450 substrates and inhibitors 
were chosen for the analysis. These molecules contain acidic, basic, and polar groups, 
aromatic and aliphatic ring systems, and range in molecular weight from 162.2 to 458.6 
AMU (Table 3.2). Despite the chemical diversity, all molecules nevertheless exhibit 
affinity for PM P450BM3 and bind with negative ∆Gb° primarily due to dispersion 
interactions, specifically with L75 in helix B', I263 in helix I, L437 and T438 in β-sheet 
4, A328, and V87 (Figure 3.2). In addition, acidic drug molecules form electrostatic 
interactions with S72 in helix B' and K69 in β-sheet 1, and basic drug molecules engage 
with heme propionate A. However, the lack of structural and electrostatic 
complementarity between nonnative substrates and the active site would have an impact 
on the turnover number and coupling efficiency of P450BM3 variants. The resulting 
increase in substrate mobility and water access to the active site could lead to 
uncoupling reactions. Substrate interaction with K69, which forms an important salt 
bridge with the heme, could lessen the oxidizing ability of the enzyme. Protein 
engineering efforts to develop more active and efficient P450BM3 variants should 
therefore focus on reducing these effects. 
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 CORRELATIONS BETWEEN THE PROMISCUITY OF 
CYTOCHROME P450BM3 VARIANTS AND OXIDATION STATE DEPENDENT 
STABILITY   
4.1 Introduction 
Cytochrome P450s (CYPs) are cysteine-ligated heme monooxygenases that 
incorporate molecular oxygen into C-H bonds. In humans, CYPs play a fundamental role 
in steroidogenesis and xenobiotic metabolism, and exhibit some variation in selectivity for 
their substrates. CYPs active in xenobiotic metabolism interact with a wide variety of 
diverse substrates. The prime example of this is CYP3A4, which metabolizes 
approximately 50% of known drugs.65, 258 This is facilitated by the fact that CYP3A4 has a 
highly flexible confirmation in which diverse substrates are able to reach the deeply buried 
active site.67 In comparison, aromatase (CYP19A1) plays a key role in estrogen synthesis, 
and is a very selective enzyme that only converts androstenedione and testosterone into 
estrone and estradiol respectively.259 Thus, while CYPs are similar in global structure and 
utilize the same catalytic cycle, they have evolved to range from selective to promiscuous 
based on their function.  
In order to investigate properties related to promiscuity, Cytochrome P450BM3 
(CYP102A1), a bacterial enzyme isolated from Bacillus megaterium, was used as a model 
system. P450BM3 is a good candidate to examine a variety of questions relating to P450 
behavior as it is soluble and can be easily expressed and purified. Most importantly for 
investigating how enzyme promiscuity either arises or the impact it has on a protein is the 
range of selectivity that can be incorporated. Wild type P450BM3 (WT) is relatively 
selective, preferentially binding medium to long chain fatty acids. Five residues 
(R47L/F81I/F87V/L188Q/E267V, the “Pentuple mutant”, PM) can be made to the WT to 
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become more promiscuous, and able to interact with drug-like molecules similar to 
xenobiotic metabolizing CYPs.128 Previous studies have documented that although the PM 
is more promiscuous, this comes at the cost of stability. We have shown that the global 
structure of the PM unfolds with a urea concentration midpoint of 2.7 ± 0.2 M compared 
to WT at 5.4 ± 0.5 M by pulse proteolysis.260 In addition, this change in stability can be 
significantly attenuated by the presence of native and non-native substrates and 
inhibitors.260  
As a follow-up study, we are interested in determining how the iron oxidation state 
impacts enzyme stability, and if correlations can be made to the overall selectivity of the 
enzyme. This is of particular importance as it was shown that both Fe(III) and Fe(II) states 
are present in cells without substrate bound for P450cam, P450cin, and five human 
xenobiotic- metabolizing CYPs.14 This finding contradicts the established model, which 
presupposes that CYPs are in a low-spin (LS) Fe(III) water bound state at rest, and do not 
become reduced until after substrate has bound and the enzyme is converted to the high 
spin state. It would be expected that a population of enzyme in the ferrous state in the 
absence of substrate would lead to an increased rate of uncoupled catalysis, thus increasing 
reactive oxygen species (ROS). While this study did not find a decrease in P450 content as 
a result of ROS production,14 they did not investigate the stability of the enzymes trapped 
in the Fe(III) or Fe(II) states.  
Several studies have investigated the stability of Cytochrome c (cyt c) as a function of 
iron oxidation state.261-265 Cyt c is similar to CYPs as it is a heme enzyme, though it is bis-
ligated to histidine and methionine. Unlike CYPs, whose main function is to catalyze 
insertion of oxygen into a substrate, cyt c’s main role is electron transfer. The stability of 
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cyt c is higher in the ferrous state (Cm of ~ 5 M guanidium hydrochloride, as determined 
by tryptophan fluorescence) than the ferric state (Cm of ~ 2.5 M guanidium 
hydrochloride).264  Interestingly, when the methionine-heme ligation was broken and 
replaced with cysteine, this relationship inverted, so that the ferric state was more stable 
than the ferrous. This change in iron state stability was also accompanied by a dramatic 
decrease in the reduction potential (290 mV vs. -390 mV), indicating the ease of electron 
transfer from NAD(P)H.266 In theory, replacing the methionine-heme ligation to a cysteine 
should make cyt c more adept at catalysis rather than electron transfer.  
We aim to discover the role of promiscuity in regulating the relationship between 
the ferrous and ferric states in CYPs. To do this, UV/Vis spectroscopy, circular dichroism 
(CD), and pulse proteolysis were used to probe active site, secondary structure, and global 
structure of the enzyme to achieve a comprehensive view of oxidation state. As CYPs play 
a vital role in health and exhibit potential biotechnical applications, understanding the 
relationship between promiscuity, oxidation state, and stability is essential. This is 
especially relevant for further understanding of how these enzymes function as well as how 
they differ from other heme-bound proteins.  
4.2 Experimental procedures 
4.2.1 Cloning and site-directed mutagenesis of P450BM3 
The heme domain (Thr 1 to Thr 463) of P450BM3 containing a C-terminal 6xHis tag 
was cloned into the pCWori vector. All point mutations were incorporated into the heme 
domain through site-directed mutagenesis using the Quikchange kit (Stratagene). The 
ligation mixture was transformed into Top10 competent cells and screened for ampicillin 
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resistance. Colonies were selected and grown in Luria Broth, followed by plasmid isolation 
and digestion with AgeI and BseRI.  Plasmids containing the heme portion of the gene 
were sequenced for verification (Eurofins Genomics). 
4.2.2 Expression and purification 
P450BM3 variants were expressed in BL21(DE3) E. coli cells which were grown in 
1 L Terrific Broth at 37oC while shaking at 180 rpm until an OD6oo of 0.7 to 0.8 was 
reached. Protein expression was induced upon addition of IPTG to a final concentration of 
0.5 mM. Cells grew for another 20 h before harvested by centrifugation (Beckman 
Avanti™ J-25 I) at 2,975 xg and 4 °C. Cell pellets were stored at -80 °C for further use.  
For purification, the cells were resuspended in lysis buffer (50 mM NaH2PO4, 300 
mM NaCl, 10 mM imidazole, and 0.1 mM EDTA, pH 8.0) with 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF) added. Afterwards, cells were lysed by sonication 
on ice for 15 min using a microtip (Branson Sonifier 250) with output control of 3 and duty 
cycle of 50%.  This was followed by centrifugation at 20,000 xg for 1 h at 4 °C. The 
supernatant was decanted and passed through a 0.45 µM polytetrafluoroethylene syringe 
filter before being loaded onto a His-Trap column (GE Healthcare) equilibrated in Buffer 
A (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole. Protein was eluted as the imidazole 
gradient gradually increased from 20 mM to 200 mM upon the addition of Buffer B (50 
mM NaH2PO4, 300 mM NaCl, 200 mM imidazole) by an Äkta explorer. The protein 
containing fractions were collected based on absorbance at 420 nm and concentrated to 
approximately 2 ml using Amicon Ultracel-30K Millipore centrifugal units. Protein was 
then loaded onto a Hi-Pre 26/60 Sephacryl S200 HR column equilibrated in gel filtration 
buffer (20 mM Tris, 150 mM NaCl, pH 8.0). Fractions with a 420/280 absorbance ratio 
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>1.4 for WT, and >1.2 for F81I, I401P, and PM were concentrated to below 20 mg/ml. Co-
binding was used to determine concentration.267 Glycerol was added to approximately 
20%; aliquots were made, snap-frozen, and stored at -80 °C until use.  
4.2.3 Pulse proteolysis 
The pulse proteolysis procedure was adapted from work by Park and Marqusee.137 
The enzyme was diluted to 0.75 mg/ml in various concentrations of urea from 0 – 6.8 M 
made in pulse buffer (20 mM Tris, 10 mM CaCl2, and 20 mM NaCl, pH 7.4). After a 2 h 
incubation at room temperature, 10 mg/ml thermolysin was added and vortexed. After 1 
min, the reaction was stopped by addition of EDTA to a final concentration of 37 mM and 
samples were immediately placed on ice. β-laemmli was added to each sample, which were 
subsequently placed in a hot block for 1 min at 95 °C. Denatured protein was then loaded 
and run on a 4-12% tris-glycine gel for 1 h at 120 volts. Gels were stained in Coomassie 
blue for approximately 2 h and left overnight in destain (45% water, 45% methanol, 10% 
acetic acid). The next day gels were imaged using a ChemiDoc™ MP with Image Quant 
software (Biorad). Concentration midpoint (Cm) values were determined using Graphpad 
Prism graphing software. Data was normalized to fraction folded and fit with either a 
sigmoidal or biphasic equation. For Fe(III)-4-cyanopyridine (CNPy) systems, substrate 
was added to enzyme before dilution in urea for approximately 5 min. Excess CNPy was 
also added to each urea concentration. For Fe(II)-CO systems, all buffer and urea was CO-
saturated before use. Fresh dithionite at a concentration of 2 mM was added to enzyme 
before dilution and was also present in each urea sample. For Fe(II)-CNPy systems, 
enzyme was reduced with 2 mM dithionite and CNPy was immediately added. After a 5 
min incubation reduced and bound enzyme was diluted in urea with excess dithionite and 
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CNPy added. All states were checked by UV/VIS to ensure they were in the proper state 
before the experiment was performed.  
4.2.4 Circular dichroism (CD) 
CD spectroscopy was performed to investigate the unfolding of protein secondary 
structure by following the signal at 222 nm. The protein was diluted to a concentration of 
0.1 mg/ml in urea ranging from 0 - 6.8 M made in 100 mM KPi buffer, pH 7.4.  After a 2 
h incubation, spectra were obtained using a Jasco J-815 CD spectrometer. The settings 
were as follows: sensitivity – standard, bandwidth – 1.00 nm, D.I.T – 0.5 sec, measure 
range 260-200 nm, scanning speed – 50 nm/min, and 2 accumulations. Enzyme in various 
iron states was prepared as written in the pulse proteolysis section. Data was plotted using 
Graphpad Prism software. Ellipticity (mdeg) at 222 nm was plotted versus urea 
concentration, and a sigmoidal regression equation was applied to determine the Cm value.  
4.2.5 UV/Vis spectroscopy 
Absorbance spectra were taken to examine the direct consequences of unfolding on 
the heme environment. The protein was diluted to 0.15 mg/ml in varying concentration of 
urea from 0 – 6.8 M made in 100 mM KPi buffer, pH 7.4. After a 2 h incubation, absorbance 
spectra were obtained using an Agilent 8453 UV-visible spectrometer. Results were plotted 
using Graphpad Prism. To determine which wavelength experienced the greatest change 
as a result of unfolding, difference spectra were produced. The Cm value was found by 
plotting the normalized absorbance of λmax versus urea concentration. For the various iron 
states studied, the enzyme was prepared as described for pulse proteolysis.  
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4.2.6 Determination of reduction potential 
Reduction potentials of P450BM3 variants were estimated using a modified 
procedure from Ost et al.268 The enzyme was diluted in 100 mM KPi, pH 7.4 to 0.15 mg/ml 
in a 3 mL quartz cuvette. A few granules of dithionite were added to the cuvette followed 
by CNPy to saturation. An absorbance spectrum was taken once the enzyme was fully 
reduced and CNPy bound. Data was plotted using Graphpad Prism, with an emphasis on 
the metal-to-ligand charge transfer absorption band (MLCT) from 600-700 nm. The λmax 
was determined in the MLCT region, and using the equation, EMLCT = (3.53 x Em) + 17,005 
cm-1 ,268 the reduction potential was estimated. Each experiment was performed in 
triplicate. 
4.3 Results 
4.3.1 Selectivity of P450BM3 can be modulated by strategic mutations. 
 
 
Figure 4.1 Crystal structures of the active site of A)WT (PDB ID: 4ZFA) and B) PM 
P450BM3 (PDB ID: 4ZF6). Residues highlighted by green denote location and 
orientation of mutations. A ribbon diagram of WT (blue) and PM (orange) overlaid is 
depicted in panel C) indicating a similarity in global structure.  
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 For this study, four variants of P450BM3 were chosen that exhibit a range of 
promiscuity. This study includes the wild type (WT), F81I, I401P, and pentuple mutant 
(R47L, F81I, F87V, L188Q, E267V; PM), (Figure 4.1).  The mutation in the first of these 
variants, F81I, is also present in PM. The residue is located in the B’-helix, and though the 
side chain is not directly in the active site, it is oriented to the interior, allowing for 
interactions with amino acids in the F-helix, specifically L181. According to van Vugt-
Lussenburg et al., though the I81 mutation only has a subtle shift in position compared to 
F81, it subsequently changes the location of L181. This leads to a conformational change 
in the active site that impacts how the ligand fits into the hydrophobic interior.269 
Additionally, a further study using MD simulations indicated that the F81I mutation shifts 
the B’-helix slightly further away from other helices in the interior, leading to a widening 
of the access channel to the active site.128 It was also shown that inclusion of I81 to PM 
increases the rate of dextromethorphan and MDMA turnover by 3 to 5 fold.128 Our 
examination of the F81I P450BM3 enzyme indicates that it has behavior similar to WT in 
regards to binding of substrates. Specifically, in that binding of several substrates (ie. 
metyrapone, Figure C1) is not observable by typical type I or II spectral shifts.  
The I401P P450BM3 mutant was first published by Whitehouse et al. in 2009.270 
Isoleucine is a hydrophobic residue located beside the cysteine proximally ligated to the 
Fe-heme. Though prolines are thought to be disruptive residues, for select heme-Cys 
ligated enzymes this position is naturally a proline.192, 193 Distinct changes are seen to the 
overall protein structure based on this single mutation (Figure C2 A). The most obvious 
change is the spin state of the heme in the resting state. Unlike WT P450BM3, the I401P 
P450BM3 mutant was mostly in the high spin state159, which is typically seen upon substrate 
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binding. In addition, a broad metal to ligand transition (MLCT) band appeared from 600 – 
700 nm as shown in Figure C2. The I-helix experiences the impact of this mutation, with 
the positions of G265 and H266 being slightly altered. These changes lead to a loosening 
of contacts as they prevent intrahelical hydrogen bond formation.270 These structural 
changes lead to an enzyme that is in its catalytically active state in the absence of substrate, 
allowing it to avoid the conformational changes other P450BM3 variants must go through 
before catalysis can occur. It is not clear if the structure enjoys added flexibility, but if it 
does, this may be one of the reasons why I401P P450BM3 is able to turnover a more diverse 
substrate class than WT. The I401P  P450BM3 mutant is able to metabolize a large class of 
substrates, such as fluorene, toluene, 3-methylpentane, and (+)-α-piene, but it has the same 
high reactivity as WT P450BM3.270, 271 It was determined by GC/MS that oxidation of lauric 
acid by both the WT and I401P P450BM3 enzymes yielded three major products, where the 
ω-1, ω-2, or ω-3 carbon was hydroxylated at a ratio of approximately 30% each.270 This 
trend was also replicated with palmitic acid.271 
PM P450BM3 is an extremely promiscuous P450BM3 variant that is able to turnover drug-
like molecules such as dextromethorphan,269 MDMA,269 amitriptyline,272, 273 and 
buspirone.272, 273 The decrease in selectivity for this variant is also accompanied by a 
decrease in stability as compared to WT  P450BM3, which can be attributed to the 
cumulative impact of the five mutations made to PM P450BM3.260 As mentioned above, 
changing a larger hydrophobic residue to a smaller residue for the F81I mutation impacts 
hydrophobic contacts of the lid domain. The E267V and R47L mutations both eliminate 
salt bridges that provide important contributions to protein stability. When L188 is mutated 
to the polar glutamine residue, it causes a negative interaction with Q73, decreasing 
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stability. While these mutations decrease stability, their combination causes a closed 
conformation of the enzyme that increases its catalytic activity towards non-native 
substrates.  
Table 4.1 Concentration midpoint (Cm) values of P450BM3 variants determined by UV/Vis 
spectroscopy.a 
a. All values are in molar urea.b. Two values are listed for ferrous states as two separate 
unfolding events occurred. c. Two values separated by a comma indicate biphasic 
unfolding. 
 
4.3.2 Changes in active site stability are observed by UV/Vis spectroscopy. 
UV/Vis spectroscopy is a robust technique to evaluate the protein environment 
around chromophores.274 As P450s have a heme porphyrin ligated to a cysteine thiol, 
absorbance methods can be used to examine how the active site environment is perturbed 
by various factors, including effects on the distal and proximal faces, along with hydrogen 
bonding interactions with the heme propionates. Conformational rearrangements are 
 Fe(III)-
H2O 
Fe(III)-CNPy Fe(II)-CNPy b Fe(II)-CO b 
WT 4.0 ± 0.4, 
5.6 ± 0.3c 
5.5 ± 0.1 4.2 ± 0.2 (426 nm) 
4.9 ± 0.2 (445 nm) 
3.0 ± 0.2, 5.6 ± 0.1 
(420 nm) c 
3.1 ± 0.1, 5.6 ± 0.1 
(450 nm) c 
F81I 5.3 ± 0.1 - - 3.6 ± 0.1 (420 nm)  
3.1 ± 0.1, 5.1 ± 0.2 
(450 nm) 
I401P 3.6 ± 0.1 - - 3.6 ± 0.1 (420 nm) 
3.4 ± 0.1, 5.1 ± 0.2 
(450 nm) 
PM 2.3 ± 0.2, 
3.9 ± 0.2c 
3.1 ± 0.1 3.4 ± 0.1 (426 nm) 
2.9 ± 0.1 (445 nm) 
2.2 ± 0.1 (420 nm) 
2.3 ± 0.1 (450 nm) 
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associated with reduction of the iron heme, so the impact of the oxidation state of the iron 
was evaluated in the different variants. 
Four states were studied for comparison purposes for the two extreme variants, WT 
and PM P450BM3 were examined while F81I and I401P P450BM3 were examined as 
intermediates. While the water-bound and carbon monoxide-bound states are commonly 
used as the resting state and a model for the Fe(II)-O2  state,275 4-Cyanopyridine (CNPy) 
was chosen as it binds to both the Fe(II) and Fe(III) states (Figure C3). This ligand is bound 
to the Fe-heme via the nitrogen pyridine as previously shown for P450BM3 268 and 
P450cam.276 Binding dissociation constants (Kd) for CNPy were found for WT and PM 
P450BM3 in the Fe(III) and Fe(II) states (Figure C3, Table C1). Consistent with literature268, 
tighter binding was observed for the ferrous states as opposed to the ferric states (Table 
C1). Thus, the states compared were Fe(III)-H2O, Fe(III)-CNPy, Fe(II)-CNPy and Fe(II)-
CO. For the two single point variants, only the resting Fe(III)-H2O and Fe(II)-CO states 
were investigated, as to simplify analysis. All concentration midpoint values are shown in 
Table 4.1. 
104 
 
 
Figure 4.2 Reduction of P450BM3 variants impacts stability as detected by UV/Vis 
spectroscopy. In each case, the left absorbance spectra is the Fe(III)-H2O state, 
monitored over 0 – 6.8 M urea; the middle absorbance spectra is the Fe(II)-CO state 
monitored over 0 – 6.8 M urea. Insets show difference spectra, where the blue line = 
0 urea, and the red line is the last urea addition. The fits to the data on the right are the 
normalized absorbance of Fe(III)-H2O P450BM3 at 418 nm (closed circles) and Fe(II)-
CO P450BM3 at 450 nm (open squares), which were used to determine Cm for both 
states. A-C)  WT P450BM3. D-F) PM P450BM3.  G-I) F81I P450BM3. J-L) I401P 
P450BM3. Studies were performed in 100 mM KPi pH 7.4 buffer with protein at a 
concentration between 0.15 – 0.25 mg/mL. All experiments were done in a 1-cm 
quartz cuvette. Concentrated urea was made in 100 mM KPi pH 7.4 buffer before 
dilution. For CO-bound studies, KPi buffer was first saturated with CO. Sodium 
dithionite was made immediately before use and dissolved in CO-saturated 100 mM 
KPi pH 7.4 buffer. All samples were incubated for 2 hr at RT before absorbance 
spectra were taken. For results with one transition, data was fit on Graphpad prism 
with the sigmodial dose-response (variable slope) equation. For results with two 
unfolding transitions data was fit with a biphasic nonlinear fit equation. 
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Unfolding of the WT Fe(III)-H2O state was demonstrated by a decrease in 
absorbance of the Soret band at 418 nm and the q-bands from 500 - 600 nm (Figure 4.2A) 
as the urea concentration was increased. The WT Fe(III)-H2O state was best fit by a 
biphasic equation as opposed to a monophasic equation as shown by residual plots (Figure 
C5). It was the most stable state, exhibiting a Cm of 4.0 ± 0.4 M for the first unfolding event 
and 5.6 ± 0.1 M for the second. This biphasic fit hinged on one point around 4 M urea, but 
was observed consistently through three separate experiments. Unfolding of the WT Fe(II)-
CO state was observed optically by a disappearance of the P450 state and a rise of the P420 
state as denaturant increased (Figure 4.2B). As two distinct processes occurred, two Cm 
values are reported, 3.0 ± 0.2 M and 5.6 ± 0.1 M for the process at 420 nm and 3.1 ± 0.1 
M and 5.6 ± 0.1 M  for the process at 450 nm (Figure 4.3, Table 4.1). For the P450 state, a 
majority of the protein (60%) was denatured during the first unfolding event (3.1 ± 0.1 M) 
and 40% unfolded over 2 M later, with a Cm  of 5.6 ± 0.1 M shown in Figure 4.2C. The WT 
Fe(III)-CNPy state exhibited a decrease in absorbance of the slight red shifted Soret band 
with very little change to the q-bands (Figure C6). Similarly to the Fe(II)-CO state, the WT 
Fe(II)-CNPy state unfolded by two processes- disappearance of  the properly ligated state 
at 445 nm and appearance of the misligated state277 at 426 nm. There was also a slight blue 
shift of the q-bands as the active site unfolded (Figure C6). Unlike the water and carbon 
monoxide states, the CNPy bound states unfolded monophasically with a Cm of 5.5 ± 0.1 
M for the ferric state and 4.2 ± 0.2 M (426 nm) and 4.9 ± 0.2 M (445 nm) for the ferrous 
state (Figure 4.3, Table 4.1). The stability of the WT ferrous states were, in general, lower 
than the WT ferric states. The most obvious example is of the Fe(II)-CO state compared to  
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the WT Fe(III)-H2O state where there is over a two molar unit difference in stability (Figure 
C7).   
 
The PM P450BM3 species studied were less stable than the same WT P450BM3 
species by UV/Vis. All four states unfolded optically similar to the WT species with the 
exception of the Fe(II)-CNPy state (Figure C6). The extinction coefficient for the 426 nm 
state for the PM P450BM3 species was observably higher than that of the WT, shown by the 
higher absorbance of the 426 state compared to the 445 state. The PM P450BM3 Fe(III)-
H2O state studied by UV/Vis (Figure 4.2D) was the only PM P450BM3 state that displayed 
biphasic unfolding by any technique. The first phase had a Cm  = 2.3 ± 0.2 M and 
contributed approximately 50% to the overall unfolding event. The second higher Cm  was 
 
Figure 4.3 Unfolding of WT and PM P450BM3 as detected by UV/Vis spectroscopy. 
A) and D) the Fe(II)-CO state;  B) and E) the Fe(III)-CNPy state; C) and F) the Fe(II)-
CNPy state. A) through C) WT P450BM3;  D) through F) PM P450BM3. For the ferrous 
states the open circles represent the appearance  of the inactive state (420 nm for the 
Fe(II)-CO state and 426 nm for the Fe(II)-CNPy state) and the closed circles are 
disappearance of the active state (450 nm for the Fe(II)-CO state and 445 nm for the 
Fe(II)-CNPy state). 
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3.9 ± 0.2 M (Table 4.1).  The Cm values of the Fe(II)-CO transitions were similar to the 
first unfolding event for the water bound state, with Cm values of 2.2 ± 0.1 M (420 nm) and 
2.3 ± 0.1 M (450 nm). Similar values were also found between the CNPy bound PM 
P450BM3 states, in fact one of the ferrous transitions exhibited a higher Cm than the ferric 
state, 3.4 ± 0.1 (426 nm) for the Fe(III) state vs 3.1 ± 0.1 M for the Fe(II) state (Figure 4.3, 
Table 4.1).  
Unfolding of the F81I P450BM3 species occurred similarly to the corresponding WT 
and PM P450BM3 states. For the water bound state this meant a decrease in the Soret band 
and for the Fe(II)-CO state a decrease in the P450 state with an increase of the P420 state 
(Figure 4.2G,H). Concentration midpoint values were comparable to WT, though not 
biphasic for the water bound state (Cm = 5.3 ± 0.1 M). Cm values for the Fe(II)-CO 
transitions were 3.6 ± 0.1 M (420 nm) and 3.1 ± 0.1 M, 5.1 ± 0.2 M (450 nm) as seen in 
Table 4.1. As the I401P P450BM3 is naturally high spin in the resting state, it unfolded 
differently than all other variants. Upon denaturation, the Soret band red shifted from the 
HS resting state at 395 nm to an inactive state at 420 nm. As the urea concentration 
continued to increase, the absorbance at 420 nm decreased, indicating a loss of the heme 
from the active site.  This shift in absorbance was accompanied by the appearance of a 
large shoulder at the HS position and a decrease in absorbance of the MLCT band (Figure 
4.2J). The Cm for the water bound state was between that of PM and WT P450BM3 with a 
Cm of 3.6 ± 0.1 M (Table 4.1). When reduced and CO-bound, the I401P P450BM3 variant 
shows the typical red shift expected to approximately 450 nm. Upon denaturation by urea, 
this peak shifts to an inactive species at approximately 425 nm (Figure 4.2K). As compared 
to the Fe(III)-H2O state, unfolding of the Fe(II)-CO state unfolds more rapidly evidenced 
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for the steepness of the slope of the unfolding plot (Figure 4.2L).  The Cm values at both 
425 nm and 450 nm were close to those observed for CO bound ferrous WT P450BM3 with 
a biphasic unfolding pattern apparent at 450 nm. Though close in stability, for WT 
P450BM3, the ∆Cm between the resting state and the Fe(II)-CO bound state is 0.4 – 0.9 M 
for the first transitions. For I401P P450BM3, this difference is only 0.1-0.2 M. The smaller 
difference in ∆Cm is similar to the pattern seen for PM P450BM3 in which the ferrous and 
ferric states are closer in stability as seen in Table 4.1. 
 Besides the presence of biphasic unfolding, other interesting observations were 
made for the various BM3 variants. Of the Fe(II)-CO states, WT and PM P450BM3 
unfolding occurred synergistically meaning both the P420 and P450 Cm values were within 
error. Additionally, for WT P450BM3 this was surprising as both states unfolded via 
biphasic mechanisms. For all the variants in the resting state (Fe(III)-H2O for WT and F81I, 
Fe(III) HS for I401P), except PM P450BM3, an initial compaction event was evident upon 
unfolding. This initial compaction may be due to urea displacing water around the enzyme 
by an indirect mechanism,278-280  placing a force on the enzyme that allows it to constrict. 
As PM P450BM3 is already significantly destabilized it is likely that urea was more readily 
able to reach the hydrophobic core than the other P450BM3 variants. 
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4.3.3 Circular dichroism monitored changes in α-helical content. 
 
The denaturation of the α-helical content of WT, F81I, I401P, and PM P450BM3 
variants was investigated by Circular Dichroism spectroscopy (CD) in the far-UV region, 
as shown in Figure 4.8 and Table 4.2. In general, an increase of the denaturant 
concentration was correlated with a decrease in α-helical content as shown by a decrease 
in ellipticity at 222 nm (Figure C8).  Of the four WT P450BM3 species studied, the most 
stable was the resting state, Fe(III)-H2O, which exhibited a Cm of 5.6 ± 0.2 M; the ferric 
CNPy state was within error of this value at 5.5 ± 0.2 M (Table 4.2). The Fe(II)-CO state 
 
Figure 4.4 Reduction from Fe(III) to Fe(II) states of selective and promiscuous 
variants has an opposing effect on secondary structure stability. Change in ellipticity 
at 222 nm as a function of urea concentration for A) WT P450BM3, B) PM P450BM3, 
C) F81I P450BM3, and D) I401P P450BM3. In all panels, black circles are the water 
bound resting state, blue triangles represent the ferric CNPY state, green triangles the 
ferrous CNPy state, and the red squares represent the ferrous CO-bound state. 
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was approximately 1 M less stable, exhibiting a Cm  of 4.4 ± 0.4 M. Results for the ferrous 
CNPy bound state were not included due to signal interference. 
Table 4.2 Concentration midpoint (Cm) values of P450BM3 variants by circular dichroism 
spectroscopy.a 
 Fe(III)-
H2O 
Fe(III)-CNPy Fe(II)-CNPy Fe(II)-CO 
WT 5.6 ± 0.2 5.5 ± 0.2 - 4.4 ± 0.4 
F81I 5.2 ± 0.1 - - 4.4 ± 0.1 
I401P 3.9 ± 0.1 - - 3.9 ± 0.1 
PM 3.7 ± 0.2 3.6 ± 0.1 3.7 ± 0.2 3.8 ± 0.1 
a. All Cm values are molar urea.  
In marked contrast, the four PM P450BM3 states had similar Cm values within error 
of each other ranging from 3.6 ± 0.1 M to 3.8 ± 0.1 M (Table 4.2). The same trend followed 
for the I401P P450BM3 variant as for PM P450BM3 in which the ∆Cm between the Fe(III) 
and Fe(II) states is negligible or non-existent. The Cm values for both the resting state and 
Fe(II)-CO bound I401P P450BM3 variant are within error of the PM P450BM3 values, with 
stability in the high 3 M range. Interestingly, as seen by UV/Vis spectroscopy for the I401P 
P450BM3 variant, the slope of the unfolding curve for the Fe(II)-CO state is steeper than 
that of the Fe(III)-H2O state (Figure 4.4D). As the I401P P450BM3 variant parodies PM 
P450BM3, so does F81I P450BM3 to WT P450BM3. There is a larger gap in stability for the 
two selective water bound states, than for the two promiscuous variants (∆Cm of 0.4 M for 
the selective variants vs ∆Cm of 0.2 M for the promiscuous variants), but they are still 
overall much more stable than their counterparts. For F81I P450BM3, there is a noticeable 
drop in stability for the Fe(II)-CO bound state when compared to the resting state of almost 
1 M, similar to what is seen with WT P450BM3 ferric and ferrous states. 
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4.3.4 Pulse proteolysis uses a protease to investigate global structure stability. 
 
Pulse proteolysis was first described by Park and Marqusee as a method to 
investigate the stability of global protein structure.137 In this technique, the protein is first 
denatured by urea subsequently, cleaved by the protease thermolysin and then run on a 4-
12% bis-tris protein gel. The more unstable the protein, the more denatured it will become 
by urea and therefore, more exposed to thermolysin. Concentration midpoints (Cm) are 
calculated in which the protein is 50% unfolded (Figure 4.5, Table 4.3). An example of a 
gel is shown in Figure C10. 
 
Figure 4.5 A greater disparty in stability of the global structure occured as a function 
of iron oxidation state for  selective P450BM3 variants. A) WT P450BM3 stability 
monitored by pulse proteolysis in which a decrease in protein content was observed. 
B) PM P450BM3 and D) I401P P450BM3 are promiscuous variants whereas C) F81I 
P450BM3 is more selective. In all panels, black circles represent the ferric H2O state, 
blue triangles the ferric CNPy bound state, green triangles the ferrous CNPy bound 
state, and red squares represent the ferrous CO bound state.   
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Table 4.3 Concentration midpoint (Cm) values of P450BM3 variants by pulse proteolysis. a 
 Fe(III)-H2O Fe(III)-CNPy Fe(II)-CNPy Fe(II)-CO 
WT 3.2 ± 0.2,  
5.3 ± 0.1 b 
4.5 ± 0.1 3.6 ± 0.2 2.2 ± 0.4, 
 5.0 ± 0.2 b 
F81I 4.6 ± 0.1 - - 4.7 ± 0.2 
I401P 3.3 ± 0.1 - - 2.7 ± 0.1 
PM 2.9 ± 0.1 3.0 ± 0.1 2.7 ± 0.1 2.1 ± 0.1 
a. All Cm values are molar urea. b. Two values separated by a comma indicate 
biphasic unfolding. 
 
As measured by pulse proteolysis, WT P450BM3 Fe(III)-H2O exhibited biphasic 
unfolding and was the most stable of the four WT P450BM3 species studied, exhibiting a  
Cm of 5.3 ± 0.1 M for the second transition (Table 4.3). Residual plots indicating the 
suitability of biphasic fits are shown in Figure C11. For the water bound state, the biphasic 
transition split the population in half; approximately 50% of the enzyme was unfolded at 
the first Cm of 4.0 ± 0.4 M and 50% at the higher (Figure 4.5A). If reflecting on the total 
population as a whole, the Fe (III)-CNPy state could be considered more stable than the Fe 
(III)-H2O as the Cm for the Fe(III)-CNPy state was 4.5 ± 0.1 M. The WT P450BM3 Fe(II)-
CO state also displayed biphasic unfolding but with a much lower initial Cm. Unlike the 
water bound state, the ferrous CO bound state exhibited an immediate drop-off in stability 
when exposed to urea with a Cm of 2.2 ± 0.4 M. Approximately 90% of the enzyme 
unfolded in this first phase, and 10% in the last phase with a Cm of 5.0 ± 0.2 M (Figure 
4.5A). This small portion of the enzyme population could represent molecules that reverted 
to the Fe(III)-H2O state as this Cm value is within error of the higher value for that system, 
5.3 ± 0.1 M. Unlike the Fe(III)-H2O and Fe(II)-CO states, both the WT P450BM3 ferric and 
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ferrous CNPy bound states exhibited monophasic unfolding, although the ferric state was 
more stable by approximately 1 M with a Cm of 4.5 ± 0.1 M vs 3.6 ± 0.2 M, respectively 
(Table 4.3). 
Unlike the WT P450BM3 species, none of the other P450BM3 variants exhibited 
biphasic unfolding profiles. Of the four PM P450BM3 states studied, the HS Fe(III)-CNPy 
state was the most stable, however, the stability of the Fe(III)-H2O and Fe(II)-CNPy states 
were also comparable. The biggest difference observed was for the Fe(II)-CO state, which 
had the lowest Cm of 2.1 ± 0.1 M (Table 4.3). Compared to the other techniques, pulse 
proteolysis shows the greatest difference in stability for the PM  and I401P P450BM3 ferric 
vs ferrous states. In both cases the ferrous states are less stable than the ferric, the most 
drastic example is the ∆Cm (0.8 M) between the resting state and ferrous CO-bound state 
for PM P450BM3 (Figure C12). This gap is a bit smaller for I401P P450BM3 with a ∆Cm of 
0.6 M. Though, these ∆Cm values are larger than expected, they are still smaller than those 
seen for WT P450BM3.  
4.3.5 Promiscuous P450BM3 variants have a more positive reduction potential than more 
selective variants 
To determine if there was a relationship between stability and ease of reduction, the 
reduction potential of all four P450BM3 variants was calculated. A method first published 
by Ost et al. was used in which MLCT between the iron heme and CNPy ligand was related 
to reduction potential using the equation EMLCT = (3.53 x EM) +17,005 cm-1 where EM is the 
reduction potential and EMLCT is the wavelength of the maximum absorbance of the MLCT 
band in cm-1.268 In short, after the enzyme was reduced with sodium dithionite, CNPy was 
added to saturation and the maximum wavelength of the MLCT band (600-700 nm) was 
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determined by UV/Vis spectroscopy (Figure C13). Using the above equation, reduction 
potential was calculated and corrected based on previously published values for WT and 
I401P P450BM3. As expected, WT P450BM3 exhibited the lowest reduction potential of - 
429 ± 8 mV. Values from literature for reduction potential of WT P450BM3 vary from -449 
to -368 mV,268, 270, 271, 281-284 placing our value within agreement. Also in agreement with 
literature, is our calculated reduction potential for I401P P450BM3 of - 284 ± 28 mV as 
compared to – 303 mV.270 Reduction potentials for F81I and PM P450BM3 were determined 
to be - 429 ± 8 mV  and -341 ± 23 mV,  respectively.  
 
 
Figure 4.6 Redox potential is correlated to iron state stability of selective vs. 
promiscuous P450BM3 variants. A) Concentration midpoints as determined by pulse 
proteolysis for ferric water bound P450BM3 variants are plotted against calculated 
reduction potential. B) Ferrous CO-bound P450BM3 variants in relation to calculated 
reduction potentials. In both panels, blue circles represent WT P450BM3, and two data 
points are shown as both ferrous and ferric states exhibited biphasic unfolding by 
pulse proteolysis. Green circles show F81I P450BM3, orange diamonds show I401P 
P450BM3, and purple circles are PM P450BM3. The reduction potential was calculated 
by determining the λmax of the MLCT band (600 – 700 nm) of the ferric-CNPy bound 
species. All UV/Vis experierments were done in a 1-cm pathlength quartz cuvette 
with 0.15 mg/ml protein diluted in 100 mM Kpi pH 7.4 buffer at RT. The enzyme was 
reduced with freshly made sodium dithionite made in 100 mM Kpi pH 7.4 buffer. 
CNPy was used at saturating concentrations.  
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 Not surprisingly, the more promiscuous the variant, the higher the reduction 
potential, implying an ease of reduction by NADPH (-320 mV)285 as compared to the more 
selective variants. In addition, there seems to be a correlation between stability of the global 
structure as determined by pulse proteolysis and reduction potential. Upon comparing the 
Cm of the resting state (Fe(III)-H2O for WT, F81I, and PM P450BM3 variants and Fe(III)-
HS for I401P P450BM3) to reduction potential, there are two clusters apparent, one 
consisting of the WT and F81I P450BM3 variants and another of the PM and I401P P450BM3 
variants, indicating a similarly in behavior (Figure 4.6A). The same is obvious for the 
correlation between Cm of the Fe(II)-CO state with reduction potential (Figure 4.6B). As 
WT P450BM3 unfolds biphasically by pulse proteolysis, both Cm values are included.  
4.4 Discussion 
Though PM and I401P P450BM3 are more promiscuous, this loss of selectivity 
comes at the cost of stability. By all three methods – pulse proteolysis, CD, and UV/Vis 
spectroscopy, WT and F81I P450BM3 were in general 1-2 M more stable than PM and I401P 
P450BM3 when exposed to increasing concentrations of urea. Generally, as compared to the 
WT and F81I P450BM3 species investigated, the stability of the states studied for PM and 
I401P BM3 were very similar regardless of oxidation state, summarized in Figure 4.7. The 
general trend for WT P450BM3 states studied was that the ferric states were more stable 
than the ferrous states. Comparing just the oxidized and reduced WT-CNPy bound states, 
the smallest ∆Cm was 0.9 M urea by pulse proteolysis and the greatest ∆Cm was 1.3 M urea 
by UV/Vis spectroscopy.  In contrast, for the PM P450BM3 ferric and ferrous forms bound 
to CNPy the greatest ∆Cm was 0.3 M, observed by both pulse proteolysis and UV/Vis 
spectroscopy.   
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The similarity in stability between the oxidized and reduced states of PM and I401P 
P450BM3 variants indicates structural regularity between the two states. For the selective 
P450BM3 variants to undergo turnover there must be a larger rearrangement in overall 
 
Figure 4.7 Change in concentration midpoint (Cm) of all tested variants by pulse 
proteolysis. The Cm is compared to an estimation of promiscuity and the 
reduction potential. Purple squares represent WT, green triangles are I401P, 
pink stars are F81I, and blue circles are PM. Open purple squares and filled 
purple squares indicate a biphasic unfolding, in which the open square is the 
lower Cm value and the closed square is the higher Cm value.  
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structure as there is a greater difference in stability. In essence, the energy barrier between 
the Fe(III) and Fe(II) state is greatly reduced for the promiscuous P450BM3 variants as 
opposed to the more selective P450BM3  variants. In addition, the increase in positivity of 
the reduction potential of the promiscuous variants indicates they can more readily accept 
an electron from their reductase partner. As the rate limiting step of P450 catalysis is the 
first electron transfer to the substrate bound HS Fe(III) state,207 this finding is extremely 
important. Because non-native substrates disrupt natural contacts in the active site, the 
quicker rearrangement in protein structure between the Fe(III) and Fe(II) states may help 
account for why promiscuous P450s are able to successfully turnover a plethora of  diverse 
substrates.  
 
Though all variants exhibited biphasic unfolding for particular states, it was more 
ubiquitous for WT P450BM3. Biphasic unfolding was apparent for both the resting state and 
the Fe(II)-CO state by UV/Vis spectroscopy and pulse proteolysis. This is in contrast to 
 
Figure 4.8 Possible pathways for biphasic unfolding. In both depictions, “N” 
represents the native population and “U” the unfolded population. “NA” and “NB” 
represent the possibility of two native states. 
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biphasic unfolding only occurring for F81I and I401P P450BM3 for the Fe(II)-CO state and 
the Fe(III)-H2O state for PM P450BM3 by UV/Vis spectroscopy. Two-stage unfolding could 
be occurring via two separate pathways expressed in Figure 4.8.  Panel A depicts a scenario 
in which biphasic unfolding occurs via an intermediate which indicates a metastable form 
of the enzyme appears as it unfolds. Panel B in contrast, depicts a situation in which 
biphasic unfolding occurs as the result of two native populations (NA and NB), in 
equilibrium with each other, unfold at different rates. If the true unfolding pathway is 
attributed to the later, it could be rationalized that the presence of two native states could 
be an artifact of protein purification. This line of reasoning is unlikely as biphasic unfolding 
for WT P450BM3 has been observed in previous studies in which protein was purified using 
a different method.132 
If biphasic unfolding occurred due to the presence of an intermediate, for the Fe(II)-
CO state it would be expected that the Cm values for the appearance of the P420 state and 
disappearance of  the P450 state are similar. This is consistent for WT P450 BM3 in which 
the Cm values at 420 nm are 3.0 ± 0.2 and 5.6 ± 0.1 M and are 3.1 ± 0.1 and 5.6 ± 0.1 M at 
450 nm (Table 4.1). Unfortunately, this trend does not follow for F81I and I401P P450BM3 
in which only the P450 state unfolds via a biphasic mechanism.  
A third possibility for biphasic unfolding is especially relevant for the WT P450BM3 
Fe(II)-CO state as detected by pulse proteolysis. It is possible that a small population of 
the enzyme reverted from the ferrous-CO bound state to the ferric water bound state as 
90% unfolded at 2.2 ± 0.4 M and 10% later at 5.0 ± 0.2 M (Table 4.3). The higher Cm of 
5.0 ± 0.2 M is within error of the higher Cm for the water bound state (5.3 ± 0.1 M) which 
lends credence to this hypothesis. It is possible that all three mechanisms discussed are 
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relevant to biphasic unfolding of the various P450BM3 states. Work is currently being done 
utilizing single molecule pulsed interleaved excitation-forster resonance energy transfer 
(PIE-FRET) to parse which hypothesis is more accurate for the systems investigated in this 
study.  
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5.1 Introduction 
Cytochrome P450s are essential enzymes that catalyze challenging organic 
transformations for the biosynthesis and metabolism of various key molecules, including 
steroids, retinoic acid, and vitamin D. In addition, hepatic P450s are responsible for the 
 
Figure 5.1 Design of dual action inhibitors. 
DNA 
Damage 
Enzyme 
Inhibition 
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degradation of xenobiotics, and thus, play a central role in drug metabolism and 
deactivation. One problematic issue is that their substrates include many anticancer agents, 
decreasing the effective drug concentration in the body. Compounding this problem, some 
P450s are found specifically in tumors, where they are over expressed and play a direct 
role in cancer initiation, progression, and drug resistance. For example, CYP1B1 has been 
shown to metabolize procarcinogens to carcinogens to initiate DNA damage, and 
subsequently induce resistance to DNA damaging chemotherapeutics.286-288 Alternatively, 
CYP19A (aromatase) converts androgens to estrogens, and is an important target in the 
treatment of estrogen driven cancers.289-293 CYP17A1 is responsible for androgen 
synthesis, and abiraterone is a first-in-class steroidal inhibitor of this enzyme used in late-
stage prostate cancer.294-297  
Currently, P450 inhibitors have been used as treatments for the inhibition of steroid 
biosynthesis, as for breast and prostate cancer, and for other indications, such as Cushing’s 
disease.298-300 The dangers associated with clinical use of P450 inhibitors is that they are 
generally not isoform selective (<103 difference in Kd), and long-term systemic inhibition 
of P450s can result in adverse drug interactions and altered hormone levels.301, 302 An 
alternative approach to avoid these consequences would be to develop agents that can be 
activated to selectively inhibit desired P450 enzymes in a spatially and temporally 
regulated manner. In the context of anti-cancer agents, inhibition of P450s in cancerous 
tissues is also a rational strategy to sensitize the cells to DNA damaging agents,286 while 
reducing the bioactivation of procarcinogens as a cancer driver. Furthermore, if the 
inhibition of the P450 could occur concurrently with the local administration of a cytotoxic 
agent only within the tumor, deactivation of the drug by hepatic P450s could be avoided. 
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Accordingly, we have synthesized dual action Ru(II) complexes as pro-drugs that can be 
triggered with light to simultaneously release a P450 inhibitor and a DNA damaging metal 
center.  
Photocaging is a well-established means to selectively release biologically active 
agents with temporal and spatial control.303 Metal complexes have been used as 
photocaging groups with great success, with pioneering work by Etchenique,304-306 
Franz,307-309 and Kodanko.310-312 Our approach differed slightly from traditional 
photocaging, however, as the metal complex is intended to act as a caging group that would 
transform into an active biological effector in its own right, in addition to the ligand that it 
protected in the intact complex form. 
 
In order to test this strategy, three P450 inhibitors were chosen that could be 
coordinated to Ru(II) complexes. These compounds all contain nitrogen heterocycles, and 
 
Figure 5.2 Structures of P450 inhibitors and Ru(II) complexes. Complexes synthesized 
by A. Zamora. 
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thus are able to directly ligate both the Ru(II) center and, after photorelease, the iron heme 
in P450s. Metyrapone and etomidate have been primarily used to inhibit P450 11B1, also 
known as steroid 11-beta-monooxygenase.313 Both compounds appear to bind similarly to 
the binding site of CYP11B1, where the N-heterocycle is capable of ligating the catalytic 
heme iron while the other ring interacts with Arg110 and Phe130 via π-stacking.314 A third, 
novel small molecule, compound 1, was synthesized;315 it has the metyrapone molecular 
skeleton with etomidate features: imidazole and benzene rings (Figure 5.2). 
5.2 Experimental Procedures 
5.2.1 Materials and instrumentation 
Chemicals used for synthesis were purchased from VWR or Fisher Scientific and 
used without further purification. cis-Dichlorobis(2,2’-bipyridine)ruthenium(II) dihydrate  
was purchased from Strem chemicals. Human liver microsomes were purchased from 
Sekisui Xenotech.  
A Varian Mercury spectrometer was used to obtain 1H NMR (400 MHz) and 13C 
(100 MHz) spectra. Chemical shifts are reported relative to the solvent peak (CD3CN – δ 
1.94 or CDCl3 – δ 7.24 for 1H NMR; CD3CN – δ 1.39 for 13C NMR). Electrospray 
ionization (ESI) mass spectra were obtained using a Varian 1200L mass spectrometer at 
the University of Kentucky Environmental Research Training Laboratory (ERTL). 
Absorption spectra for the extinction coefficient determination, acetonitrile photoejection 
and binding constant (Kd) determination for ligands were obtained on a Cary 60 UV/Vis 
spectrophotometer. Full spectrum absorbance readings to study the photoejection for 
complexes 1–3 in different aqueous media were obtained using a BMG Labtech FLUOstar 
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Omerga microplate reader. Binding saturation studies for each compound as well as Kd 
determination for irradiated complexes 1–3 were completed using an Agilent 8453 UV/Vis 
spectrometer. Compound purity was determine with an Agilent 1100 Series HPLC using a 
previously reported method.316 Light activation for photoejection experiments was 
achieved using a 470 nm LED array from Elixa. An Indigo LED array from Loctite was 
used for light activation for the enzyme assays. A Tecan SPECTRAFluorPlus Plate Reader 
was used to determine change in fluorescence for the enzyme activity assay and IVTT 
assay. Agarose gels were digitally imaged using a BioRad ChemiDoc System. 
5.2.2 Compound synthesis, characterization, and ion exchange 
2-(1-Imidazolyl)-2-methyl-1-phenyl-2−1-propanone) (1) was synthesized 
following a previously published procedure.52 All metal complexes were synthesized under 
low ambient light and were protected using aluminum foil throughout each step of 
synthesis, isolation, and characterization. Silver salts were used to facilitate ligand 
exchange; the choice of the specific salts in the different reactions was due only to reagent 
availability.  
5.2.2.1 [Ru(bpy)2(Met)2](PF6)2 (2) 
[Ru(bpy)2Cl2]·2 H2O (125 mg, 0.240 mmol) was dissolved in water (7 mL) under 
N2 at 80 °C. To this 2-methyl-1,2-di-3-pyridil-1-propanone (136 mg, 0.6 mmol) was added, 
and the red solution was stirred overnight at 80 °C. The resulting solution was cooled to 
room temperature (RT) and extracted into CH2Cl2 (3x10 mL) to remove the excess free 
ligand. The complex was precipitated out of the aqueous phase with 1–2 mL of a saturated 
aqueous KPF6 solution and extracted with CH2Cl2/MeCN (3x10 mL). The crude complex 
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was purified by column chromatography using H2O:MeCN:KNO3 as eluent (from 0:100:0 
to 12:87.2:0.8). The product was obtained in 38% yield (104 mg) as an orange solid. ESI 
MS C48H44N8O2Ru: m/z calcd [M]2+ 433.13, found 433.2 [M]2+. Purity by HPLC: 99.3 % 
by area; UV/Vis in CH3CN, λmax (ε M-1 cm-1) = 290 (43200), 345 (12100), 445 (8400). 
Note: NMR was not completed due to the compound containing a mixture of isomers. 
5.2.2.2 [Ru(bpy)2(Eto)2](PF6)2 (3) 
Silver triflate (99 mg, 0.384 mmol) was added to a suspension of [Ru(bpy)2Cl2]·2 
H2O (100 mg, 0.192 mmol) in water (15 mL) and the mixture was stirred overnight at RT. 
The solution was filtered under N2. Etomidate (94 mg, 0.384 mmol) and 15 mL of EtOH 
were added to the solution, which was then stirred at 85 °C under N2 for 24 hr. After cooling 
the reaction, the solution was concentrated, 1-2 mL of a saturated aqueous KPF6 solution 
was added, and the precipitate was extracted into CH2Cl2 (3x15 mL). The crude was 
purified by column chromatography using H2O:MeCN:KNO3 as eluent (from 0:100:0 to 
20:80:0.4). The product was obtained in 47% yield (108 mg) as a crystalline red solid. 1H 
NMR (CD3CN, 400 MHz): δ 9.03 (d, J = 5.6 Hz, 1H), 8.97 (d, J = 5.2 Hz, 1H), 8.35 (d, J 
= 8.4 Hz, 2H), 8.27 (d, J = 8.0 Hz, 1H), 8.24 (d, J = 8.4 Hz, 1H), 8.12 (q, J = 8.4 Hz, 2H), 
8.00 (d, J = 5.2 Hz, 1H), 7.87 (m, 3H), 7.70 (m, 3H), 7.49 (s, 1H), 7.37-7.19 (m, 10H), 6.88 
(d, J = 6.4 Hz, 2H), 6.72 (d, J = 7.2 Hz, 2H), 6.29 (q, J = 7.0 Hz, 1H), 6.19 (q, J = 7.2 Hz, 
1H), 4.15 (m, 4H), 1.75 (d, J = 7.2 Hz, 3H), 1.71 (d, J = 7.2 Hz, 3H), 1.19 (m, 6H); 13C 
NMR (CD3CN, 100 MHz): δ 159.57, 159.48, 159.01, 158.96, 158.47, 158.37, 154.10, 
154.00, 153.96, 153.83, 142.93, 142.82, 141.88, 141.52, 138.42, 138.35, 138.16, 138.10, 
129.90, 129.23, 129.09, 128.46, 128.10, 128.03, 126.95, 126.63, 126.10, 126.05, 124.70, 
124.48, 62.41, 57.86, 57.62, 22.35, 22.12, 14.46, 14.42 ppm; ESI MS C48H48N8O4Ru: m/z 
126 
calcd [M]+ PF6- 1047.25, [M]2+ 451.14, found 1047.1 [M]+ PF6-, 451.1 [M]2+. Purity by 
HPLC: 98.3 % by area; UV/Vis in CH3CN, λmax (ε M-1 cm-1) = 235 (50900), 290 (53900), 
325 (8900), 475 (8200). 
5.2.2.3 [Ru(bpy)2(1)2(PF6)2 (4) 
Silver nitrate (65.2 mg, 0.384 mmol) was added to a suspension of [Ru(bpy)2Cl2]·2 
H2O (100 mg, 0.192 mmol) in water (15 mL), and the mixture was stirred overnight at RT. 
The solution was filtered under N2. 2-(1-Imidazolyl)-2-methyl-1-phenyl-2−1-propanone; 
compound 1) (102.8 mg, 0.480 mmol) and 15 mL of EtOH were added to the solution, 
which was stirred at 85 °C under N2 for 24 hr. After cooling the reaction, the solution was 
concentrated, 1–2 mL of a saturated aqueous KPF6 solution was added and the precipitate 
was extracted into CH2Cl2 (3x15 mL). The crude was purified by column chromatography 
using H2O:MeCN:KNO3 as eluent (from 0:100:0 to 10:90:0.2). The product was obtained 
in 73% yield (158 mg) as a crystalline red solid. 1H NMR (CD3CN, 400 MHz): δ 8.66 (d, 
J = 5.2, 2H), 8.22 (d, J = 8.0 Hz, 2H), 8.08 (d, J = 8.0 Hz, 2H), 7.99 (t, J = 8.0 Hz, 2H), 
7.75 (m, 4H), 7.53 (m, 4H), 7.29 (s, 2H), 7.25 (s, 2H), 7.17 (m, 6H), 7.06 (d, J = 7.6 Hz, 
4H), 6.53 (s, 2H), 1.78 (s, 12H); 13C NMR (CD3CN, 100 MHz): δ 158.67, 158.16, 153.58, 
153.25, 139.57, 137.97, 137.54, 135.15, 134.23, 130.68, 129.61, 128.80, 128.12, 127.76, 
124.54, 124.26, 120.71, 67.75, 30.99, 27.54, 27.26 ppm; ESI MS C46H44N8O2Ru: m/z calcd 
[M]+ PF6- 987.23, [M]2+ 421.13, found 987.4 [M]+ PF6-, 421.1 [M]2+. Purity by HPLC: 97.5 
% by area; UV/Vis in CH3CN, λmax (ε M-1 cm-1) = 245 (41200), 290 (50400), 335 (8200), 
485 (8300).  
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Compounds 2–4 were converted to Cl- salts by dissolving 5–20 mg of product in 
1–2 mL methanol. The dissolved product was loaded onto an Amberlite IRA-410 chloride 
ion exchange column, eluted with methanol, and the solvent was removed in vacuo. 
The purity of each Ru(II) complex was analyzed using the method in Table D1 
(mobile phases of 0.1% formic acid in dH2O and 0.1% formic acid in HPLC grade CH3CN). 
Samples of each Ru(II)  complex were prepared in dH2O and protected from light before 
injection on the HPLC. 
5.2.3 Photoejection studies 
5.2.3.1 MeCN photoejection studies 
Photoejection studies were performed on the PF6- salts of 2–4 (30 μM) in 3 mL of 
acetonitrile in a 1 cm pathlength quartz cuvette placed 12 inches below a 470 nm LED 
array in duplicate. Each sample was prepared from the dissolution of the pure solid in 
acetonitrile and diluting it to the above final concentration. The samples were protected 
from ambient light until irradiated with the LED array. Ligand ejection was monitored by 
taking absorption spectra after specific time points until the spectra ceased to evolve. The 
half-life (t1/2) of photoejection was determined by plotting the difference in absorbance 
between two points around the isosbestic point versus time using Graphpad Prism software.  
5.2.3.2 Aqueous photoejection studies 
Photoejection studies using the Cl- salts of 2–4 in aqueous media (water, 1X PBS 
and Opti-MEM with 1% FBS) were performed in triplicate using a Greiner UV clear half-
area 96-well plate. The kinetics for ligand ejection were determined for 2–4 (40 µM) with 
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a final volume of 200 µL. The well plate was positioned 12 inches below a 470 nm LED 
array, and full spectra were collected after set time points of light exposure for a total of 5 
hrs. The change in absorbance was plotted using the same method as described for 
acetonitrile.  
5.2.4 Expression and purification of P450BM3 
The pCWori vector containing the gene for the heme domain (Thr 1–Thr 463) of 
P450BM3 with five mutations incorporated (R47L, F81I, F87V, L188Q, E267V, “PM 
BM3”) was transformed into BL21(DE3) cells. After transformation, cells were grown 
overnight on 50 μg/ml carbenicillin plates at 37 °C.  
Small 5 mL growths in Luria Broth (LB) with 100 μg/mL ampicillin were grown 
overnight and then added to 1 L of Terrific Broth (TB) with 100 μg/mL ampicillin and 
0.4% glycerol. Cells were grown at 180 rpm and 37 °C until an OD600 of 0.6–0.8 was 
reached. Protein production was induced by addition of 0.5 mM isopropyl β-D-1 
thiogalactopyranoside (IPTG). Temperature and shaking were decreased to 30 °C and 150 
rpm, respectively. After 16-20 hrs, the cells were harvested by centrifugation at 4,000 rpm 
for 15 min at 4 °C. The supernatant was decanted, and the cell pellet was resuspended in 
lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.1 mM EDTA, and 0.1 
μM phenylmethylsulfonyl fluoride (PMSF), pH 8.0). The resuspended pellet was sonicated 
on ice using a Branson Sonifer 250 microtip, for 15 min with output control of 3 and duty 
cycle of 50%. The lysate was then centrifuged for 1 hr at 17,000 x g and 4 °C.  
The supernatant was decanted, and syringe filtered with a 0.45 μm 
polytetraflurorethylene filter prior to addition to a His-Trap column (GE Healthcare) 
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equilibrated in buffer A (50 mM NaH2PO4, 300 mM NaCl, and 20 mM imidazole, pH 8.0). 
PM BM3 was eluted using a linear gradient of 20 mM to 200 mM imidazole with buffer B 
(50 mM NaH2PO4, 300 mM NaCl, and 200 mM imidazole, pH 8.0). Fractions were 
collected based on color and absorbance at 420 nm and 280 nm. PM BM3 containing 
fractions were then concentrated using Ultracel-30K Millipore centrifugal units at 4500 x 
g and 4 °C. Protein was further purified by loading onto a Hi-Prep 26/60 Sephacryl S200 
HR (GE Healthcare) sizing column equilibrated with gel filtration buffer (20 mM Tris, 150 
mM NaCl, pH 8.0).  
All fractions with a 420/280 nm ratio above 1.2 were concentrated using Ultracel-
30K Millipore centrifugal units. For storage, glycerol was added to give a final 
concentration of 50%, the protein was aliquoted, snap frozen, and stored at –80 °C.  
Prior to using PM BM3, glycerol was removed, and the buffer was exchanged to 
assay buffer (20 mM Tris, 20 mM NaCl, 10 mM CaCl2, pH 7.4) using a PD-10 desalting 
column (GE Healthcare). To determine protein concentration, a CO binding assay was used 
as previously described.138 
5.2.5 P450BM3 binding affinity 
To determine if the inhibitors could saturate PM BM3, the protein was added to a 
3 mL 1 cm pathlength quartz cuvette at a final concentration of 2.5 µM. UV/Vis spectra 
were taken before and after the addition of compound. Ligands were tested at 10 µM, 
whereas Ru(II) complexes were tested at 25 µM in the dark and after 1 min irradiation. 
After the addition of compound, the samples were incubated at RT for 30 sec before data 
collection.  
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Absorbance binding titrations of ligands and light activated complexes 2–4 were 
performed in a 1 cm pathlength quartz cuvette with 2.5 µM protein and a total volume of 
3 mL. The absorbance was measured after each ligand or Ru(II) addition from 0–64.0 µM 
(metyrapone), 0–30.3 µM (etomidate and 1), 0–64.7 µM (2), 0–54.2 µM (3) and 0–45.8 
µM (4). The Ru(II) only absorbance was measured and blanked in parallel. Binding 
constants were determined by plotting the change in absorbance at 425 nm vs. 
concentration of ligand or Ru(II). Data was plotted using Graphpad Prism software and fit 
using a one site-total binding equation.  
5.2.6 Enzyme inhibition assay 
5.2.6.1 Inhibition assay with purified PM BM3 
An enzymatic turnover assay was utilized to determine the inhibition of resorufin 
ethyl ether metabolism by PM BM3 in the presence of added compound. Each compound 
was added to 250 nM PM BM3 in 1X PBS (phosphate buffered saline, pH 7.5) at varying 
concentrations between 0–10 μM in Greiner clear 96 well plates and incubated for 10 min.  
Ru(II) complexes were tested in the presence and absence of light, where stock solutions 
were irradiated for 1 min prior to incubation with PM BM3. Following incubation with 
compound, 5 μM resorufin ethyl ether was added and incubated at RT for 5 min. To initiate 
enzymatic turnover, 5 mM hydrogen peroxide was added, and changes in fluorescence of 
resorufin ethyl ether were monitored over 5 min using a Tecan Spectrafluor plus microplate 
reader at excitation 535 nm and emission 595 nm.  
5.2.6.2 Inhibition assay with Human liver microsomes (HLMs) 
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An enzymatic turnover assay was utilized to determine the inhibition of resorufin 
ethyl ether metabolism by enzymes responsible for first-pass metabolism in pooled human 
liver microsomes (HLMs) in the presence of added compound. 125 μM of 1 or 4 was added 
to 20 mg/mL HLM to a final concentration of 100 μM in 100 mM KH2PO4, 10 mM MgCl2 
buffer, pH 7.5. After incubation with compound for 10 min, 5 μM resorufin ethyl ether was 
added followed by 1.3 mM NADPH to initiate enzymatic turnover. Changes in 
fluorescence of resorufin ethyl ether were monitored over 30 min using a Tecan 
spectrafluor plus microplate reader at the same settings as above. Compound 4 was 
incubated with HLMs in the dark and after 1 min irradiation with the Indigo LED.  
5.2.7 In vitro transcription and translation 
A 1-Step Human Coupled IVT Kit–DNA (Thermo Scientific) was used to carry out 
the experiment.317  For each reaction, 0.5 µg of the pCFE-GFP plasmid and 5–20 μM 4 
was used. Complex 4 was either irradiated for 1 min with the Indigo LED or kept in the 
dark. Prior to carrying out the IVT reaction, 4 was incubated with the plasmid overnight in 
the presence or absence of PM BM3 (0.5 μg). All IVT reactions were scaled to 12.5 µL 
total volume. Following the completion of the IVT reaction, the GFP emission was read in 
a Greiner-Bio One 384-well small volume plate on a Tecan SPECTRAFluorPlus Plate 
Reader with 485 nm excitation and 535 nm emission filters. 
5.2.8 DNA gel electrophoresis 
Compounds were mixed with 40 μg/mL pUC19 plasmid in 10 mM potassium 
phosphate buffer, pH 7.4. To determine the effect of light, samples were irradiated with a 
470 nm LED for 1 hr. Samples were then incubated for 12 hr at 37 °C in the dark. Single 
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and double-strand DNA break controls were prepared, and the DNA samples were resolved 
on agarose gels, as described previously.318 
In brief, samples were resolved on a 1% agarose gels prepared in tris-acetate buffer 
with 0.3 μg of plasmid/lane. The gels were stained with 0.5 μg/mL ethidium bromide in 
tris-acetate buffer at RT for 40 min, destained with tris-acetate buffer, and imaged on a 
ChemiDoc MP System (Bio-Rad).  
5.2.9 Singlet oxygen assay 
Compounds were serially diluted in 96 well plates in extracellular solution (10 mM 
HEPES pH 7.5, 145 mM NaCl, 10 mM glucose, 1.2 mM CaCl2, 1.2 mM MgCl2, 3.3 mM 
KH2PO4, 0.8 mM K2HPO4, 50 U mL-1 penicillin and 50 mg mL-1 streptomycin). To this 
was added Singlet Oxygen Sensor Green (SOSG) reagent to give a final concentration of 
5 µM. The plates were read on a SprectraFluor Plus plate reader with an excitation filter of 
485 nm and emission of 535 nm both pre- and post- irradiation with the Loctite Indigo 
LED for 1 min. The relative values of the SOSG emission were plotted as a function of 
compound concentration to give a dose response.  
5.3 Results and Discussion 
5.3.1 Light triggered P450 inhibitors were synthesized from Ru(bpy)2Cl2. 
Ruthenium complexes 2–4 (Figure 5.2) were synthesized by refluxing the 
respective inhibitors with Ru(bpy)2Cl2 (bpy = 2,2’-bipyridine) or the corresponding bis-
aqua Ru(bpy)2(OH2)2 in EtOH/H2O (1:1) while protected from light. Abstraction of the 
chlorides was carried out with a silver salt in order to diminish the percentage of the 
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undesired monocoordinate complexes, [Ru(bpy)2LCl]+, which complicated the 
purification. All complexes were formed in good yields (38–73% yield) and exhibited 
moderately intense metal-to-ligand charge transfer (MLCT) bands centered around 450–
490 nm. Not surprisingly, compound 2 was isolated as a mixture of the possible 
coordination isomers, as either pyridyl ring in the asymmetric ligand (A- or B-ring, as 
shown in Figure 5.2) can coordinate to the Ru(II) center. 
Light-triggered release of the coordinated ligands was monitored under different 
solvent conditions by UV/Vis absorption spectroscopy, HPLC, and mass spectrometry. All 
complexes were able to cleanly release both monodentate ligands in acetonitrile (MeCN) 
after irradiation with blue light (470 nm). A biphasic blue-shift was observed in their 
spectra (Figures D6 - D8), and a common final 425 nm band was found for 2–4, which 
indicated the formation of a unique product, [Ru(bpy)2(MeCN)2]2+, after the release of the 
corresponding inhibitors.  
The photoproducts formed in aqueous solution were identified using HPLC and 
mass spectrometry analysis (Figures D9-D14). The chromatograms showed the appearance 
of new signals in irradiated samples, which corresponded to the free inhibitor and the 
mono-aqua Ru(II) complex. This was confirmed by the mass spectrum of the solution, with 
peaks corresponding to [Ru(bpy)2L(H2O)]2+, [Ru(bpy)2L]2 and [L+H]+ (Figures D10, D12, 
D14). It is to be noted that the UV/Vis profile of the products for 3 and 4 did not differ 
significantly from that of the complex protected from light. The extent of the photoejection 
reaction varied from 40 to 65%. This observation is consistent with other [Ru(bpy)2L2]2+ 
and [Ru(phen)2L2]2+ complexes, where substitution of the second N-monodentate ligand, 
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L, requires much longer irradiation times or does not occur.304 310, 319-322  Finally, in the 
dark, all complexes were stable at room temperature and at 37 °C (Figure D5). 
5.3.2 Complex 2-4 bind and inhibit P450BM3 and human liver microsomes (HLMs) after 
light irradiation. 
In order to directly investigate the interactions of the metal complexes with a P450, 
cytochrome P450BM3 (CYP102A1), a soluble bacterial P450, was chosen as a model 
system. A mutant form of P450BM3 has been shown to recapitulate the activity of 
mammalian drug metabolizing P450s,323 which has made P450BM3 a commonly used 
experimental system.324 Importantly, while mammalian P450s are generally membrane 
associated, which complicates analysis, P450BM3 is soluble and thus amenable to various 
spectroscopic investigations as well as enzyme turnover assays. Furthermore, the in vitro 
system was chosen due to the intrinsic complications of studying P450 inhibition in cells 
or cell lysates, due to the need to create cell lines that overexpress the enzyme and reductase 
partners, and to provide exogenous reductants such as NADPH. 
 
 
Figure 5.3 Absorption spectrum of P450BM3 inhibitor saturated and Ru(II) dark and 
light systems: 2 (A), 3 (B), 4 (C). The ratio used was  2.5 µM P450:  25 µM Complex 
(1:10) and  2.5 µM P450: 10 µM Ligand (1:4) for each of the respective ligands used 
to generate the complexes. Experiments were carried out in a 3 mL 1 cm pathlength 
quartz cuvette at RT.  
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As all three free P450 inhibitors directly ligate the heme iron, either through a 
pyridyl of imidazole ring, a type II spectra shift was observed upon inhibitor binding 
(Figure 5.3). A 7 nm red-shift in the heme soret was observed for metyrapone, etomidate, 
and compound 1, with the appearance of a second minor peak around 360 nm, where a 
shoulder is observed in the free enzyme. Difference spectra for all compounds show a 
trough maxima around 410 nm (Figure D17). Significant shoulders are observed on the 
troughs at 390 nm, consistent with a mixture of type IIa and type IIb spectra325-327 (type IIa 
spectra are observed when the enzyme is in the high-spin state in the absence of ligand; 
type IIb is seen when the enzyme is in the low-spin state).327 The ∆Amax  between the peak 
and trough and the intensity of the shoulder varied as a function of the nitrogen containing 
coordinating ligand, as previously reported.325 
Upon exposure to an Indigo LED array (28 J/cm2), each complex induced the same 
type IIa and IIb spectral shift observed with the free inhibitors. Conversely, when the Ru(II) 
complexes 3 and 4 were kept in the dark there was little or no observed change in the 
P450BM3 absorption spectra, indicating that the complexes function as pro-drugs and do not 
directly affect the active site of the enzyme. Complex 2, containing the pendant 
metyrapone, did exhibit a slight change in absorption profile, suggesting the intact complex 
containing the pendant pyridyl ligand was capable of interacting with the enzyme enough 
to perturb the absorption spectra. While unexpected, previous structural studies have shown 
that small molecules that are tethered to large fluorophores328-330 or even metal 
complexes331-335 can bind P450s and induce opening of the substrate channel. Interestingly, 
the difference spectrum (Figure D17 A) indicates a different binding mode than either free 
metyrapone or the light-activated 2 complex, and appears to be more a type I spectrum, 
136 
consistent with displacement of water from the heme, but with no direct ligation of a 
coordinating nitrogen.327 
 
Enzyme inhibition was tested using resorufin ethyl ether as a substrate in a 
fluorescence based assay.336, 337 Each of the free ligands exhibited inhibition of enzyme 
activity (Figure 5.4 and Figure D18). As anticipated, the three Ru(II) complexes all 
demonstrated triggerable enzyme inhibition. Compound 4 gave the largest window for dark 
vs. light activity (Figure 5.4), with IC50 values for enzyme inhibition of 6.8 and 0.05 µM, 
respectively. This compound thus provides a 136-fold difference between activity in the 
dark and the light. The IC50 value for the free ligand 1 was 0.06 µM, in excellent agreement 
with the activity of the complex in the light. Each light activated system displayed very 
 
Figure 5.4 (A) Relative activity of 250 nM P450BM3 in the presence of  0-10 µM 1 (red 
diamonds) and 4 in the dark (black circles) and following irradiation (blue squares) in 
1X PBS pH 7.5 buffer. 5 mM H2O2 was added to intiate turnover. B) IC50 values for all 
three complexes and the respective free ligands. C) Inhibition of CYPs in 20 mg/mL 
HLMs by 125 µM free ligand 1 (red circles) and  125 µM complex 4 (blue squares) after 
irradiation compared to no compound (black circles) and 4 in the dark (green triangles). 
HLM experiments were done in 100 mM KPi, 10 mM MgCl2 pH 7.5 buffer with 1.3 
mM NADPH added to intiate turnover. All experiments were carried out in a Greiner 
clear 96 well plate. Flourescence of 5 µM resorufin ethyl ether was monitored over a 
length of 5 min for P450BM3 and 30 min for HLMs at 37 °C at excitation 535 nm and 
emission of 595 nm by a Tecan spectralfuor plus microplate reader.    
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similar activity to the free inhibitor (Figure 5.4B; compound 2 IC50 = 0.19 µM vs. 0.75 µM 
for metyrapone; compound 3 IC50 = 0.04 µM vs. 0.02 µM for etomidate). 
To extend the investigation to a medically validated, commonly used experimental 
system, pooled human liver microsomes (HLMs) were used to study the light-triggered 
inhibition of enzyme turnover. HLMs contain membrane-bound human CYPs which play 
major roles in first pass metabolism of xenobiotics.338, 339 Incubation of HLMs with 
compound allows study of how these compounds impact activity of multiple CYPs at once, 
and in a membrane environment. This provides a good model for human CYPs. Compound 
4 exhibited the largest window for light-mediated enzyme inhibition for P450BM3, so it was 
tested along with the free ligand 1. In the dark, at 100 µM, compound 4 was found to 
minimally inhibit CYPs in HLMs, but complete inhibition was observed after irradiation 
(Figure 5.4C). A similar trend was seen with free ligand 1, with nearly complete inhibition 
of enzyme turnover. 
5.3.3 DNA damage is induced by complex 2-4 after light irradiation. 
Having confirmed the utility of the light active compounds for inhibition of 
cytochrome P450 activity, DNA damage was investigated using agarose gel 
electrophoresis. Dose responses were performed with compound 2–4  with pUC19 plasmid, 
and the solutions were either protected from light or irradiated for 1 or 3 h (60.4 or 181.4 
J/cm2) before incubation at 37 °C for 12 h (Figure 5.5). No effect was seen for any of the 
intact pro-drug forms of the complexes, but all induced DNA damage upon light activation. 
DNA damage was visualized by reduced mobility of DNA, consistent with direct adduct 
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formation, as demonstrated in classical experiments on cisplatin340-342 and more recently 
with analogous light-activated ruthenium compounds.318, 343  
 
Very little relaxed circular DNA was observed, but what was formed likely resulted 
from single strand breaks induced by singlet oxygen (1O2).  Ligand ejection proceeds from 
an excited state that is populated from the 3MLCT state, which also generates 1O2; thus, 
there is a competition in relaxation pathways, and complexes that have longer t1/2  values 
have been found to induce more single strand breaks. We318, 344 and others345 have thus 
observed that the combination of the different relaxation pathways makes these agents 
capable of “dual photoreactivity” independent of the biological activity of the released 
ligands. However, little 1O2 was detected, as shown in Figure D19, consistent with the DNA 
damage study and relaxation primarily through ligand ejection. Finally, all the free ligands 
 
Figure 5.5 Agarose gels showing the dose response of 2 (A), 3 (B), and 4 (C) with 40 
μg/mL pUC19 plasmid with and without irradiation (λ>470 nm). Dark, left; 1 hr 
irradiation, middle; 3 hr irradiation, right. Lane 1 and 12: DNA ladder; Lane 2: EcoRI; 
Lane 3: Cu(OP)2; Lanes 4–11: 0, 7.8, 15.6, 31.3, 62.5, 125, 250, 500 μM (500 μM 
corresponds to a metal center:base ratio of 4:1). EcoRI and Cu(OP)2 are used as controls 
for linear and relaxed circular DNA. EtBr was used to visualize the DNA. DNA damage 
gels performed by A. Zamora. 
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were tested as controls, and as anticipated, they had no impact on the plasmid DNA (Figure 
D20). 
5.3.4 Transcription and translation in the presence of P450BM3 and complex 2-4 after light 
irradiation is inhibited. 
 
The ultimate experiment was to investigate if the light activated metal 
complexes were able to inhibit DNA function in the presence of the P450 enzyme. 
Accordingly,  an in vitro transcription and translation experiment 317 was performed, 
as shown in Figure 5.6A. A plasmid coding for green fluorescent protein (GFP) was 
incubated with compound 4 in the dark or following activation with light. The 
experiment was also performed in the presence of P450BM3. No impact on GFP 
production was observed for 4 in the dark, while a dose dependent inhibition of 
 
Figure 5.6 (A) An in vitro transcription and translation experiment allows for 
detection of DNA damage that results in inhibition of GFP production. Compound 
4 was incubated in the presence of both plasmid and P450BM3 at equal 
concentrations. (B) GFP production was unaffected by the addition of P450BM3 (+ 
P450; lane 2) and the protein had no impact on the ability of compound 4 to 
damage DNA upon light activation (lanes 3–6). IVTT assay carried out by L. 
Nease and D. Heidary. 
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protein production was found following activation with light as shown in Figure 5.6B. 
The addition of P450BM3 had no impact on GFP transcription or translation in the 
absence of the Ru(II) complex, or in its presence. Thus, the P450BM3 enzyme does 
not serve as a “sink” for the activated metal center and does not interfere with the 
DNA damage mechanism. This validates that the Ru(II) center can target DNA while the 
released ligands target the P450 enzyme.  
5.4 Conclusions 
The three complexes described in this report serve as proof-of-concept systems for 
single agent “drug cocktails” and demonstrate that, upon light activation, the metal center 
is able to damage DNA while the liberated ligand acts as a cytochrome P450 inhibitor. The 
best system, compound 4, exhibited a 136-fold difference in protein inhibition when 
irritated with light as compared to in the dark, with an IC50 of 0.05 µM upon activation. In 
the absence of irradiation, the complexes did not damage or interfere with its function, as 
indicated by gel electrophoresis and activity in a transcription and translation assay. Upon 
light activation, protein production was inhibited with an IC50 between 5 and 10 µM in the 
light. Furthermore, the metal center damages the DNA even in the presence of protein, 
indicating that DNA is the preferred target. 
The choice to inhibit P450 enzymes is a key feature in the design of these pro-
drugs. The targeting of enzymes implicated in drug resistance could result in synergistic 
activity for DNA damaging agents in cancer cells and tissues, though more involved studies 
in cancer cell lines engineered and optimized to detect P450 activity and inhibition will be 
required for full validation of this potential therapeutic approach. However, the clear 
141 
inhibition of P450 activity and the DNA damage and suppression of transcription and 
translation in vitro, combined with the well-established cytotoxicity of light activated, 
ligand deficient Ru(II) complexes in cells are strongly promising.  This is also, to the best 
of our knowledge, the first report of photocaged P450 inhibitors. These compounds may 
be useful for basic research applications as tools that provide spatial and temporal control 
over P450 inhibition and could answer several open questions in the role that P450s play 
in malignant cell transformation and drug resistance. Single mode of action photocaged 
systems, which do not damage DNA, are also under development to allow for the triggered 
control of P450 activity without complications from the activity of the metal center.  
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 CONCLUSIONS 
The central dogma of biology is a simple yet elegant process that details how life is 
able to exist. DNA, which stores information, is transcribed into mRNA which is then 
translated into proteins. Proteins are the “workhorse” of the cell and perform a majority of 
the actions that need to occur for life to be viable. Investigating protein function is key to 
understanding part of what makes us human, but also what allows for life to flourish. There 
are several variables that can be studied that impact protein function and stability, 
including, but not limited to, cell localization, solubility, substrate preference, impact of 
residues, and if a metalloprotein, the impact of charge and electron transfer systems.  
Cytochrome P450s (CYPs) are a family of heme enzymes present in almost all forms 
of life that use oxygen to make hydrophobic substrates more hydrophilic. In humans this 
means they are crucial for steroidogenesis and xenobiotic metabolism346, 347 while in plants 
they are necessary for defense,348, 349 and they aid in antifungal resistance in some fungi.350-
352 We used CYP102A1 (P450BM3), a bacterial CYP, as a model system to understand 
particular properties of human CYPs. Using a variety of biophysical techniques, we 
investigated the role of specific residues in increasing promiscuity, how native and non-
native substrates can bind favorably, and how iron oxidation state impacts stability.   
By investigating the above three variables, we elucidated some requirements of 
promiscuity, but also some of its costs, which are important for any possible biotechnical 
applications incorporating these enzymes. The main cost is that increased promiscuity 
translates to increased flexibility of the enzyme. Though flexibility is necessary for binding 
of non-native substrates, it leads to a decrease in stability and increase in uncoupled 
catalysis. The consequences are an increase in ROS generation, accelerated degradation of 
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the enzyme, and limited function. In theory, mutating smaller residues external to the active 
site to bulkier residues should help alleviate the stress caused by promiscuity without 
impacting the openness of the interior. Though we have not studied this in-depth, it would 
make a good follow-up study to this work. From studying the role of promiscuity on 
oxidation state it has become clear that there is a relationship between the energy barrier 
needed to move between various iron oxidation states and ligand selectivity. Promiscuous 
CYPs are more likely to have a lower energy barrier between initial steps in their catalytic 
cycles as compared to more selective variants. This was expressed by a similarity in 
stability between the ferrous and ferric states as well as an increase in reduction potential 
of the more promiscuous enzymes.  
George E. P. Box was a famous statistician, (if modern mathematicians can be 
considered famous) who is perhaps most known for saying, “All models are wrong, but 
some are useful.”353  This dissertation is a detailed study of using P450BM3 as a model for 
human CYPs. Of the several variables that impact CYP function and stability that can be 
studied, three were investigated. These variables were: the role of residues in selectivity, 
substrate specificity of native and non-native substrates, and the impact of promiscuity on 
iron oxidation state. Work is currently on-going to elucidate the mechanism of biphasic 
unfolding for P450BM3, as well as research initially started by the Ru(II) dual mechanism 
project. Further studies would use rational mutagenesis to make our promiscuous mutant 
more stable, determine methods or models to study more states of the catalytic cycle, and 
incorporate a larger body of biophysical methods such as electron paramagnetic resonance 
(EPR).  
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APPENDICES 
Appendix A: Chapter 2 Additional Figures and Tables 
 
Figure A1. UV-Vis spectra of purified P450BM3 oxidase domain. (A) WT oxidase spectra 
is in the water-bound form after gel filtration chromatography with a peak at 418 nm (black 
line) and undergoes a spin shift to 394 nm when bound to the substrate, palmitic acid (blue 
line). (B) The behavior of the purified PM oxidase is similar to the WT oxidase domain 
indicating that the purified form is water-bound and undergoes a spin shift with palmitic 
acid. 
 
 
Figure A2. UV-Vis spectra of WT and PM spin shift from 418 nm to 450 nm upon carbon 
monoxide binding. (A) WT oxidase domain absorption spectra in the water-bound form 
(black line) and after CO coordination to the heme (red line). (B) The PM oxidase domain 
undergoes the same absorption change as WT. 
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Figure A3. RMSD of heme heavy atoms in (A) substrate-free WT, (B) WT:metyrapone, 
and (C) WT: palmitic acid during the 300-K simulations. Ring atoms are shown in black 
lines, while propionate and vinyl atoms are shown by gray lines. Planarity of heme in (D) 
substrate-free WT, (E) WT:metyrapone, and (F) WT:palmitic acid during the 300-K 
simulations. The dihedral angle between the carbon atoms connecting the four pyrrole 
subunites is shown in black lines, while that between the pyrrole nitrogen atoms are shown 
in gray lines.  
 
Figure A4. Crystal structures of PM in the presence of polythylene glycol (4ZF6, green) 
and substrate-free R47L/Y51F/F87V/E267V/I401P mutant (4RNS, gray). The heme and 
residues of interest are shown in stick and polyethylene gycol in ball-and-stick. (A) Overall 
structure. (B) Substrate channel. Among the common mutations, only L47 differed 
significantly in side chain position, The Q73 side chain also points outward unlike in PM.  
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Figure A5. Comparison of crystal (gray) and MD-averaged (green) structures. (A) 
Substrate-free L188Q and IBU7 (molecule B). Helix A and β-sheet 1 of L188Q moved 
closer to the protein core during the 300-K simulation, partially closing the channel. This 
was also observed in the MD-averaged structures of substrate-free WT and E267V. (B) 
Substrate-free PM and 4ZF6. Helices F and G moved away from the protein core during 
the 300-K simulation, partially opening the channel. (C) PM:palmitic acid and 4ZFB. 
Palmitic acid moved closer to the heme and formed a hydrogen bond with S72 during the 
300-K simulation. (D) PM:metyrapone and 4ZF8. Metyrapone rotated during the 300-K 
simulation, bringing the unbound pyridine ring in close contact with V87, T260, and I263. 
MD simulations performed by I. Geronimo. 
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Table A1. Backbone RMSD (Å) of average structures with respect to wild-type P450BM3 
(IBU7, molecule B). MD simulations performed by I. Geronimo. 
Region R47L F81I F87V L188Q E267V 
Helix      
A 1.07 0.95 0.92 1.28 
1.16 
B 0.80 0.58 0.44 1.25 
0.98 
B' 0.95 0.77 0.62 1.08 
0.63 
C 0.83 0.58 0.80 0.69 
0.80 
D 0.47 0.33 0.45 0.59 
0.50 
E 0.64 0.61 0.55 0.79 
0.86 
F 0.79 0.80 0.71 0.88 
0.84 
G 1.14 1.01 0.92 1.43 
1.27 
H 1.26 0.88 1.12 1.02 
0.87 
I 0.74 0.70 0.68 0.72 
0.82 
J 0.40 0.36 0.55 0.60 
0.73 
J' 0.54 0.39 0.59 1.00 
0.82 
K 0.52 0.45 0.43 0.75 
0.57 
K' 0.37 0.32 0.39 0.72 
0.49 
K" 0.30 0.43 0.47 0.57 
0.53 
L 1.07 0.83 0.90 2.23 
1.21 
β-sheet      
1 
0.79 0.62 0.44 1.03 
0.86 
2 
0.64 0.66 0.56 0.65 
0.53 
3 
1.06 0.95 1.08 1.47 
1.41 
4 
0.72 0.79 0.86 0.69 
1.32 
5 
0.35 0.44 0.47 0.59 
0.51 
Cys loop 1.97 0.46 0.65 0.92 0.61 
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Figure A6. Plot of native contacts of residues in helices F (171-190) and G (197-226) of 
substrate-free (A) WT and (B) PM as a function of simulation time at 550 K. The number 
of contacts is the average from three independent simulations. MD simulations performed 
by I. Geronimo. 
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Figure A7. Plot of native contacts of residues in the Cys ligand loop of substrate-free (A) 
WT and (B) PM as a function of simulation time at 550 K. The number of contacts is the 
average from three independent simulations. MD simulations performed by I. Geronimo. 
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Figure A8. High-temperature (550 K) simulations of substrate-free P450BM3 variants 
(cartoon representation).The heme, cys ligand, bound water, and water withing 10 Å of the 
heme are shown in stick. Snapshots of WT at (A) 0 ns and (B) 50 ns. Snapshots of PM at 
(C) 0 ns and (D) 50 ns. Helices D and E of PM unfolded concurrently with sections of the 
substrate channel unlike in WT. MD simulations performed by I. Geronimo. 
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Figure A9. RMSD of backbone atoms in substrate-free (A) WT, (B) PM, (C) R47L, (D) 
F81I, (E) F87V, (F) L188Q, and (G) E267V.Three independent simulations at 550 K were 
performed for each system. MD simulations performed by I. Geronimo. 
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Figure A10. High-temperature (550 K) simulations of P450BM3 variants with metyrapone  
(cartoon representation). The heme, Cys ligand, metyrapone, and water within 10 Å of the 
heme are shown in stick. Snapshots of WT at (A) 0 ns and (B) 50 ns. Snapshots of PM at 
(C) 0 ns and (D) 50 ns. The heme region of both enzymes is destroyed at the end of 
simulation. MD simulations performed by I. Geronimo. 
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Figure A11. High-temperature (550 K) simulations of P450BM3 variants with palmitic acid 
(cartoon representation). The heme, Cys ligand, metyrapone, and water within 10 Å of the 
heme are shown in stick. Snapshots of WT at (A) 0 ns and (B) 50 ns. Snapshots of PM at 
(C) 0 ns and (D) 50 ns. MD simulations performed by I. Geronimo. 
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Figure A12. RMSD of backbone atoms in (A) WT:palmitic acid, (B) WT:metyrapone, (C) 
PM: palmitic acid, and (D) PM:metyrapone complexes.  Three independent simulations at 
550 K were performed for each system. MD simulations performed by I. Geronimo. 
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Table A2. Salt bridge occupanices calculated from the 300-K MD simulation.a,b MD 
simulations performed by I. Geronimo. 
Salt bridge WT-SF WT-MYT WT-PLM PM-SF PM-MYT PM-PLM 
E38-R56 0.949 0.907 0.839 0.921 0.914 0.953 
E60-R66 0.828 0.741 – 0.722 0.723 0.806 
D68-H92 – – 0.631 – – – 
D84-R79 – – 0.947 – – 0.805 
E93-R79 1.000 1.000 – 0.861 1.000 – 
D121-R161 0.925 0.880 0.638 0.984 0.946 0.904 
D144-K129 0.985 0.984 0.679 0.908 0.910 0.859 
E183-R190 0.995 0.999 0.657 1.000 1.000 0.999 
E200-R203 0.618 0.566 0.552 – 0.526 0.606 
E207-K210 0.563 – – – – – 
D208-R179 0.933 0.925 0.941 0.917 0.937 0.943 
D214-K210 – 0.572 – – 0.549 – 
D217-R255 0.816 0.894 0.539 0.985 0.702 0.666 
D222-K218 0.572 0.681 – – – 0.781 
D232-R223 1.000 1.000 0.995 0.974 1.000 1.000 
E247-K94 0.717 – 0.567 0.524 – – 
E247-K98 0.801 0.693 0.749 0.765 0.675 – 
D250-K98 – 0.529 0.683 0.694 0.676 – 
D251-K224 0.934 – – – – – 
E267-K440c 0.783 0.969 0.987    
E292-R296 – 0.746 – 0.836 – – 
E293-R296 0.845 0.522 0.577 0.699 – – 
E320-R323 0.955 0.875 0.823 0.964 0.885 0.887 
E320-R378 0.711 0.623 0.689 – 0.667 0.835 
E344-K3 0.720 0.692 0.712 0.656 0.627 0.694 
E344-R56 0.960 0.974 0.931 0.915 0.954 0.962 
D351-R50 0.557 – 0.589 0.571 – – 
E352-R47d 0.812 0.650 –    
D370-R375 – 0.916 0.688 0.877 0.682 – 
D370-R378 0.653 – – 0.946 – 0.969 
E372-R362 – 0.557 0.707 0.761 0.701 0.558 
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Table A2 (continued) 
E377-K289 – – 0.539 – 0.728 0.705 
E380-K312 – – – – 0.573 – 
D425-K282 0.867 0.705 0.535 0.729 – – 
D432-K24 0.744 0.640 0.513 0.538 0.861 – 
E442-K434 – – 0.610 – – – 
a Salt bridge defined as interaction between O atom of Asp/Glu and protonated N atom of 
Arg/Lys/His within a distance cutoff of 4.0 Å. “–” indicates that the occupancy is < 0.5 b SF, 
substrate-free; MYT, metyrapone; PLM, palmitic acid c Residue 267 is Val in PM d Residue 47 is 
Leu in PM 
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Table B1. Predicted protonation states of subtrates at physiological pH.a  Predictions 
determined by I. Geronimo. 
Substrate Number of 
titratable atoms 
Strongest 
acidic/basic pKa 
Charge at pH 7.4 
diclofenac 2 4.00 -1.00 
naproxen 1 4.19 -1.00 
warfarin 1 5.56 -0.99 
lovastatin 1 14.91 0.00 
dextromethorphan 1 9.85 1.00 
MDMA 1 10.14 1.00 
astemizole 2 8.73 1.02 
nicotine  2 8.58 0.94 
cotinine 2 4.79 0.00 
metyrapone 2 4.87 0.00 
a https://chemicalize.com (accessed April 2018) 
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Table B2. Van der Waals component of pairwise interaction energy (kcal/mol) for 
diclofenac (DIF), naproxen (NPS), S-warfarin (SWF), R-warfarin (RWF), and lovastatin 
(LVA) complexes. Mean and standard deviation were calculated by averaging over 5-ns 
blocks. MD simulations performed by I. Geronimo. 
Residue DIF NPS SWF RWF LVA 
S72 0.14 ± 0.57 1.02 ± 0.20 -0.54 ± 0.12 -0.18 ± 0.15 -0.76 ± 0.25 
A74 -1.23 ± 0.20 -0.44 ± 0.08 -1.17 ± 0.04 -0.77 ± 0.17 -1.18 ± 0.36 
L75 -4.20 ± 0.72 -3.60 ± 0.16 -4.05 ± 0.14 -2.67 ± 0.15 -3.99 ± 0.18 
V78 -0.98 ± 0.10 -0.15 ± 0.01 -1.04 ± 0.05 -3.86 ± 0.20 -1.64 ± 0.12 
V87 -2.50 ± 0.32 -1.71 ± 0.22 -3.01 ± 0.10 -2.19 ± 0.21 -2.11 ± 0.13 
L181 -0.63 ± 0.33 -0.05 ± 0.02 -0.08 ± 0.01 -0.96 ± 0.04 -1.29 ± 0.15 
T260 -0.15 ± 0.01 -0.06 ± 0.01 -0.08 ± 0.01 -1.31 ± 0.27 -0.48 ± 0.13 
I263 -1.21 ± 0.24 -0.27 ± 0.08 -0.19 ± 0.03 -2.07 ± 0.10 -1.31 ± 0.15 
A264 -1.52 ± 0.22 -1.10 ± 0.16 -0.92 ± 0.06 -2.06 ± 0.28 -1.21 ± 0.08 
V267 -0.73 ± 0.08 -0.41 ± 0.21 -0.38 ± 0.07 -0.73 ± 0.08 -1.05 ± 0.30 
T268 -0.93 ± 0.07 -0.79 ± 0.09 -0.82 ± 0.02 -0.58 ± 0.07 -1.25 ± 0.12 
A328 -0.55 ± 0.42 -1.50 ± 0.07 -1.62 ± 0.21 -1.21 ± 0.21 -1.04 ± 0.17 
A330 -0.47 ± 0.25 -1.89 ± 0.04 -1.33 ± 0.03 -0.50 ± 0.11 -2.91 ± 0.19 
M354 -0.09 ± 0.04 -0.93 ± 0.06 -0.33 ± 0.09 -0.05 ± 0.01 -1.24 ± 0.07 
L437 -3.37 ± 0.64 -1.64 ± 0.17 -3.79 ± 0.13 -3.76 ± 0.10 -4.99 ± 0.54 
T438 -2.32 ± 0.42 -1.26 ± 0.11 -0.94 ± 0.04 -2.47 ± 0.30 -3.30 ± 0.36 
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Table B3. Van der Waals component of pairwise interaction energy (kcal/mol) for DEX, 
MDMA, and AST complexes. Mean and standard deviation were calculated by averaging 
over 5-ns blocks. MD simulations performed by I. Geronimo. 
Residue DEX MDMAa MDMAb ASTa ASTb ASTc 
S72 -0.01 ± 
0.01 
-0.64 ± 
0.11 
-0.19 ± 
0.03 
-0.20 ± 
0.11 
-1.71 ± 
0.90 
-0.70 ± 
0.52 
A74 -0.04 ± 
0.01 
-0.15 ± 
0.02 
-0.88 ± 
0.07 
-0.59 ± 
0.12 
-0.97 ± 
0.63 
-1.13 ± 
0.46 
L75 -1.48 ± 
0.19 
-2.24 ± 
0.14 
-2.02 ± 
0.11 
-1.48 ± 
0.42 
-3.86 ± 
1.10 
-2.40 ± 
0.82 
V78 -1.34 ± 
0.27 
-0.06 ± 
0.01 
-0.99 ± 
0.11 
-5.41 ± 
0.38 
-2.15 ± 
0.40 
-2.76 ± 
0.45 
V87 -3.78 ± 
0.08 
-1.22 ± 
0.16 
-2.06 ± 
0.18 
-1.82 ± 
0.12 
-5.37 ± 
0.37 
-3.22 ± 
0.40 
L181 -1.17 ± 
0.34 
-0.02 ± 
0.01 
-0.17 ± 
0.06 
-3.20 ± 
0.41 
-0.58 ± 
0.29 
-1.05 ± 
0.16 
T260 -2.20 ± 
0.15 
-0.04 ± 
0.01 
-0.13 ± 
0.02 
-1.71 ± 
0.09 
-0.27 ± 
0.03 
-1.12 ± 
0.22 
I263 -3.88 ± 
0.45 
-0.10 ± 
0.01 
-0.70 ± 
0.18 
-4.65 ± 
0.32 
-1.45 ± 
0.29 
-2.80 ± 
0.34 
A264 -1.35 ± 
0.17 
-0.83 ± 
0.04 
-1.71 ± 
0.08 
-3.02 ± 
0.14 
-1.73 ± 
0.19 
-2.53 ± 
0.23 
V267 -1.47 ± 
0.55 
-0.02 ± 
0.01 
-0.60 ± 
0.14 
-1.08 ± 
0.09 
-1.48 ± 
0.53 
-1.17 ± 
0.08 
T268 -1.59 ± 
0.10 
-1.10 ± 
0.06 
-1.12 ± 
0.04 
-1.54 ± 
0.05 
-1.37 ± 
0.17 
-1.15 ± 
0.16 
A328 -0.95 ± 
0.21 
-1.36 ± 
0.05 
-1.16 ± 
0.34 
-2.40 ± 
0.09 
-1.17 ± 
0.25 
-2.84 ± 
0.53 
A330 -0.12 ± 
0.03 
-2.39 ± 
0.12 
-0.38 ± 
0.07 
-1.57 ± 
0.20 
-0.57 ± 
0.24 
-1.25 ± 
0.19 
M354 0.00 -0.72 ± 
0.05 
-0.03 ± 
0.01 
-0.14 ± 
0.03 
-0.08 ± 
0.05 
-0.05 ± 
0.01 
L437 -2.33 ± 
0.44 
-2.65 ± 
0.11 
-1.94 ± 
0.14 
-5.22 ± 
0.92 
-2.60 ± 
0.31 
-3.86 ± 
0.57 
T438 -1.40 ± 
0.28 
-1.28 ± 
0.03 
-2.09 ± 
0.08 
-3.14 ± 
0.11 
-1.37 ± 
0.21 
-2.76 ± 
0.61 
a positioned for N-dealkylation b positioned for O-dealkylation c positioned for C–H hydroxylation 
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Table B4. Van der Waals component of pairwise energy (kcal/mol) for nicotine (NCT), 
cotinine (CTN), and metyrapone (MYT) complexes. Mean and standard deviation were 
calculated by averaging over 5-ns blocks. MD simulations performed by I. Geronimo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Residue NCT CTN MYT 
S72 -0.12 ± 0.04 -0.19 ± 0.05 -0.01 ± 0.01 
A74 -0.04 ± 0.01 -0.10 ± 0.02 -0.04 ± 0.01 
L75 -1.35 ± 0.16 -2.23 ± 0.10 -1.34 ± 0.09 
V78 -0.07 ± 0.01 -0.40 ± 0.06 -1.40 ± 0.07 
V87 -1.61 ± 0.12 -1.66 ± 0.05 -3.78 ± 0.08 
L181 -0.04 ± 0.01 -0.08 ± 0.03 -0.91 ± 0.12 
T260 -0.11 ± 0.01 -0.14 ± 0.02 -1.82 ± 0.04 
I263 -0.41 ± 0.08 -1.11 ± 0.19 -2.91 ± 0.05 
A264 -1.54 ± 0.06 -2.17 ± 0.17 -2.89 ± 0.07 
V267 -0.11 ± 0.03 -0.20 ± 0.06 -1.15 ± 0.02 
T268 -1.02 ± 0.03 -0.79 ± 0.19 -1.21 ± 0.03 
A328 -1.77 ± 0.14 -1.78 ± 0.11 -0.68 ± 0.13 
A330 -0.94 ± 0.15 -0.39 ± 0.04 -0.07 ± 0.01 
M354 -0.05 ± 0.01 -0.02 ± 0.01 0.00 
L437 -1.84 ± 0.23 -2.41 ± 0.20 -2.12 ± 0.08 
T438 -1.55 ± 0.09 -1.60 ± 0.08 -1.46 ± 0.06 
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Table B5. Hydrogen bond occupanices of substrates. Occupanices determined by I. 
Geronimo. 
 
 
 
 
 
 
 
 
Table B6. Hydrogen bond occupancies of heme propionate A oxygen atoms. Occupancies 
determined by I. Geronimo. 
Substrate Heme propionate O atom Hydrogen bond donor Occupancy (%) 
dextromethorphan O1A K69:NZ 24 
O2A K69:NZ 27 
MDMA O1A K69:NZ 74 
O2A MDMA:N 61 
astemizole O1A K69:NZ 34 
O2A K69:NZ 27 
nicotine O1A K69:NZ 
nicotine:N 
16 
39 
O2A nicotine:N 46 
naproxen O1A N395:N 19 
O2A N395:N 17 
S-warfarin O1A K69:NZ 53 
O2A K69:NZ 27 
Substrate Residue Occupancy (%) 
diclofenac:O1 S72:OG 28 
diclofenac:O2 S72:OG 12 
naproxen:O1 S72:OG 98 
naproxen:O1 S72:N 40 
naproxen:O2 S332:N 87 
naproxen:O2 K69:NZ 88 
S-warfarin:O2 K69:NZ 73 
MDMA:N L437:O 61 
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Figure B1. Absorption spectra of PM P450BM3 bound to omeprazole (inset). The black solid 
curve indicates the resting, low spin state when water is bound to ferric iron. The red dotted 
curve represents the 100% high spin state in which water is no longer bound and 
omeprazole is in the active site.  
 
 
Figure B2. Gibbs free energy of the enzyme-substrate complexes during the last 2 ns of 
FEP/ λ -REMD. The substrates are dextromethorphan (DEX), metyrapone (MYT), 
lovastatin (LVA), cotinine (CTN), astemizole (AST), MDMA, R-warfarin (RWF), S-
warfarin (SWF), nicotine (NCT), naproxen (NPS), and diclofenac (DIF). Different binding 
poses were modeled for MDMA and astemizole, including N-dealkylation (N), O-
dealkylation (O) and C–H hydroxylation (C6). MD simulations performed by I. Geronimo. 
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Figure B3. Replusive, dispersive, and electrostatic energy contributions to the binding of 
(A) diclofenac (DIF), naproxen (NPS), S-warfarin (SWF), R-warfarin (RWF), lovastatin 
(LVA), (B) dextromethorphan (DEX), MDMA, astemizole (AST), (C) nicotine (NCT), 
cotinine (CTN), and metyrapone (MYT). Different binding poses were modeled for 
MDMA and astemizole including N-dealkylation (N), O-dealkylation (O), and C-H 
hydroxylation (C6). MD simulations performed by I. Geronimo. 
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Figure B4. Water density at the PM P450BM3 substrate channel with the reference structure 
averaged from the MD simulation. T268, located at the distal side of the heme (helix I) and 
believed to play a role in proton delivery and oxygen activation, is also shown. MD 
simulations performed by I. Geronimo. 
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Figure B5. Plot of the distance between heme Fe and reacting atom of (A) diclofenac(C4'), 
(B) naproxen (methoxy C), (C) lovastatin (C6), (D) S-warfarin (C7), (E) R-warfarin (C4'), 
(F) dextromethorphan (protonated N), (G–I) astemizole (protonated N, methoxy C, C6), 
(J, K) MDMA (protonated N, C2), (L) nicotine (C5'), and (M) cotinine (C4'). MD 
simulations performed by I. Geronimo. 
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Figure B6. Plot of the cosine of the heme propionate A dihedral angle in (A) 
dextromethorphan, (B) MDMA, (C) astemizole, and (D) nicotine complexes of PM 
P450BM3. The cosine of the dihedral angle in the PM-palmitic acid crystal structure (PDB 
ID:4ZFB) is approximately -1. MD simulations performed by I. Geronimo. 
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Appendix C: Chapter 4 Additional Figures and Tables 
Figure C1. Binding of metyrapone to A) WT, B) F81I, and C) PM P450BM3 where the black 
line represents the Fe(III)-H2O resting state and the red line indicates saturation with 
metyrapone. Metyrapone binds WT and F81I P450BM3  by a reverse type I mechanism 
while it binds PM P450BM3 via a type II mechanism.  
  
 
Figure C2. A) Overlay of WT (blue, PDB ID:4ZFA) and I401P P450BM3 (green, PDB 
ID:3hf2)  showing differences to the overall global structure. B) Zoomed in view of the 
cys-ligand loop depicting the I401P mutation in WT and the I401P P450BM3 variant.  
C)Absorbance of the I401P P450BM3 variant in the resting state (blue line) as compared to 
WT P450BM3 (black line). Unlike WT P450BM3 in its resting state (Fe(III)-H2O), the I401P 
P450BM3 mutant was naturally high spin as shown by the Soret band at ~394 nm as opposed 
to 418 nm. In addition, for I401P P450BM3 the β-band appeared prominently with less 
definition between the α and β-bands as seen for WT P450BM3. Lastly, the MLCT band 
was quite sharp for the I401P P450BM3 mutant. 
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Figure C3. 4-Cyanopyridine (CNPy) had a higher binding affinity for the ferrous state than 
ferric state. A) Binding titration of CNPy to ferric WT P450BM3. The inset is the 
∆Absorbance plot in which maximum changes to the Soret, Q-, and MLCT bands were 
most apparent. The blue line is no substrate bound and the red line is CNPy saturation. B) 
Binding of CNPy to ferric PM P450BM3, C) binding of CNPy to ferrous WT P450BM3, D) 
CNPy bound to ferrous PM P450BM3. The green dashed line in panels C) and D) represent 
the ferric state before reduction with dithionite. 
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Figure C4. Plots of curves used to determine Kd of CNPY for WT and PM P450BM3. A) 
WT Fe(III)-CNPy, B) WT Fe(II)-CNPY, C) PM Fe(III)-CNPy, and D) PM Fe(II)-CNPy. 
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Figure C5. Residual plots of monophasic and biphasic fits for unfolding by UV/Vis 
spectroscopy. Black circles represent monophasic fit residuals and red squares represent 
biphasic fit residuals. For fits shown, smaller residuals were apparent for biphasic fits as 
compared to monophasic fits to determine Cm values. A) residual plot of WT Fe(III)-H2O 
and B) residual plot of PM Fe(III)-H2O. Residual plots of WT Fe(II)-CO bound are shown 
in C) and D) where C) indicates appearance of the inactive state at 420 nm and D) indicates 
disappearance of the P450 state. Residuals for the disappearance of the P450 for the F81I 
Fe(II)-CO state are shown in E). The P420 state is not included as a biphasic equation does 
not fit the data. Residuals for the disappearance of the P450 for the I401P Fe(II)-CO state 
are shown in F). As with the F81I P450BM3 variant, the P420 state is not included as a 
biphasic equation does not fit the data.  
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Figure C6. Active site stability of WT and PM P450BM3 was evident by changes to the 
Soret band for CNPy bound species. A) Urea titration of ferric WT P450BM3 with CNPy 
bound and B) ferrous WT P450BM3 with CNPy bound by UV/Vis spectroscopy in which 
the blue line is no urea, and the red is the final urea addition (6.8 M).  C) and D) are PM 
P450BM3 species in the ferric and ferrous states CNPy bound, respectively. The insets are 
the ∆Absorbance plots indicating where maximum changes in absorbance occurred.  
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 Figure C7. ∆Cm of unfolding for A) WT and B) PM P450BM3 as determined by UV/Vis 
spectroscopy. ∆Cm was calculated for WT P450BM3 by subtracting the Cm for the major 
water bound population (5.6 M) from the Cm for each specific state.  ∆Cm for PM P450BM3 
was calculated by subtracting the Cm for the major water bound population (2.3 M) from 
all other states. Blue represents states where the Fe(III)-H2O state was less stable and red 
represents where the Fe(III)-H2O state was more stable than the state the ∆Cm was 
determined for. 
 
Figure C8. Example urea titration as monitored by Circular Dichroism spectroscopy.  Plot 
shows unfolding of 𝛂𝛂-helical content for WT Fe(III)-H2O. The blue line represents the 
properly folded state with no urea while the red line is with the maximum urea 
concentration of 6.8 M.  
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Figure C9. ∆Cm of unfolding for A) WT and B) PM P450BM3 as determined by CD. ∆Cm 
was calculated for WT P450BM3 by subtracting the Cm for the water bound population 
(5.6 M) from the Cm for each specific state.  ∆Cm for PM P450BM3 was calculated by 
subtracting the Cm for the water bound population (3.7 M) from all other states. Blue 
represents states where the Fe(III)-H2O state was less stable and red represents where the 
Fe(III)-H2O state was more stable than the state the ∆Cm was determined for. Values were 
not included for the WT Fe(II)-CNPy because data was not included for this study. For the 
PM P450BM3 Fe(II)-CNPy state, the ∆Cm was zero.  
 
 
Figure C10. Pulse proteolysis gel of WT P450BM3 water bound. As the urea concentration 
increased, degradation of WT P450BM3 increased as shown by a decrease in the protein 
band at 50 kD. The protease used to cleave WT P450BM3, thermolysin, is shown in the 
bands at 37 kD. 
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Figure C11. Residual plots of monophasic and biphasic fits for unfolding detected by pulse 
proteolysis. Black circles represent monophasic fit residuals and red squares represent 
biphasic fit residuals. A) residual plot of WT Fe(III)-H2O and B) residual plot of WT Fe(II)-
CO. 
 
 
Figure C12. ∆Cm of unfolding for A) WT and B) PM P450BM3 as determined by pulse 
proteolysis. ∆Cm was calculated for WT P450BM3 by subtracting the Cm of the higher 
transition for the water bound population (5.3 M) from the Cm for each specific state. For 
the WT P450BM3 Fe(II)-CO state, the lower Cm value was used (2.2 M) as it is the major 
population (90%).  ∆Cm for PM P450BM3 was calculated by subtracting the Cm for the water 
bound population (2.9 M) from all other states. Blue represents states where the Fe(III)-
H2O state was less stable and red represents where the Fe(III)-H2O state was more stable 
than the state the ∆Cm was determined for.  
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Figure C13. The MLCT region (600-700 nm) of the P450BM3 variants in the Fe(II)-CNPy 
state was used to calculate reduction potential. The black line represents WT P450BM3, the 
blue line F81I P450BM3, the green line I401P P450BM3, and the red line PM P450BM3. 
 
 
Table C1. Binding dissociation constants (Kd) for the ferric and ferrous WT and PM 
P450BM3 states. 
 
 
 
a.  Previously published data.268 b. Data from this study. 
 
 
 
 
 
BM3 Variant  Fe(III)-CNPy 
(µM) 
Fe(II)-CNPy 
(µM) 
WTa 1130 ± 45 1.80 ± 0.7 
WTb 2440 ± 570 9.93 ± 2.9 
PMb 240 ± 40 17.6 ± 12.2 
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Table D1. HPLC method 1. 
Time (min) 0.1% formic acid in dH2O 0.1% formic acid in CH3CN 
0 98 2 
2 95 5 
5 70 30 
15 70 30 
20 40 60 
30 5 95 
35 98 2 
40 98 2 
 
Table D2. HPLC method 2. 
Time (min) 0.1% formic acid in dH2O  0.1% formic acid in CH3CN 
0 98 2 
2 95 5 
5 95 5 
10 90 10 
20 90 10 
25 70 30 
30 40 60 
35 5 95 
40 98 2 
45 98 2 
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Figure D1. 1H NMR spectrum of 3 (400 MHz, CD3CN). Synthesis by A. Zamora. 
 
Figure D2. 13C NMR spectrum of 3 (100 MHz, CD3CN). Synthesis by A. Zamora. 
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Figure D3. 1H NMR spectrum of 4 (400 MHz, CD3CN). Synthesis by A. Zamora. 
 
 
Figure D4. 13C NMR spectrum of 4 (100 MHz, CD3CN). Synthesis by A. Zamora. 
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Figure D5. Thermal stability for complexes 2–4. (A) 2, (B) 3, and (C) 4 at RT (−) and 37 
ºC (– –) after 30 min incubation in MeCN. Studies were also performed in H2O over 48 
hours at 37 ºC, and no changes were observed. Studies by A. Zamora. 
 
 
 
 
 
 
 
 
 
 
Figure D6. Photoejection of 2 (30 μM) followed by UV/Vis absorption spectroscopy in 
different media; (A) water, (B) 1X PBS, (C) Opti-MEM with 1% FBS, (D) CH3CN. Studies 
by A. Zamora. 
 
   
A B C 
A B 
C D 
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Figure D7. Photoejection of 3 (30 μM) followed by UV/Vis absorption spectroscopy in 
different media; (A) water, (B) 1X PBS, (C) Opti-MEM with 1% FBS, (D) CH3CN. Studies 
by A. Zamora. 
 
 
 
 
 
 
 
 
A B 
C D 
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Figure D8. Photoejection of 4 (30 μM) followed by UV/Vis absorption spectroscopy in 
different media; (A) water, (B) 1X PBS, (C) Opti-MEM with 1% FBS, (D) CH3CN. The 
blue line is the initial and the red line is the final spectra. Inset: The kinetics curve was 
produced by monitoring the change in absorbance at 450-485 nm (blue) and 430-450 nm 
(black) and fit with a one phase decay equation using GraphPad Prism software. Studies 
by A. Zamora. 
 
Table D3. Half-lives (t1/2) for photoejection for 2.a 
Condition t1/2 (min)b 
Water 0.6 ± 0.1 and 58 ± 12 
1X PBS 0.6 ± 0.1 and 32 ± 3 
Opti-MEM with 1% FBS 0.6 ± 0.1 
Acetonitrile 0.07 ± 0.02 and 2.5 ± 0.5 
aHalf-lives determined by A. Zamora. bKinetics were determined using the change in 
absorbance at 470-440 nm for aqueous conditions and 425-445 nm for acetonitrile and fit 
to a two phase decay except for Opti-MEM, which was fit to a one phase decay equation. 
A B
C D 
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Table D4. Δabs of photoejection for 3.a 
Condition Δabs @ 470 nm 
Water 0.028 ± 0.001 
1X PBS 0.038 ± 0.002 
Opti-MEM with 1% FBS 0.041 ± 0.006 
Acetonitrileb 0.15 ± 0.02 and 7.8 ± 0.5 
aKinetics determined by A. Zamora. bKinetics were determined using the changes in 
absorbance at 475-440 nm for the initial fast phase and 425-440 nm for the slow phase and 
fit to a one phase decay. 
 
Table D5. Δabs of photoejection for 4. a 
Condition Δabs @ 485 nm 
Water 0.012 ± 0.001 
1X PBS 0.013 ± 0.001 
Opti-MEM with 1% FBS 0.012 ± 0.003 
Acetonitrileb 1.3 ± 0.2 and 55.8 ± 0.3 
aKinetics determined by A. Zamora. bKinetics were determined using the changes in 
absorbance at 450-485 nm for the initial fast phase and 430-450 nm for the slow phase and 
fit to a one phase decay. 
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Figure D9. HPLC chromatograms of 2 in the dark and after 1 min irradiation with 470 nm 
light. For all graphs black (−): 2 in the dark, red (– –): 2 after 1 min irradiation, blue (--): 
metyrapone. (A) Full HPLC chromatograms, where 17.5 min = free metyrapone, 26.5–27.8 
min = 2 after 1 min irradiation, 28.5–29.5 min = 2. Intact complex 2 has three peaks with 
the same absorption profiles due to the presence of the different isomers. (B) Ru(II) 
complex region of the HPLC chromatograms showing decreased signal for intact complex 
(26.5–27.8 min) and onset of shorter retention time products (28.5–29.5 min) following 
irradiation. (C) Metyrapone region of the HPLC chromatograms showing appearance of 
the signal in the irradiated sample. (D) UV/Vis absorption traces of the peaks showing a 
red-shifted MLCT band of 2 when irradiated with light. Extent of the photoejection 
reaction is 53%. HPLC performed by A. Zamora. 
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Figure D10. ESI-MS of 2 after being irradiated with 470 nm light. Ejection of one 
metyrapone ligand was confirmed by appearance of the peaks corresponding to free ligand 
and [Ru(bpy)2(Met)]2+ or [Ru(bpy)2(Met)(H2O)]2+, as well as the reduction in the signal of 
the intact complex. ESI-MS performed by A. Zamora. 
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Figure D11. HPLC chromatograms of 3 in the dark and after 1 min irradiation with 470 nm 
light. For all figures black (−): 3 in the dark, red (– –): 3 after 1 min irradiation, blue (--): 
etomidate. (A) Full HPLC chromatograms, where 11 min = 3 after 1 min irradiation, 16 
min = free etomidate, 21.5 min = 3 in the dark). (B) Intact 3 region of the HPLC 
chromatograms showing decreased signal following irradiation. (C) Irradiated product 
region of the HPLC chromatograms showing increased signal following irradiation. (D) 
Etomidate region of the HPLC chromatograms showing appearance of free ligand 
following irradiation. (E) Full and (F) zoomed UV/Vis absorption traces of the peaks 
showing a slight red-shifted MLCT band of 3 when irradiated with light. Extent of the 
photoejection reaction is 65%. HPLC performed by A. Zamora. 
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Figure D12. ESI-MS of 3 after being irradiated with 470 nm light. Ejection of one 
etomidate ligand was confirmed by appearance of the peaks corresponding to free ligand 
and [Ru(bpy)2(Eto)]2+ or [Ru(bpy)2(Eto)(H2O)]2+, as well as the reduction in the signal of 
the intact complex. ESI-MS perfomed by A. Zamora. 
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Figure D13. HPLC chromatograms of 4 in the dark and after 1 min irradiation with 470 nm 
light. For each figure black (−): 4 in the dark, red (– –): 3 after 1 min irradiation, blue (--): 
1. (A) Full HPLC chromatograms, where 23 min = 1, 28.8 min = 4 after 1 min irradiation, 
30.6 min = 4 in the dark. (B) Ru(II) complex region of the HPLC chromatograms showing 
decreased signal for intact 4 and appearance of the Ru(II) product following irradiation. 
(C) Compound 1 region of the HPLC chromatograms showing the appearance of the signal 
following irradiation. (D) Full UV/Vis absorption traces of the peaks showing slight 
changes in the MLCT band of 4 when irradiated with light. Extent of the photoejection 
reaction is 40%. HPLC performed by A. Zamora. 
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Figure D14. ESI-MS of 4 after being irradiated with 470 nm light. Ejection of one 1 ligand 
was confirmed by appearance of the peaks corresponding to free ligand and [Ru(bpy)2(1)]2+ 
or [Ru(bpy)2(1)(H2O)]2+, as well as the reduction in the signal of the intact complex. ESI-
MS perfomed by A. Zamora. 
 
 
 
 
 
 
Figure D15. UV/Vis spectral traces of PM BM3 (2.5 µM) at RT in assay buffer with 
increasing ligand concentration: (A) metyrapone, (B) etomidate, (C) and 1. The blue line 
is the initial and the red line is the final spectra. Inset: The binding curves were produced 
by monitoring the change in absorbance at 425 nm and fit with a one site-total non-linear 
equation using GraphPad Prism software.  
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Figure D16. UV/Vis spectral traces of PM BM3 (2.5 µM) at RT in assay buffer with 
increasing concentration of complexes: (A) 2, (B) 3, and (C) 4 after irradiation with the 
Indigo LED. The blue line is the initial and the red line is the final spectra. Inset: The 
binding curves were produced by monitoring the change in absorbance at 425 nm and fit 
with a one site-total non-linear equation using GraphPad Prism software. 
 
Table D6. Kd values for ligands and light-activated complexes. 
Ligand Kd (µM) Complex Kd (µM)  
Metyrapone 1.09 ± 0.18 2 6.13 ± 1.46  
Etomidate 0.83 ± 0.22 3 3.20 ± 0.59  
1 0.93 ± 0.18 4 4.63 ± 1.75  
 
 
Figure D17. Difference spectra of P450BM3 inhibitor saturated and Ru(II) dark and light 
systems: 2 (A), 3 (B), 4 (C). The ratio used was P450: Complex (1:10) and P450: Ligand 
(1:4) for each of the respective ligands used to generate the complexes. The absolute 
spectra are shown in Figure 1.  
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Figure D18. P450BM3 activity assay for (A) metyrapone, (B) etomidate, (C) 2 and (D) 3. 
For (C) and (D), complexes 2 and 3 were tested in the absence of light (—) and following 
1 min of irradiation with the Indigo LED (—) 
 
Table D7. P450BM3 activity assay IC50 values. 
Ligand IC50 (μM) Complexes IC50 (μM)a 
Metyrapone 0.75 ± 0.43 2 0.19 ± 0.02  3.47 ± 0.74 
Etodimate 0.02 ± 0.00 3 0.04 ± 0.01  0.61 ± 0.05 
1 0.06 ± 0.03 4 0.05 ± 0.00  6.82 ± 2.06 
a. Values listed first in black are light activated complexes. Values listed in blue are IC50 
values for complexes in the dark. 
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Figure D19. Singlet Oxygen Sensor Green detection of 1O2 demonstrated low levels are 
produced by complexes 2-4. Ru(dip)3 (dip = bathophenanthroline) was used as a control.  
Assay performed by L. Nease and D. Heidary.  
 
 
Figure D20. Agarose gels showing the dose response of ligands with 40 μg/mL pUC19 
plasmid with and without irradiation (470 nm). (A) Dark and (B) 3 hr irradiation. Lane 1 
and 14: DNA ladder; Lane 2: EcoRI; Lane 3: Cu(OP)2; Lane 4: 0 mM, Lanes 5–7: 7.8, 
62.5, 500 mM metyrapone; Lanes 8–10: 7.8, 62.5, 500 mM etomidate; Lanes 11–13: 7.8, 
62.5, 500 mM 1. EcoRI and Cu(OP)2 are used as controls for linear and relaxed circular 
DNA, respectively. EtBr was used to visualize the DNA. Gels run by A. Zamora.  
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